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ABSTRACT 
 
Cancer cells take more glucose to provide energy and phosphoryl intermediates for cancer 
progression. Meanwhile, energy-provider function of mitochondria in cancer cells is disrupted. 
This phenomenon is so-called Warburg effect, which is discovered over eighty years ago. The 
detail mechanisms for Warburg effect are not well defined. How glycolytic enzymes contribute to 
cancer progression is not well known. PKM2 is a glycolytic enzyme dominantly localized in the 
cytosol, catalyzing the production of ATP from PEP. In this study, we discovered that there were 
more nuclear PKM2 expressed in highly proliferative cancer cells. The nuclear PKM2 levels are 
correlated with cell proliferation rates. According to our microarry analyses, MEK5 gene was 
upregulated in PKM2 overexpression cells. Our studies showed that PKM2 regulated MEK5 gene 
transcription to promote cell proliferation. Moreover, nuclear PKM2 phosphorylated Stat3 at Y705 
site using PEP as a phosphoryl group donor to regulate MEK5 gene transcription. Our study also 
showed that double phosphorylated p68 RNA helicase at Y593/595 interacted with PKM2 at its 
FBP binding site. Under the stimulation of growth factors, p68 interacted with PKM2 to promote 
the conversion from tetrameraic to dimeric form so as to regulate its protein kinase activity. 
Overexpression PKM2 in less aggressive cancer cells induced the formation of multinuclei by 
regulating Cdc14A gene transcription. Overall, this study presents a step forward in 
understanding the Warburg effect.   
 
 
INDEX WORDS: PKM2, P68 RNA helicase, MEK5, Stat3, Cdc14A, Tyrosine phosphorylation, 
Gene transcription, Cell cycle, Glycolysis.  
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CHAPTER I 
GENERAL INTRODUCTION 
Cancer is a serious human disease and the detail mechanism is not well 
understoond. Cancer cells uptake more glucose to provide energy and phosphoryl 
intermediates for macromolecule systhesis, and their oxidative phosphorylation activity is 
decreased, so-called Warburg effect. Warburg effect has been known for decades and the 
detail mechanisms are not well defined. In this project, we studied how a glycolytic 
protein played a role to regulate gene transcription in cells. Moreover, we investigated 
how phosphorylated proteins affect the glycolytic process by regulating the quaternary 
structure of a glycolytic enzyme, which provided part explanations for Warburg effect.  
 
1.1 Cancer Metabolism  
1.1.1 Tumors and Cancer 
In general, tumors are the outcome of abnormal growth of normal cells. There are 
three continuous stages normal cells go through to completely develop into tumor cells. 
The first stage is hyperplasia, and at this stage the cells grow out of control but still 
behave like normally physiological cells. At this stage, tumors can be removed by 
surgery; also at this point they are called benign tumors. The second stage is dysplasia, 
which is also called the early form of cancerous lesions. At this stage, cells change their 
behavior and the differentiation and mature processes of cells are delayed. However, cells 
are not invasive to the basement membrane of the soft tissues. Dysplasic cells can be 
further graded into different levels even though cells at the highest level of this stage are 
still considered very low level cancers. The third stage is anaplasia, which is a reversion 
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process of cell differentiation. At this stage, cells lose their functional and structural 
differentiations at physiological conditions. The nuclei of anaplasic cells become 
astoundingly hyper-chromatic and large. The nuclear-cytoplasmic ratio increases to 1:1 
instead of 1:4~1:6 for normal cells. At this stage, cells gain the ability to invade the blood 
system as well as neighboring tissues, which are called malignant tumors; these are also 
defined as cancers.  
According to their original tissue location, cancers are further divided into five 
groups: Carcinoma is originally generated from epithelial cells covering the surface of 
internal organs. Sarcoma is a cancer initially from muscle, bone or connective tissues. 
Leukemia is generated from white blood cells. Lymphoma is originally from lymphatic 
cells. Myeloma is from mature B lymphocyte.  
Cancer cells are characteristically different from normal cells. For example, the 
disruption of cytoskeletons in cancer cells, such as microfilaments and microtubules, 
changes their interactions with neighboring cells as well as their appearances. The change 
in cell to cell adhesion helps cancer cells to lose the restrictions of contact inhibition so 
that cancer cells can grow unlimitedly even surrounded by other cells. The secretion of 
enzymes from cancer cells facilitates them in degrading the basement membrane to 
invade into deep tissues. Therefore, these changes create six functional characteristics for 
cancer cells with the presence of variously genetic alterations, such as avoidance of 
apoptosis, constant reaction to growth signals or stimuli, unrestricted replicative 
capability, angiogenesis capacity, invasion ability and metastasis potential.  
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1.1.2 Cancer Metabolism and Warburg Effect 
The metabolism in cancer cells is, to a certain extent, different from normal cells 
(Merida and Avila-Flores 2006). One important characteristic of cancer cell metabolism 
is the consistent switch of the energy production pathway from oxidative phosphorylation 
to glycolysis (Kondoh, Lleonart et al. 2007). In most normal mammalian cells, glycolysis 
flux is tightly regulated, and the glycolysis process is inhibited by the presence of 
oxygen, which was first discovered by Louis Pasteur. For decades, it has been known that 
cancer cells utilize more glucose and display a higher glycolysis rate than normal cells. In 
the 1920s, Otto Warburg found that even in the presence of sufficient oxygen, cancer 
cells consume glucose for ATP production instead of using the oxidative phosphorylation 
pathway (Warburg 1956; Warburg 1956).  
In general, through the glycolysis process, one molecule of glucose generates two 
molecules of pyruvate and produces two molecules of ATP. In mammals, the product of 
the glycolysis process, pyruvate, has diverse fates. In an environment with limited 
oxygen, pyruvate is catalyzed into lactate by lactate dehydrogenase, a process which is 
called anaerobic glycolysis. In the presence of efficient oxygen, pyruvate is catalyzed 
into acetyl coenzyme A by the pyruvate dehydrogenase complex. Acetyl coenzyme A is 
consumed in the citric acid cycle to generate electrons in the mitochondria. The electrons 
create an electron gradient which generates a pH gradient across the mitochondrial 
membrane. The force motive produced by the pH gradient generates ATP by ATP 
synthases. This process is called aerobic oxidative phosphorylation. Overall, one acetyl 
CoA molecule through citric acid cycle produces two molecules of NADH, one molecule 
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of FADH2, and eight molecules of electrons. Compared to the aerobic oxidative 
phosphorylation pathway, anaerobic glycolysis only produces a small fraction of the total 
energy of glucose. One molecule of glucose can be completed degraded into H2O and 
CO2 in the oxidative phosphorylation process to produce 38 molecules of ATP. Overall, 
the oxidative phosphorylation process is more efficient in producing ATP than 
glycolysis.  
However, cancer cells desire the glycolysis process to produce ATP instead of the 
oxidative phosphorylation pathway. The reason why cancer cells prefer consuming 
glucose to produce ATP is not well defined yet. One fact is that the glycolysis process 
provides a lot of phosphointermediates besides ATP for cells to synthesize 
macromolecules such as lipids, proteins, and nucleic acids. 
 
1.2 Possible Causes of Metabolic Changes in Cancer Cells  
1.2.1 Tumor Microenvironment Affects Tumor Metabolism 
The metabolism in cancer cells is regulated by many effectors at diverse levels. 
Firstly, tumor microenvironment is, to a certain extent, different from normal cells, 
characterized by being surrounded with disorganized microvasculature (Allinen, 
Beroukhim et al. 2004; Joyce 2005; Anderson, Weaver et al. 2006; Fukumura and Jain 
2007; Mohla 2007). Tissues of human bodies need nutrients and oxygen to keep their 
normal functions, which is provided through surrounding capillary vessels. Even though 
the growth and proliferation of cancer cells is not totally controlled by the same 
mechanisms as normal cells, cancer cells still need nutrients as well as oxygen provided 
by blood vessels. In most conditions, cancer cells proliferate and grow so fast that the 
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surrounding blood vessels can not provide enough oxygen or other nutrients to them. 
Under these conditions, the solid tumor grows in a hypoxic environment (normally below 
3%–5% O2). Without enough oxygen provided to the cancer cells they begin to rely on 
glycolysis to produce ATP as the major energy providing source. Meanwhile, the 
hypoxic environment surrounding cancer cells induces continuous expression and 
activation of hypoxia-inducible transcription factor (HIF-1) to regulate the expression of 
glycolytic enzymes as well as glucose transporters. Under anoxic conditions, HIF-1 is 
degraded by proteasomes due to the recognition by the von Hippel-Lindau (VHL) tumor 
suppressor (Mahon, Hirota et al. 2001). Under hypoxic conditions, HIF-1 is activated and 
translocates into the nucleus and binds to β-subunit of aryl hydrocarbon receptor nuclear 
translocator (ARNT) to regulate O2-induced gene transcriptions (Wiesener and Maxwell 
2003). Nearly all the expression of the glycolysis enzymes, such as hexokinase, 
phosphofructokinase, aldolase, glyceraldehyde 3-phosphate dehydrogenase, 
phosphoglycerate kinase, enolase, pyruvate kinase, lactate dehydrogenase is regulated by 
HIF-1 activity (Semenza 2007). The overexpression of these glycolysis enzymes 
enhances the glycolysis process to provide more energy to cancer cells. On the other 
hand, under hypoxic conditions, HIF-1 induces VEGF expression from cancer cells 
which facilitates the growth of blood vessels to provide more oxygen. However, the 
blood vessels surrounding tumor cells are so disorganized that they can not provide 
enough oxygen and nutrients as in normal physiological conditions. Under these 
conditions, the blood vessels surrounding tumor cells still can not alleviate the hypoxic 
levels of cancer cells. Therefore, aerobic glycolysis is still dominant in these tumor cells.  
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1.2.2 Oncogenes and Tumor Suppressor Genes Regulate Cancer Cell Metabolism 
Some oncogenes and tumor suppressor genes regulate the glycolysis process in 
cancer cells, such as c-Myc, AKT, AMPK, Ras and p53.  
Akt, a Serine/Theronine kinase, was initially discovered as a cellular homolog of a 
viral oncoprotein; this protein is amplified in diverse cancers, such as ovarian, breast 
carcinomas, and gastric adenocarcinoma (Vivanco and Sawyers 2002). Akt is the 
downstream target of phosphatidylinositide-3-kinase (PI-3 kinase) in growth factor 
induced signal pathways. Under the stimulation of diverse survival signals such as IL-6 
and IGF-1, PI-3K is activated by phosphorylation to generate phosphoinositides. Akt is 
then recruited by phosphoinositides to the cellular membrane to be phosphorylated at 
Serine 473 and Threonine 308 residues (Kitamura, Kitamura et al. 1999). Akt can be 
dephophorylated by protein phosphatase 2A (PP2A). The PI3K-Akt pathway is an 
important signal transduction pathway, playing crucial roles in regulating the cell cycle, 
apoptosis, cell survival and cell proliferation (Thompson and Thompson 2004). Cellular 
Akt is also activated by the deletion of phosphatase and tensin homolog on chromosome 
10 (PTEN), an antagonist of PI-3, in many cancers, such as brain, breast, and prostate 
cancers (Li, Yen et al. 1997). In addition, Akt is activated by a number of oncoproteins, 
such as Bcr-Abl in chronic myelogenous leukemia, Her2 in breast cancer, as well as Ras. 
Activated Akt has many downstream targets, such as nuclear factor-kappa B (NF- B), 
GSK-3, and Bad. Activated Akt is pluripotent in contributing to tumorigenisis, such as 
avoiding apoptosis and promoting cell proliferation. In leukemia cells, the overexpression 
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of Akt promotes its survival capability by inceasing glycolysis levels. Akt regulates 
glycolysis though many aspects. Firstly, the activated Akt pathway in respiration 
deficient cancer cells increases glucose consumption by regulating the transcription and 
translation of glucose transporter1 (GLUT1) to support their survival and growth (Plas, 
Talapatra et al. 2001; Rathmell, Fox et al. 2003). Second, activated Akt stimulates 
hexokinase activity to convert glucose to glucose-6-phosphate, a modified form of 
glucose which can not diffuse freely out of the cell, so as to increase the cellular amount 
of glucose (Gottlob, Majewski et al. 2001) (Rathmell, Fox et al. 2003). Third, Akt 
regulates phosphofructokinase (PFK-1) activity, a key enzyme in controlling the 
glycolysis rate, through phosphorylating and activating PFK-2. PFK-2 catalyze the 
production of fructose 2,6-bisphosphate, which is an allosteric regulator of PFK-1 to 
overcome the inhibition effect of high ATP levels on PFK-1 (Deprez, Vertommen et al. 
1997). In addition, it is reported that the overexpression of Akt is sufficient to promote 
transformed cells’ aerobic glycolysis without affecting their oxidative phosphorylation 
level (Elstrom, 2004 #5019). Furthermore, the inactivation of mitochondrial respiration 
in human leukemia and lymphoma cell activates PI-3K-Akt pathway by oxidating the 
tumor suppressor PTEN. The activated PI-3K-Akt pathway benefits cell survival 
(Pelicano, Xu et al. 2006). The direct effect of Akt on glycolysis may contribute to the 
Warburg effect  (Coloff and Rathmell 2006). 
c-Myc is a nuclear oncoprotein, which is constantly active in many malignant 
tumor cells independent of growth factor stimulations (Elliott, Ge et al. 2000). It is 
reported that c-Myc regulates many glycolysis-related gene transcriptions to control 
energy production, such as glucose transporters, hexokinase, phosphoglucose isomerase,   
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phosphofructokinase, aldolase, enolase and pyruvate kinase (Gordan, Bertout et al. 
2007). Interestingly, c-Myc not only upregulates glycolysis-related genes transcriptions 
for energy production, but also promotes mitochondrial biosynthesis through targeting 
the mitochondrial transcription factor A (TFAM) (Li, Wang et al. 2005). The products 
from mitochondrial biosynthesis provide intermediates for macromolecular synthesis, 
such as fatty acid, nucleotide, polyamine as well as amino acids (Coller et al., 2000; 
O’Connell et al., 2003).  
AMP-activated protein kinase (AMPK), is a master regulator controlling energy 
metabolism, which was first identified in 1994 as an inhibitor of acetyl-CoA carboxylase 
and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) (Kemp, Stapleton et al. 2003). 
AMPK activity is stimulated by its upstream effetor, AMPK kinases (AMPKKs), with 
the phosphorylation at Threonine172 residue. AMPK is also directly activated by AMP. 
AMPK is reported to regulate glucose consumption by controlling the transcription of 
GLUT1 and the translocation of GLUT1 to cellular surface (Russell, Bergeron et al. 
1999). AMPK activates 6-phosphofructo-2-kinase (PFK-2), the enzyme that synthesizes 
fructose 2,6-bisphosphate in cardiac muscle cells under ischaemic conditions (Marsin, 
Bertrand et al. 2000).  
p53, an important tumor suppressor, plays important roles in regulating apoptosis, 
cell cycle arrest, and DNA replication. p53 is inactive in more than half of cancers 
(Hainaut and Hollstein 2000). It is reported that the activation of p53 causes the 
downregulation of several glycolytic enzymes’ transcription, such as phosphoglycerate 
mutase (PGM), and GLUT (Schwartzenberg-Bar-Yoseph, Armoni et al. 2004). In the 
glycolysis process, PGM converts 3-phosphoglycerate to 2-phosphoglycerate to decrease 
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the glycolysis flux. Interestingly, the activation of p53 increases the oxidative 
phosphorylation rate by upregulation of the synthesis of cytochrome oxidase 2 (SCO2). 
SOC2 is crucial for regulating cytochrome c oxidase (COX) complex activity to use 
oxygen in oxidative phosphorylation pathway. Therefore, the loss of p53 activity benefits 
cell proliferation by increasing the glycolysis rate and decreasing mitochondrial oxidative 
phosphorylation activity, which is another possible explanation for the Warburg effect 
(Matoba, Kang et al. 2006). p53 is a nuclecytoplasmic shuttling protein which depends 
on its leucine-rich nuclear export signal (Stommel, Marchenko et al. 1999). It is reported 
that p53 also translocates to mitochondria under stimuli to induce apoptosis by directly 
interacting with a Bcl-2 family protein (Erster, Mihara et al. 2004). Moreover, p53 plays 
important functions in maintaining mtDNA integrity in response to mtDNA damage by 
interacting with mtDNA and DNA polymerase γ to enhance poly γ transcriptional 
activity (Achanta, Sasaki et al. 2005). 
   
1.2.3 Mitochondrial Malfunction in Cancer Cells 
Mitochondrion is an important cellular organelle which takes part in regulating cell 
metabolism, producing reactive oxygen species (ROS) as well as inducing apoptosis (Lu, 
Sharma et al. 2009). Mitochondria have their own DNA as well as DNA transcription, 
replication and repair system to encode 13 polypeptides as the components of oxidative 
phosphorylation chain (Anderson, Bankier et al. 1981). In cancer cells the energy 
producer function of mitochondria is decreased for many reasons. First, in cancer cells, 
the transcription rate of the mitochondrial genome is reduced to a certain level compared 
to normal cells (Gogvadze, Orrenius et al. 2008; Bellance, Lestienne et al. 2009). Second, 
  10
mtDNA lacks histone protection from damages. Third, mitochondrial DNA is circular, 
supercoiled, and is easily damaged due to diverse exogenous or endogenous effects, such 
as radiation and ROS. Fourth, there are few DNA repair mechanisms in mitochondria 
compared to the nuclear genome (Achanta, Sasaki et al. 2005). All these properties make 
mitochondrial DNA to be easily affected by mutations, which disrupts the electron 
transport chain to decrease mitochondrial respiration rate. In addition, the malfunction of 
the electron transport chain in cancer cells produces superoxide, which forms ROS with 
other radicals. The accumulation of ROS damage mtDNA and nuclear DNA causes 
genetic instability as well as cancer progression (Pelicano, Carney et al. 2004). Usually, 
there are two characteristics of mtichondrial DNA mutations in cancer cells. First, the 
mutations are base transitions from T to C or G to A. Second, the mutations in the 
mitochondrial genome frequently occur in the 1.1 kb displacement-loop region (Ding, Ji 
et al. 2009).  
The malfunction of mitochondrial genome decreases oxidative phosphorylation 
efficiency for ATP production. On the other hand ATP produced in the oxidative 
phosphorylation process is an inhibitor for phosphofructokinase 1 (PFK1) in glycolysis. 
PFK1 is the major pace-keeping enzyme in glycolysis, and activated PFK1 increases 
glycolysis flux, which makes a transition for energy production from oxidative 
phosphorylation to glycolysis in cancer cells. Moreover, studies show that the disruption 
of mitochondrial respiration function in cancer cells induces tumorigenesis. For example, 
the interruption of mitochondrial respiration with genetic, chemical and 
microenvironmental methods, activates the PI3K-Akt pathway (Robey and Hay 2009). It 
is well known that the PI3K-Akt pathway in cancer cells plays important functional roles 
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in cell survival, proliferation and migrations (Robey and Hay 2009). In mitochondria-
deficient human leukemia and lymphoma cells, glycogen synthase kinase-3 (GSK-3), the 
substrate of Akt, is activated by Akt phoshphorylation. Therefore, the malfunctions of 
mitochondrial respiration in cancer cells may present part of the full explanation for the 
Warburg effect.  
 
1.2.4 Metabolic Malfunction is a Potential Cancer Therapy Method. 
Even though the mechanisms of the Warburg effect are not fully understood, thus 
far, the theory of the Warburg effect has been applied clinically in cancer diagnosis and 
therapy. For example, the Warburg effect has been used in cancer imaging for tumor 
detection by a glucose analogue, fluorodeoxyglucose, Positron Emission Tomography 
(FdG-PET) (Weber, Schwaiger et al. 2000). The fact that cancer cells require more 
glucose for energy production leads to FdG-PET, a powerful method in cancer diagnosis 
and prognosis (Kelloff, Hoffman et al. 2005). In addition, the increase of protein 
expression in glycolysis in cancer cells, such as HK2, and the decrease of the expression 
of components in the oxidative phosphorylation pathway, such as β-F1-ATPase,  are 
also applied as biomarkers for cancer diagnosis (Cuezva, Ortega et al. 2009).    
On the other hand, Akt/mTOR/HIF-1, a major regulatory signal pathway for the 
Warburg effect, has been targeted as a cancer therapy method to switch the energy 
production sources, that is, to decrease glycolysis efficiency and increase oxaditive 
phosphorylation competence (Jiang and Liu 2008). The activation of HIF-1 induced by 
Akt under hypoxia environment promotes cancer cell survival. By these methods, the 
survival advantages of cancer cells in hypoxic environments will be removed so that the 
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cancer cells cannot survive in the abnormal physiological conditions. For this purpose, 
some inhibitors for mTOR, such as RAD001, AP-23573 and CCI-779, and HIF-1a 
inhibitors, such as NSC644221, PX-478 and YC-1 are applied to impact cancer cell 
metabolism (Yeo, Chun et al. 2004; Smolewski 2006; MacKenzie and von Mehren 2007; 
Sun, Liu et al. 2007; Wan and Helman 2007; Gridelli, Maione et al. 2008; Jiang and Liu 
2008).   
Moreover, the fact that cancer cells depend on increased glycolysis as an ATP 
provider in hypoxic environments, brings a basis for disruption glycolysis as a potent 
cancer therapy. The disruption of the glycolytic pathway in order to limit the energy 
production has been studied as a promising cancer therapeutic method (Pelicano, Martin 
et al. 2006). For example, 3-BrPa, a hexokinase inhibitor, shows effective anti-cancer 
properties in colon cancer cells and lymphoma cells (Chen, Hewel et al. 2007). 2-
deoxyglucose, a glucose analogue, which cannot be metabolized to produce ATP, is in 
clinical trails as an interruptor of the glycolytic pathway which induces tumor cell death 
(Mohanti, Rath et al. 1996). A hexokinase inhibitor, lonidamine, releases hexokinase 
bound to mitochondria, and inhibits oxygen consumption and glycolysis effectively in 
cancer cells (Brawer 2005). Glufosfamide, an alkylating agent from D-glucose, which 
damages DNA and activates PARP, is also in phase II clinical trials in patients with 
advanced non-small cell lung cancer (Giaccone, Smit et al. 2004). Evasion from 
apoptosis is one of the characteristics of cancer cells. Tumor cells that are defective in 
cell apoptosis can be diverted into another cell death pathway, necrosis (Zong and 
Thompson 2006) (Nelson and White 2004). Necrosis is happening in tumor cells when 
the cell cannot provide itself enough energy for consumption. The dismantling of the 
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glycolysis pathway may induce tumor cell necrosis. Even though chronic necrosis may 
trigger chronic inflammation, it still is a potent method for tumor therapy.   
 
1.3 The Introduction of Glycolysis---Functional and Regulational Mechanisms of 
Glycolysis in Cancer Cells 
Glucose is a very important energy source for the human body, and the body can 
use many sources for producing glucose. Glucose is a monosaccharide which can be 
generated from the hydrolysis of polysaccharides and disaccharides, such as starch and 
lactose. In some tissues, such as brain cells, glucose is the only available energy source, 
under non-starvation conditions. Glucose can also be synthesized from non-carbohydrate 
precursors, such as lactate, amino acids and glycerol. The formation of glucose from 
other non-cabohydrate carbon substrates, such as glycerol, lactate and glucogenic amino 
acides is called gluconeogenesis. The gluconeogenic pathway occuring in mitochondrial 
and cytosol, converts pyruvate into glucose. Gluconeogenesis is not simply the reverse 
process of glycolysis, as it takes two steps to convert pyruvate into PEP. The first step is 
the carboxylation of pyruvate to generate oxaloacetate catalyzed by pyruvate carboxylase 
at an expense of one molecule of ATP. The second step is under the function of 
phosphoenolpyruvate carboxykinase to generate PEP from oxaloacetat at the expense of 
one molecule of GTP.   
Glycolysis is the metabolic process for cells to catalyze one molecule of glucose to 
produce two molecules of pyruvate, with a net energy production of two molecules of 
ATP. There are 10 reaction steps in this process carried out by 10 distinct enzymes. In 
mammals, glucose is first taken into cells with a family of glucose transporters (GLUT). 
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The sequence of glucose transporters is 500 amino acids long and consists of 12 
transmembrane α helices. There are five members of GLUT family presented in specific 
tissues. GLUT1 and GLUT3 are responsible for controlling basal glucose uptake. GLUT2 
exists in liver and pancreatic β cells to control glucose uptake from the blood with a very 
high Km value. GLUT4 is present in muscle and fat cells. GLUT5 exists in the small 
intestine. Once glucose is transported into the cells through GLUT, hexokinase, the first 
enzyme in the glycolysis process, phosphorylates glucose to form glucose 6-phosphate. 
Once phosphorylated, glucose 6-phosphate can not diffuse through the cell membrane 
and is trapped in the cytosol. Glucose 6-phosphate is further converted into fructose-6-
phosphate through the function of phosphoglucose isomerase. In the next stage, the six-
carbon fructose is cleaved by aldolase to generate two molecules of three-carbon 
fructose, glyceraldehyde 3-phosphate (GAP) and dihydroxyacerone phosphate (DHAP). 
GAP is the only form of the two, three-carbon molecules that can be used in the 
glycolysis process. Triose phosphate isomerase converts one molecule of DHAP into one 
molecule of GAP. Next, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyzes 
the formation of 1,3-bisphosphoglycerate (1,3-BPG) from GAP with the production of 
NADH. In this step, phosphorylation is coupled to the oxidation of three-carbon 
molecules. 1,3-BPG is an acyl phosphate, which has a high phosphoryl-transfer potential. 
The phosphate is transferred to ADP in the next step under the catalytic function of 
phsophglycerate kinase with the production of ATP. In the next step, the phosphoryl 
group is shifted with the conversion of 3-phosphoglycerate to 2-phosphoglycerate by 
phosphoglycerate mutase. Enolase catalyzes the conversion from 2-phosphoglycerate to 
phosphoenolpyruvate (PEP) with the formation of an enol in PEP and the production of a 
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molecule of H2O. The enol phosphate in PEP has a high potential to transfer phosphate. 
In the final step, pyruvate kinase catalyzes this reaction and a phosphate is transferred to 
ADP with the production of a molecule of ATP committed with the formation of 
pyruvate.   
The fates of pyruvate are diverse in different living organisms. In yeast and some 
other microorganisms, pyruvate is converted into ethanol catalyzed by pyruvate 
decarboxylase. In mammalian cells pyruvate is catalyzed into lactate by lactate 
dehydrogenase when oxygen is lacking. Most pyruvate produced in the glycolysis 
process enters into the citric acid cycle and the electron-transport chain in mitochondria 
to generate energy needed for higher organisms.  
The pace of glycolysis is tightly regulated by the catalytic enzymes. Three 
glycolytic enzymes, which catalyze these irreversible glycolytic reactions, are involved 
in the regulatory process; they are hexokinase, phosphofructokinase and pyruvate kinase 
(Weber, Convery et al. 1966). Among these three enzymes, phosphofructokinase is the 
predominant regulator in the glycolytic pathway whose enzymatic activity is tightly 
controlled by the ATP/AMP ratio in mammalian cells. Phosphofrucokinase catalyzes the 
third step in the glycolysis process, which is the conversion from fuctose 6-phosphate to 
fructose-1,6-bisphosphate (FBP). During this process, fructose 2,6-bisphosphate formed 
from the phosphorylation of fructose 6-phosphate by phosphofuctokinase 2, regulates the 
activity of phosphofuctokinase. Fructose 2,6-bisphosphate activates 
phosphofructoskinase by increasing the affinity for fructose 6-phosphate as well as 
decreasing the ATP inhibitory effect to phosphofructokinase. Meanwhile, as an important 
regulator in the glycolytic pathway, the concentration of fructose 2,6-bisphosphate is 
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tightly controlled by its phosphorylation status. Fructose 2,6-bisphosphate can be 
dephosphorylated by fructose bisphosphatase 2 (FBPase 2). Phosphofuctokinase 2 and 
FBPase 2 are in a single peptide chain as a bi-functional enzyme. This bi-functional 
enzyme has five isoforms presenting as tissue specific. Overexpression of fructose 2,6-
bisphosphatase decreases glycolysis flux and delays cell cycle progression (Perez, Roig 
et al. 2000). 
Hexokinase is the second control element for the glycolytic pathway and it 
phosphorylates glucose to phospholate-6-glucose in the first step of the glycolysis 
process. Hexokinase activity is inhibited by its catalytic product, phospholate-6-glucose. 
Under these circumstances in which cells have enough energy production or high sources 
for macromolecule biosynthesis, phospholate-6-glucose will pass these signals to 
decrease the glycolysis process. In livers hexokinase has another isozyme, glycokinase, 
whose affinity to glucose is 50 folds lower than that of hexokinase. The function of 
glycokinase in liver is to provide phospholate-6-glucose for glycogen synthesis as well as 
fatty acid synthesis.  
 
1.4 Pyruvate Kinase Type M2 
Pyruvate kinase (PK) is the third rate-limiting enzyme in glycolysis process. 
Pyruvate kinase catalyzes the transfer of phosphoryl group from phosphoenolpyruvate 
(PEP) to ADP to produce pyruvate and ATP (ΔG°’PEP=58 kJ/mol, ΔG°’ATP=29 
kJ/mol). This reaction is chemically irreversible. In mammalian cells, there are four types 
of pyruvate kinases in different tissues. L type is expressed exclusively in liver and R 
type is found in erythrocytes. M1 type is dominant in adult muscles tissues. M2 type is 
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expressed in fetal tissues and some proliferating tissues, such as tumor cells. During 
tumorigenesis, the tissue specific forms of PK, such as L and M1 types, lose their 
expression and M2 type is expressed (van Berkel, de Jonge et al. 1974; Miwa, 
Nakashima et al. 1975; Etiemble and Boivin 1976; Marie, Kahn et al. 1976). The L and R 
types are generated from one gene with different transcriptional start sites. M1 and M2 
types are isoforms derived from the same gene but are different due to alternative 
splicing (Saheki, Saheki et al. 1982; Noguchi, Inoue et al. 1986). The M gene consists of 
12 exons and 11 introns. In M2 type, exon 10 is spliced out, and in M1 type, exon 9 is 
spliced out. The splicing generates 23 different amino acids in a 56 stretch between M1 
and M2 types at the carboxyl terminal from 378-434. During tumorigenesis, M1 type 
expression is replaced by M2 type. The replacement of M1 type by M2 type changes the 
glycolysis rate to produce more phosphoryl intermediates for cell proliferation.  
The PKM2 protein consists of 531 amino acids and each monomer has four 
designated domains, such as A, B, C and N domains. Two monomers contact each other 
through the A domain interface to form a dimeric structure. Two dimers form a tetramer 
through the A and C domain interface (Dombrauckas, Santarsiero et al. 2005). The N-
domain consists of residues 1-43. The A domain, consisting of residues 44-116 and 219-
389, and is the core structure of the monomer. The B domain comprises residues 117-
218. The C-domain is made of residues 390-531. The active site of PKM2 is located in 
the cleft constructed by A and B domains. The FBP binding site for PKM2 is positioned 
at the C-domain. Lysine 433, Serine 434, Serine 437, and Glycine 520 residues are 
backbone amides that bond to the 6’-phosphate oxygens of FBP. Among these residues, 
Lysine 433 is important for the binding of FBP to PKM2 as well as for PKM2 binding to 
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Tyrosine phosphorylated peptides (Christofk, Vander Heiden et al. 2008; Christofk, 
Vander Heiden et al. 2008; Spoden, Morandell et al. 2009). Lysine 270 is a conserved 
site for all four types of pyruvate kinases and is crucial for its kinase activity 
(Dombrauckas, Santarsiero et al. 2005).  
In mammalian cells PKM2 has two known quaternary structures, dimeric and 
tetrameric forms. Tetrameric PKM2 has a higher affinity to its glycolysis substrate, PEP, 
compared to its dimeric form. In tumorigenesis, there is more dimeric PKM2 expressed 
with low affinity to PEP, which is called human tumor PKM2. The presence of dimeric 
PKM2 in patients feces, blood is utilized as a biomarker for the diagnosis of many 
cancers, such as colorectal cancer, prostate cancer and pancreatic cancer (Hardt, 
Ngoumou et al. 2000; Ahmed, Dew et al. 2007; Chung-Faye, Hayee et al. 2007; Dube, 
Grigull et al. 2007; Ewald, Schaller et al. 2007; Goonetilleke, Mason et al. 2007; Haug, 
Rothenbacher et al. 2007).  
The low affinity of tumor PKM2 (dimeric PKM2) to PEP decreases the glycolysis 
rate so as to produce more phosphor intermediates, which are used to synthesize lipids, 
amino acids and some other macromolecules for cell growth and proliferation. The 
quaternary structure of PKM2 is regulated by many factors, such as fructose 1, 6-
bisphosphorylate (FBP), Serine and some oncoproteins (Mazurek, Grimm et al. 2002). 
Fructose 1, 6-bisphosphate (FBP), a proceeding molecule in the glycolysis process, binds 
to PKM2 to induce its conformational change to the exposed active sites binding to PEP. 
The allosteric activity of PK is also regulated both by ATP and alanine, an important 
amino acid used in the building blocks for macromolecular synthesis. The activities of 
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PK are also controlled by reversible phosphorylation. Phosphorylated PK is less active 
than non-phosphorylated form.  
Tetrameric PKM2, not dimeric PKM2, is associated with many other glycolytic 
enzymes to perform its glycolytic function, such as hexokinase (HK), glyceraldehyde 3-P 
dehydrogenase (GAPDH), phosphoglycerate kinase, phoglyceromutatse (PGM), enolase 
and lactate dehydrogenase (LDH) (Mazurek, Hugo et al. 1996). However, the interaction 
of PKM2 with some other proteins in the cytosol may change its glycolytic activity. 
Some oncoproteins, such as pp60V-src kinase and HPV-16E7 proteins directly interact 
with PKM2, individually to help the conversion of dimeric forms from tetrameric form, 
which results in a decreased ATP/ADP ratio and upregulated FBP level in the cytosol 
(Zwerschke, Mazurek et al. 1999). On the other hand, some tumor suppressor proteins, 
such as promyelocytic leukemia (PML), also interact with tetrameric PKM2 to suppress 
its glycolytic activity (Shimada, Shinagawa et al. 2008). Interestingly, PKM2 is a 
phosphoTyrosine binding protein, and the binding of Tyrosine phosphorylated peptides 
to PKM2 decreases its enzymatic activity (Christofk, Vander Heiden et al. 2008). 
Moreover, it is reported that the cytosolic monomer of PKM2 binds to cytoplasmic 
thyroid hormone 3,3',5-triiodo-L-thyronine (T3) to regulate transcription activity of 
thyroid hormone receptors (Ashizawa and Cheng 1992).  
Besides its well-known glycolytic function in the cytosol, it is not known whether 
PKM2 have any other biological functions. Under the stimulation of interleukin 3 (IL-3), 
more PKM2 localizes to the nucleus to regulate cell proliferation in an IL-3-dependent 
hematopoietic cell line, Ba/F3 (Hoshino, Hirst et al. 2007). There are many reported 
nuclear partners of PKM2, such as Oct-4 and PIAS3. PKM2 interacts with Oct-4, an 
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important transcription factor for regulating the pluripotent state of embryonic stem cells, 
to positively modulate gene transcription (Lee, Kim et al. 2008). Interestingly, the N-
terminal (a.a.1–348) of PKM2, interacts with the SUMO-E3 ligase protein PIAS3 
(inhibitor of activated STAT3) in the nucleus of many cell lines, such as NIH3T3 and U-
2 OS (Spoden, Morandell et al. 2009). SUMO, the small ubiquiting modification, is a 
post-translational modification occurring at lysine residues in many proteins (Miller, 
Levy et al. 2005). Sumoylation modification changes protein properties including 
transcriptional activity, nuclear-cytosolic translocation as well as protein stability. For 
example, sumoylation of interferon regulatory factor-1 (IRF-1) induced by PIAS3, 
represses its transcriptional activity (Nakagawa and Yokosawa 2002). The transcriptional 
activity of microphthalmia transcription factor (MITF) is suppressed due to sumoylation, 
it is dependent on the targeting sequence in the promoter of TRPM1 (Miller, Levy et al. 
2005). PIAS, the protein inhibitor of activated STAT family, was originally identified as 
a cytokine-induced inhibitor of Stat3 and appears to have SUMO-E3 ligase activity 
(Chung, Liao et al. 1997; Nishida and Yasuda 2002). PIAS has several family members 
(PIAS1, PIAS2, PIAS3 PIAS3b, PIASxa, PIASxb, PIASy, and PIASyE6) sharing similar 
protein structures, such as the RING finger-like structure (Shuai and Liu 2005). PKM2 is 
sumoylated in U-2 OS cells affected by PIAS3, a human bone osteosarcoma. The 
overexpression of PIAS3 increases the sumoylation level of PKM2, which leads to the 
accumulation of nuclear PKM2 (Spoden, Morandell et al. 2009). According a SUMO 
prediction program and PKM2 X-ray structure analyses, there are eight lysine sites in 
PKM2 exposed on the protein surface possibly modified by PIAS3 (Spoden, Morandell et 
al. 2009).  
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On the other hand, somatosatin, a neuropeptide hormone and its anti-cancer 
analogues, TT-232, interact with pyruvate kinase in COS-7 cells. The interaction induces 
nuclear accumulation of PKM2 from cytosol to trigger caspase-independent apoptosis 
(Stetak, Veress et al. 2007). Moreover, UV and H2O2 also cause PKM2 nuclear 
accumulation independent of its kinase activity to induce apoptosis (Stetak, Veress et al. 
2007). PKM2 also has its function in regulating viral replication abilities. For example, 
PKM2 interacts with NS5B, the Hepatitis C virus (HCV) RNA-dependent RNA 
polymerase, in HCV replicon 9B cells (Wu, Zhou et al. 2008). The downregulation of 
PKM2 by shRNA in n HCV replicon 9B cells reduces the replication of HCV (Wu, Zhou 
et al. 2008).  
Besides its transcriptional regulatory activity, nuclear PKM2 also shows a kinase 
activity. It is reported that nuclear PKM2 isolated from Morris hepatoma 7777 tumor cell 
nuclei has kinase activity to phosphorylate histone H1 and it is speculated that PKM2 
transfers phosphate from PEP to the ε-amino group of L-lysine (Ignacak and Stachurska 
2003). 
 
1.5 p68 RNA Helicase 
p68 RNA helicase is a member of the DEAD box family proteins which share a 
conserved an Aspartic acid–Glutamic acid–Alanine–Aspartic acid (D-E-A-D) sequence  
motif (Hirling, Scheffner et al. 1989). There are many members in the DEAD family, 
such as p68, p72 and eIF-4a. All the members of the DEAD box family have a conserved 
amino acid motif, which includes the conserved DEAD box (Petry, Johnson et al. 1995; 
Shin, Rossow et al. 2007; Wilson and Giguere 2007). The conserved regions can be 
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found in many species, such as mouse, human, Escherichia coli, Drosophila and 
Saccharomyces cerevisiae (Jost, Schwarz et al. 1999). The DEAD box family proteins 
show RNA binding and unwinding activities through the conserved DEAD box amino 
acids sequence (Iggo and Lane 1989). DEAD box proteins have been shown to be 
involved in a wide range of biological processes involving interaction with specific RNA 
substrates; examples include pre-mRNA splicing, ribosome biogenesis, translation and 
embryogenesis (Stevenson, Hamilton et al. 1998).  
Many homologs of p68 RNA helicase have been discovered in chickens, yeast, 
frogs, human and mice. In humans, p68 RNA helicase is encoded by a single gene locus. 
The transcribed part of human p68 gene is ~6.7 kb long and is split into 13 exons. Human 
p68 RNA helicase was first identified as an antigen cross reacting with a monoclonal 
antibody to SV40 large-T antigen, which is a DNA dependent ATPase (Huang and Liu 
2002).  
P68 RNA helicase plays important roles in pre-mRNA splicing process (Huang and 
Liu 2002; Liu 2002). Pre-mRNA splicing is an accurate process, which requires four 
small nuclear ribonucleoprotein particles (snRNPs): U1, U2, U4/U6 and U5 as well as 
some other non-snRNPs proteins. U1 snRNP binds to the 5’ splicing site of pre-mRNA 
and U2 snRNP binds to the branch point. The spliceosome is formed when the U4/U6/U5 
triRNPs joins the intermediate spliceosome complex. The 5’ splice site is cleaved and the 
exposed 5’ end of the intron links to the branching site. Next, the 3’-OH end of the first 
exon adds to the 5’ end beginning site of the second exon. The whole intron between the 
two exons is cut off and released as a lariat and the two exons are jointed together to form 
a mature mRNA. p68 RNA helicase unwinds the transient U1-5’ splice site duplex during 
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the spliceosome assembly process. The ATPase and helicase activities of p68 are 
required for the dissociation of U1 snRNA from the 5’ slice site, which indicates that p68 
RNA helicase might play roles in unwinding U1 snRNA and 5’ splicing site complex. 
p68 RNA helicase might have functions in the formation of the spliceosome with the 
adding of U4/U6 and U5 snRNPs, which does not require the ATPase and helicase 
activities of p68 (Lin, Yang et al. 2005). As an RNA helicase, p68 is required for 
microRNA duplex unwinding, which is required for the unwinding of the transient RNA 
duplex to single stranded RNA, to take into the Argonaute protein to perform its 
silencing activity (Salzman, Shubert-Coleman et al. 2007). p68 RNA helicase plays 
important roles in early organ development and maturation. In mouse embryonic 
fibroblasts, the lack of p68 is related to the depression of many microRNAs (Salzman, 
Shubert-Coleman et al. 2007).  
In the nucleus, p68 RNA helicase interacts with many other proteins to regulate its 
gene transcription as a co-activator (Warner, Bhattacherjee et al. 2004; Fuller-Pace, 
Jacobs et al. 2007). p68 interacts with p53 through the C-terminal region of p53 to 
regulate p53 downstream targeting genes, such as p21, Fas, PIG3 and mdm2 (Bates, 
Nicol et al. 2005). p68 RNA helicase is reported to  be recruited to pS2 gene promoter, a 
downstream target of estrogen receptor alpha (ERα), to regulate its transcription 
(Watanabe, Yanagisawa et al. 2001). In these studies, neither the ATPase activity nor the 
RNA helicase activity of p68 is required for its co-activator function. p68 also interacts 
with CBP through the C-terminal of CBP to enhance CBP-mediated transcription 
(Rossow and Janknecht 2003). p68 RNA helicase interacts with Smad3, specifically the 
MH2 domains of Smad3, to form an active transcription regulator complex (Warner, 
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Bhattacherjee et al. 2004). Recently it is reported that p68 RNA helicase interacts with 
the androgen receptor (AR) in the nucleus and regulate gene transcription as a co-
activator for androgen-dependent and androgen-independent prostatic malignancy (Clark, 
Coulson et al. 2008).  
There are many post-translational modifications of p68 RNA helicase in 
mammalian cells, such as sumoylation, polyubiquitylation and phosphorylation. p68 was 
first reported to be polyubiquitylated in colorectal cells (Causevic, Hislop et al. 2001). 
Sumoylation is found at a single site of p68, Lysine 53, which is enhanced by PIAS1 
(protein inhibitor of activated STAT1) (Jacobs, Nicol et al. 2007). The sumoylated p68 
co-represses gene transcription through interacting with HDAC1 for p300 and Elk1 (Ets-
like kinase 1) (Jacobs, Nicol et al. 2007). Recombinant p68 RNA helicase purified from 
E.Coli, is phosphorylated at Serine, threonine and Tyrosine residues (Yang and Liu 
2004). In many cancer cells, p68 is phosphorylated at Tyrosine residues but not in their 
corresponding normal cell lines (Yang, Lin et al. 2005). p68 is phosphorylated at the 
Tyrosine 593 residue under the stimulation of PDGF-β in colorectal cells. The Tyrosine 
phosphorylated p68 blocks the phosphorylation of β-catenin by GSK-3β and displaces 
Axin from β-catenin distruction complex. The released β-catenine is shuttled into the 
nucleus by p68 RNA helicase which interacts with the LEF/TCF site to regulate gene 
expressions, which are required for EMT process (Yang, Lin et al. 2006). p68 is also 
double phosphorylated at Tyrosine 593 and Tyrosine 595 residues in T98G glioblastoma 
cells as well as  HeLa cells. The double phosphorylation of p68 facilitates its apoptosis 
resistance to some TRAIL-induced apoptosis. The double phosphorylation of p68 RNA 
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helicase protects T98G cells from caspase-8 activation to trigger apoptosis (Yang, Lin et 
al. 2007).   
Immunohistochemical examination shows p68 RNA helicase is dominantly 
localized in the nucleus in mammalian cells. p68 is detected in the cytosol depending on 
the cell cycle (Yang, Lin et al. 2007). Under the stimulation of growth factors, such as 
EGF, PDGF, some p68 comes out of the nucleus into the cytosol. According to the 
sequence analysis, there are many putative NES and NLS signals in p68. Two NES and 
two NLS functional signals are discovered in p68 RNA helicase sequence. Interestingly, 
the shuttling capability of p68 RNA helicase is not dependent on its ATPase activity. The 
nucleocytoplasmic shuttling function of p68 is CRM-1 dependent.   
 
1.6 MEK5 and MAP Kinase Pathway 
1.6.1 MAPK Family Members and Their Biological Functions 
The mitogen-activated protein kinase (MAPK) family is an important kinase 
family in mammalian cells, consisting of four subfamilies: extracellular-regulated protein 
kinase1 and 2 (ERK1/2), ERK5, c-jun NH2-terminal protein kinases (JNK), and p38 
MAPKs (Graves, Campbell et al. 1995; Seger and Krebs 1995; Attar, Atten et al. 1996; 
Hu and Plaxton 1996). The biological functions of MAPK pathways are diverse, playing 
roles in many cellular processes. In general, ERK subfamilies are related to cell growth, 
proliferation and survival, induced by growth factor stimulations. JNK and p38 MAPKs 
are associated with inflammation, apoptosis, cell growth and differentiation induced by 
cytokine stimulation, as well as extracellular stresses (Obata, Brown et al. 2000; 
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Hardwick, van den Brink et al. 2001; Papatsoris and Papavassiliou 2001; Saldeen, Lee et 
al. 2001).  
All the MAPK family members are activated by phosphorylation at Threonine and 
Tyrosine residues within the activation loop TxY of kinase subdomain VIII by diverse 
activators: mitogen-activated protein kinase kinase  (MEK1) and MEK2 for ERK1/2, 
MEK5 for ERK5, MKK4 and MKK7 for JNKs, MKK3 and MKK6 for p38 MAPKs 
(Graves, Campbell et al. 1995). The x in the TxY motif of the kinase subdomain VIII is 
diverse in MAPKs. For example, x is proline in JNK, glutamate in ERK, glycine in p38 
MAP kinases. MEKs are activated by an upstream activator, MEK kinase. There are 
many MEK kinases that activate MEKs: Raf-1, A-Raf, B-Raf, c-Raf, Mos, Tpl2 are for 
MEK1 and MEK2; MEKK1, MEKK2, MEKK3, Tpl2 are for MEK5; PAK is for MKK3 
and MKK6; MEKK4 and DLK are for MKK4 and MKK7. Cross-talk is always occurring 
among these MAPK signaling pathways. In addition, some activators are involved in 
more than one MAPK pathway. For example: the activators for MEK5 can also activate 
MEK1 and MEK2. In general, MAPK cascade members use docking interactions to 
regulate the efficiency and specificity between upstream activators and downstream 
substrates (Hu, Shen et al. 2007). In MAP2ks, such as MKK6, the docking domains are 
located at the N-terminal or C-terminal to bind its activator, MAP3Ks. The docking 
domain of MEK5, consisting of amino acids sequence, EYEDEDGD, is located in its N-
terminus which interacts with its upstream regulator, MEKK2 or its downstream 
substrate, ERK5 (Seyfried, Wang et al. 2005). For MAPKs, such as ERK2, the docking 
domain is located in both the N- and C-terminals. ERK2 has a CD domain (common 
domain) consisting of a group of negatively charged amino acids, which is located in the 
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C-terminal region just after its kinase domain. ERK2 also has a docking domain named 
the ED site, which is located at its N-terminal region in front of its kinase domain. 
MAPK substrates have docking domains for their regulation by MAPK. C-Jun has a D 
domain to interact with its activator, JNK. c-Fos has DEF (docking site for ERK or FX) 
domain in its C-terminal region to interact with ERK. Some ERK substrates have both D 
domain and DEF domain to interact with their activators, such as JNK and ERK. In 
addition, some MAPK cascades use scaffold proteins to assemble functional MAPK 
modules to increase the interaction specificity. For example, JIP-1, a scaffold protein in 
the JNK pathway, contains a D domain to bind JNK (Dickens, Rogers et al. 1997)  
On the other hand, the activation of MAPK is negatively controlled by MAPK 
phosphatase activity. Any dephosphorylation at either Threonine or Tyrosine residues in 
TxY motif inactivates MAPK. The dephosphorylation and inactivation process in the 
activation loop in MAPK last from minutes to hours depending on cell type and stimuli. 
Serine/Threonine protein phosphotases, such as PP2A, a member from the PPP family, 
inactivates ERKs. Members of Tyrosine protein phosphotase, such as PTP-SL, STEP, 
and HePTP, also dephosphorylate and inactivate ERKs. MAPK phosphatase plays 
important roles in diverse biological functions. For example, the JNK phosphatase 
family, the puckered mutation leads to cytoskeletal defects resulting in dorsal closure 
during Drosophola embryogensis. Interestingly, a subclass of the tyrosine phosphotase 
family called dual specificity phosphatase (DSP) dephosphorylate both tyrosine and 
threonine residues to inactivate MAPKs (Camps, Nichols et al. 2000). There are nine 
members identified in DSP family, such as CL100/MKP-1, PAC1, hVH-2/MKP-2, 
hVH3/B23, hVH-5, MKP-3/PYST1, B59, and MKP-5. PAC1, hVH-2/MKP-2, 
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hVH3/B23, hVH-5 are expressed exclusively in the nucleus and MKP-3/PYST1 is 
expressed in the cytosol. MKP-4 is expressed in both the cytosol and the nucleus.  
 
1.6.2 ERK5-MEK5 Signal Pathway  
Extracellular signal-regulated kinase 5 (ERK5), which is also named big-MAPK or 
BMK1, is one of the important MAPK family members, and it is activated through a 
cascade of signal transduction by MAP3Ks (MEKK2/3 and Cot), MEK5 and ERK5. 
ERK5 activation is exclusively activated by MEK5. The MEK5 signal pathway was first 
discovered in 1995 by Dixon and co-workers with a yeast two-hybrid screen experiment. 
ERK5 was used as the bait to interact with MEK5. ERK5-MEK5 signal pathway plays 
important roles in cell growth, cell differentiation, neuronal survival and embryonic 
angiogenesis (Sohn, Sarvis et al. 2002; Wang, Merritt et al. 2005). There are many 
transcription factors that can be phosphorylated by ERK5, such as c-Myc, MEF2 family 
members and c-Fos (Kamakura, Moriguchi et al. 1999) (Yang, Ornatsky et al. 1998). 
ERK5 has two splicing variants, ERK5 and ERK5b. ERK5b is shorter in the N-terminal 
compared with ERK5. ERK5b is a naturally dominant negative mutant which regulates 
ERK5 kinase activity. Overexpression of ERK5b inhibits ERK5b kinase function on 
nuclear substrate, such as MEF2C.  
The MEK5 gene codes a 444 amino acids protein, which has two splicing variants, 
MEK5a and MEK5b (English, Vanderbilt et al. 1995; Chao, Hayashi et al. 1999). 
MEK5a is a protein with 89 amino acids longer than MEK5b at the N-terminal.  
Both of MEK5a and MEK5b can individually interact with ERK5. Double 
phosphorylated MEK5a at Serine 311 and Threonine 315 activates ERK5 as well as its 
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nuclear translocation, but not MEK5b (Kato et al., 1997). MEK5a directly interacts and 
stimulates ERK5 kinase activity by phosphorylating threonine and Tyrosine residues in 
the TxY motif. On the other hand the overexpression of MEK5b disrupts the interaction 
of MEK5a with ERK5, which indicates MEK5b is a putative dominant negative mutant 
which regulates MEK5a kinase function to activate ERK5.  
The expression and cellular localization of MEK5a and MEK5b are tissue specific 
(English, Vanderbilt et al. 1995). MEK5a is localized dominantly in the cytosol and 
MEK5b is distributed evenly in the whole cell. MEK5a expression is abundant in actively 
mitotic tissues, such as liver and brain (English, Vanderbilt et al. 1995). MEK5b has 
more expression than MEK5a in differentiated tissues, such as muscle, lung, kidney et al.  
Many studies showed the expression of MEK5 is closely related with 
tumorigenesis. MEK5 is overexpressed in human prostate cancer cells as detected by 
antibodies that recognize the specific N-terminal of MEK5a (Mehta, Jenkins et al. 2003). 
Immunohistostaining results also show that MEK5 is overexpressed in human prostate 
cancer but not in benign prostate tissues (Mehta, Jenkins et al. 2003). Moreover, the 
expression level of MEK5 in malignant prostate cancer is correlated with its bone 
metastases (Mehta, Jenkins et al. 2003). Patients with higher expression of MEK5 had a 
shorter disease-specific survival time (52 months) compared to those with weaker MEK5 
expression which survived in 58 months. The activation of MEK5 induces prostate 
cancer cell proliferation. The overexpression of a constitutively active MEK5 mutant 
(MEK5D) in LNCaP cells, a metastatic prostatic adenocarcinoma cell line derived from 
the lymph node, induces a 3.7 fold higher cell proliferation compared to control vectors. 
In our experiments the expression of MEK5 is upregulated by PKM2 overexpression, 
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which results in cell proliferation, especially in more metastatic cancer cell lines 
compared to the less aggressive cell lines. Moreover, MEK5D overexpression in LNCaP 
cells increases cell migration by 1.8 fold and invasion ability by 2.1 fold compared to 
control vectors, which indicates that MEK5 plays a role in tumor metastasis as well as 
invasion. MEK5 is a putative modulator in regulating gene expression involved in tumor 
metastasis and migration processes. Matrix metalloproteinases 9 (MMP9), a zinc-
dependent enzyme involved in the metastasis process, is transcriptionally upregulated by 
MEK5 overexpression (Mehta, Jenkins et al. 2003).  
 
1.7 Stat Family and the Biological Function of Stat3 
Signal transducer and activator of transcriptions (Stat) is an important transcription 
factor family playing crucial roles in cell differentiation, proliferation, cell survival as 
well as other cellular activities (Johnston, Bacon et al. 1995; Ripperger, Fritz et al. 1995; 
DaSilva, Rui et al. 1996). Stat family proteins were first identified as a molecule required 
for interferon (IFN)-triggered gene expression around 15 years ago (Yang, Shi et al. 
1996). Stat is highly expressed in a large number of human malignant tumor cells, such 
as breast cancer, lung cancer, colorectal cancer and hematological malignancies. The Stat 
family consists of seven members, such as Stat1, Stat2, Stat3, Stat4, Stat5 (Stat5a, Stat5b) 
and Stat6. Stat1 and Stat2 were first identified as transcriptional factors binding to a 
consensus sequence TT(C/A)YNR(G/T)AA (Schindler, Shuai et al. 1992). Stat family 
members share a number of well conserved domains. The N-terminal domain is a binding 
region for some other transcription co-activators, such as CBP/p300, c-Jun, and Nmi 
(Giraud, Bienvenu et al. 2002; Cvijic, Bauer et al. 2009). In the middle of the sequence is 
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a DNA binding domain, which binds to cognate targeting DNA sequences. A flexible 
linker connects DNA binding domain with SH2 domain, which is required for the 
dimerization of Stat proteins as well as for Tyrosine phosphorylation binding. The C-
terminal region of Stat protein is a transactivation domain and the phosphorylation of 
Tyrosine/Serine residues at this domain is required for Stat protein activation.  
In general, Stat is a transcription factor family activated by phosphorylation 
through a cascade of signal transductions induced by interleukins or growth factors 
(Wen, Zhong et al. 1995). The Stat family of proteins is latent and inactive within the 
cytosol under normal conditions. Once ligands bind to the receptors on cellular 
membrane, autophosphorylation of the receptors is triggered, which induces the 
dimerization of these receptors. The dimerization of growth factor receptors activates 
their intrinsic Tyrosine phosphorylation activity. The phosphroylated receptors at 
Tyrosine residues subsequently create docking sites at their cytoplasmic tails for Stat 
proteins via their Src-homology (SH2) domain. Stat proteins binding to the 
phosphorylated receptors are phosphorylated by the receptors and form an activated 
form. In some cases the engagement of cytokines to their receptors results in the 
activation of these receptor-associated Tyrosine kinases, such as Janus kinase (JAK). 
Subsequently, JAK kinase phosphorylates Stat proteins at their C-terminals. The 
phosphorylated Stat proteins are released from the binding sites on the membrane and 
form homodimers or heterodimers. The dimerized Stat proteins then translocate into the 
nucleus and bind to promoter regions bearing conserved DNA sequences. Once bound, 
Stat proteins recruit other transcription elements at the promoter site to trigger gene 
transcription.  
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Stat family members can be activated by many cell-surface binding ligands 
involved in diverse signal pathways. Stat1 activation is induced by interferon signaling 
exclusively (Qing and Stark 2004; Ho and Ivashkiv 2006). Stat3 activation can be 
inducible by many cytokinses, such as interleukin-6 (IL-6) and growth factors, such as 
EGF, PDGF, VEGFR, FGFR and IGFR. In transformed cells, some oncoproteins, such as 
Src and Abl, can also activate Stat3 (Yu, Meyer et al. 1995). The activation of the Stat 
family requires Tyrosine phosphorylation at the C-terminal region, which is adjacent to 
its transcriptional activation domain. For example, Y705 in Stat3, Y694 in Stat5a and 
Y699 in Stat5b are the activation sites for these Stat family members. A phenylalanine 
substitution of the Tyrosine residue position at 705 of Stat3 results in a reduction in 
Tyrosine phosphorylation of wild type Stat3 and inhibits its endogeous activity (Kaptein, 
Paillard et al. 1996). Serine phosphorylation at the C-terminal of the Stat family is also 
important for regulating their transcriptional activity. For example, phosphorylation at 
Serine 727 in Stat3 and Stat1 upregulates their transcriptional activity mediated by 
several kinases, such as p38，JNK and protein kinase C (Nagy, Wang et al. 2002) 
(Wierenga, Vogelzang et al. 2003) (Pircher, Petersen et al. 1999). On the contrary, Serine 
phosphorylation at residue 725 in Stat5 down-regulates the transcriptional activity of 
Stat5 (Yamashita, Nevalainen et al. 2001)  (Yamashita, Xu et al. 1998) . 
An important Stat family member is Stat3, whose activity is tightly controlled 
under diverse physiological conditions. Stat3 is activated/phosphorylated in a low level 
in normal cells, which is negatively regulated by many inhibitory proteins including 
Suppressor of Cytokine Signalling (SOCS) and Protein Inhibitor of Activated Stat (PIAS) 
(Flowers, Subramaniam et al. 2005; Tokumaru, Sayama et al. 2005; Diao, Wang et al. 
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2009). It is reported that PIAS3 specificly interacts with Stat3, not other members of Stat 
family. The interaction blocks Stat3 DNA binding activity to inhibit its gene 
transcriptional regulatory activity in many cell lines, such as HepG2 cells, IL-6-treated 
M1 and MCF7 cells (Chung, Liao et al. 1997). Some protein Tyrosine phosphatases, such 
as PTP1B, SHP1, SHP2, CD45 are reported to inhibit the Stat3 pathway as well (Ohtani, 
Ishihara et al. 2000; Zhang, Chan et al. 2009). In cancer cells, such as breast cancer, head 
and neck cancer, prostate cancer, Stat3 is detected with high levels of expression and 
activation (Bromberg, Wrzeszczynska et al. 1999) (Yu and Jove 2004). Activated Stat3 is 
sufficient to mediate tumor formation in nude mice (Bromberg, Wrzeszczynska et al. 
1999). A constitutively active Stat3 mutant transfected in melanoma cells, enhances its 
brain metastasis (Xie, Huang et al. 2006). Phosphorylated Stat3 activates many genes 
related to cell proliferation and differentiation as well as anti-apoptosis, such as c-Myc, 
Cyclin D1, BCL2 family gene Bcl-XL (Nielsen, Kaestel et al. 1999) (Bienvenu, Gascan 
et al. 2001), (Song, Ethier et al. 2004). Stat3 also induces the gene expression of HIF-1, 
MMP-2 and VEGF to promote tumor metastasis and angiogenesis (Niu, Wright et al. 
2002).  
Moreover, Stat3 plays important roles as a cross-talker in regulating the activities 
between tumor cells and tumor immune microenvironments by suppressing immune 
responses from both tumor cells and immune cells (Cheng, Wang et al. 2003; 
Kortylewski and Yu 2008). In tumor cells, the overexpression of Stat3 inhibits the release 
of immuno-stimulating molecules so that the tumor cells can prevent the infiltration of 
immune cells. For example, the overexpression of a Stat3 dominant negative mutant in 
B16 melanoma, greatly enhances the release of pro-inflammatory mediators to promote 
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the infiltration of immune cells to B16 melanoma (Wang, Niu et al. 2004). Moreover, the 
releasing of pro-inflammatory mediators blocked by phosphorylated Stat3 stimulates the 
activation of innate immune response cells, such as neutrophils and macrophages (Wang, 
Niu et al. 2004). Activated Stat3 not only inhibits the release of pro-inflammatory 
mediators from tumor cells, but also prohibits the expression of pro-inflammatory 
mediators in normal immune cells. For example, the inhibition of Stat3 expression in 
macrophages results in a high level release of pro-inflammatory mediators found in 
Stat3-inactiated tumor cells (Takeda, Clausen et al. 1999). 
Stat3 is a important mediator playing roles in multiple oncogenic signaling 
pathways to regulate tumorigenesis as well as immunosuppressive pathways (Yu, 
Kortylewski et al. 2007). Stat3 has been identified as a potential target for cancer 
immuno-therapy (Zhang, Zhang et al. 2007; Zhou, Wulfkuhle et al. 2007; Al Zaid 
Siddiquee and Turkson 2008). The suppression of Stat3 activities in tumor cells induces 
cell apoptosis, decreases tumor cell proliferation, and inhibits tumor cell migration 
(Grandis, Drenning et al. 2000; Epling-Burnette, Liu et al. 2001; Wang, Ouyang et al. 
2008; Baral, Bose et al. 2009; Xin, Zhang et al. 2009; Yagil, Kay et al. 2009). Disruption 
of Stat3 activity blocks VEGF expression, a key mediator for solid tumor angiogenesis 
(Wei, Kuo et al. 2003). The interruption of the Stat3 signaling pathway activates the 
expression of IP-10 and IFN-β, both of which are inhibitors of solid tumor angiogenesis 
during malignant process (Niu, Heller et al. 1999; Niu, Bowman et al. 2002). Some Stat3 
inhibitors, such as phosphopeptide and platinum (IV) complexes, have been proven to 
inhibit Stat3 signaling so as to deregulate Stat3-dependent malignant transformation and 
cell proliferation, and induce apoptosis of cancer cells (Turkson, Ryan et al. 2001; 
  35
Turkson, Zhang et al. 2005). The suppression of Stat3 activities in many immune cells 
decreases the release of negative immune regulators such as immature dendritic cells. 
The suppression of Stat3 activities also increases the activity of CD8+ T cells, natural 
killer cells as well as neutrophils. 
Stat3 is located in diverse cellular compartments dependent on its phosphorylation 
status, such as the cytosol and the nucleus. Non-phosphorylated Stat3 shuttles between 
the nucleus and the cytosol depending on its own NLS and NES. Stat3 binds to α/β 
importin to translocate into the nucleus, and binds to CRM1 to export from the nucleus 
(Sato, Tsuruma et al. 2005). Once phosphorylated by its upstream activators, Stat3 is 
retained in the nucleus, binding to its target DNA sequence to start regulating gene 
transcription by recruiting other transcriptional factors. Recently, it is reported that Stat3 
exists in mitochondria where it interacts with GRIM-19 in complex 1 and 2 to regulate 
cell respiration (Wegrzyn, Potla et al. 2009). The functional role of Stat3 in regulating 
energy production in the oxidative phosphorylation pathway is independent of its 
transcriptional function. Moreover, unlike its transcription role in the nucleus, DNA 
binding domain, the dimerization motif or Tyrosine phosphorylation at 705, are not 
required for its mitochondrial function. Interestingly, phosphorylation at Serine 727 is 
crucial for Stat3 oxidative phosphorylation regulatory function, which indicates the 
possible involvement of either growth factor triggered phosphorylation signal pathways 
or non-receptor protein kinase induced phosphorylation pathways (Wegrzyn, Potla et al. 
2009).  
 
1.8 Cdc14 Regulates Mitosis Exit in Eukaryotic Cells 
  36
Cyclin Dependent Kinases (CDKs) play important roles in regulating the entry 
from interphase to mitosis. For cells to exit from mitosis, CDKs must be degraded or be 
dephosphorylated to inhibit their functions. How cells exit from mitosis has been well 
characterized in the budding yeast, Saccharomyces cerevisiae (Jensen and Johnston 
2002). In Saccharomyces cerevisiae, cells exit from mitosis is regulated by a cascade of 
reactions named Cdc Fourteen Early Anaphase Release (FEAR) and Mitosis exit network 
(MEN). MEN are a group of proteins that can inactivate mitotic cyclin-dependent kinases 
including Tem1p, Lte1p, Cdc5p, Cdc15p, Dbf2p, and Dbf20p, and Mob1p (McCollum 
and Gould 2001). In anaphase, MEN activated by a small G protein, Tem1, induces the 
export of Cdc14, which is located in the nucleolus held by inhibitors Cfi1/Net1 during 
interphase, from the nucleolus into cytoplasm. Cdc14 is a Serine/Threonin phoshpatase. 
In Saccharomyces cerevisiae, Cdc14 antagonize the effect of Cdc28/Clb, a key regulatory 
kinase for cell cycle in yeast, to regulate cell cycle. Cdc14 dephosphorylates several 
downstream targets of Cdc28/Clb, such as Hct1, Sic1 and Swi5, to regulate cell cycle. 
(Toyn, Johnson et al. 1997). The dephosphorylation of Hct1 results in cyclin B 
degradation. The dephosphorylation of Swi5, a transcription factor, by Cdc14 results in 
the nuclear accumulation of Swi5. Cdc14 also mediates dephosphorylation of Sic1, an 
inhibitor of Cdc28/clb, results in the accumulation of Cdc28/clb (Verma, Feldman et al. 
1997) 
In fission yeast, Saccharomyces pombe, Cdc14 has a homologous, Flp1/Clp1, 
which has a distinct functions in cell cycle regulation from Cdc14 in Saccharomyces 
cerevisiae. Flp1/Clp1 is not an essential gene in fission yeast and regulates G2 phase of 
the cell cycle.    
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In higher eukaryotes, two types of anaphase promoting complexes (APC), a large 
ubiquitin ligase, must be activated for cells to exit from anaphase. APC and their co-
effectors, such as Cdc20 and Cdh1, form a complex, such as APCCdc20 and APCCdh1. 
During G2/M phase, APCcdc20 is activated to ubiquitnate securin so that separase was 
released into the cytosol to promote sister-chromatid separation. APCcdh1 is activated 
during M/G1 phase and APCCdh1 ubiqutinates mitotic cyclins to allow cells to exit from 
mitosis. The activity of APC relies on the phosphorylation status of their co-effectors, 
Cdc20 and Cdh1. Cdh1 is phosphorylated by cyclin B-cdc2 and dephosphorylated by 
Cdc14A. In addition, Cdc14A is the major phosphatase for Cdh1 (Bembenek and Yu 
2001).  
In mammalian cells, Cdc14 has two orthologs Cdc14A and Cdc14B, encoding by 
two distinct genes. Cdc14A and Cdc14B share a conserved amino acid sequences over 
80% in their N-terminal and phosphatase domain. Cdc14A and Cdc14B have distinct 
dynamic cellular localizations spatiotemporally. Cdc14A resides in centrosome in 
interphase and Cdc14B locates in nucleolus. During mitosis Cdc14A is released into the 
cytoplasm. Cdc14A was interacted with MTOC in the cytosol.  
In human, Cdc14A gene is located on chromosome 1 on the band 1p21 and 
consists of 16 exons. The expression of Cdc14A is tightly controlled during cell cycle. 
The expression of Cdc14B is even during whole cell cycle. Cdc14A is highly expressed 
in brain, heart, small intestine and skeletal muscle. And has a low expression level in 
kidney, liver, lung, testis and pancreas (Paulsen, Starks et al. 2006). The expression of 
Cdc14A is quite differentially in cancer cells, even within the same specific tumor type.  
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In mammalian cells, Cdc14A has several putative downstream targets. Cdc14A 
interacts with tumor suppressor p53 both in vitro and in vivo. The interaction is 
dependent on the N-terminal of Cdc14A and the C-terminal of p53. The phosphorylation 
site of p53, Ser315, is specifically dephosphorylated by Cdc14A. The other 
phosphorylation site in p53, such as Ser392, is not dephosphorylated by Cdc14A. The 
phosphorylaion of p53 protein at Ser315 is related to its DNA binding activity (Li, 
Ljungman et al. 2000).  
As two isoforms, Cdc14A and Cdc14B have distinct functions in regulation 
centrosome duplication. Studies show that Cdc14A overexpression induce multinucleus 
in mammalian cells. The depletion of Cdc14A results in centrosome separation and 
cytokinesis failure (Mailand, Lukas et al. 2002). On the other hand, the depletion of 
Cdc14B results in amplification of centriole (Wu, Cho et al. 2008).  
As an important physiological regulator, the expression of either Cdc14A or 
Cdc14B affects genomic stability (Mailand, Lukas et al. 2002). So far, the mechanism of 
Cdc14A gene transcription regulation is not well defined.  
 
1.9 Aims of Dissertation  
Aerobic glycolysis is been established as a hallmark for cancer progression, which 
is well known as Warburg effect. In 1924 Otto Warburg hypothesized that cancer is 
caused by the metabolism switch from oxidative phosphorylation to glycolysis (Warburg 
1956; Warburg 1956). With the development of modern oncology and the discovery of 
many oncogenes and tumor suppressor genes, cancer is gradually recognized as a genetic 
disease and the metabolism change in cancer cells is a company phenomenon of 
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tumorigenesis. Many oncogenes as well as tumor suppressor genes results in the 
metabolism switch from oxdative phosphorylation to glycolysis by regulating metabolic 
enzymes activities, such as Ras, Akt and Myc (Gordan, Thompson et al. 2007). However, 
how glycolysis enzymes directly regulate tumorigenesis is not well studied. In this 
project, we found that a glycolytic enzyme, pyruvate kinase M2 (PKM2), plays an 
important role as a transcriptional co-activitor in regulating cell proliferation in the 
nucleus of cancer cells. PKM2 phosphorylates its downstream target, Stat3, using PEP as 
a substrate. Morover, phosphorylated p68 RNA helicase Y593/595 interacts with PKM2 
to shuttle cytosolic PKM2 into the nucleus. In addition, the interaction between 
phosphorylated p68 RNA heliase and PKM2 transforms a tetrameric PKM2 into a 
dimeric form under the stimulation of EGF. Nuclear PKM2 and p68 RNA helicase co-
regulates Cdc14A gene transcription to induce multinucleus in less aggressive cancer 
cells. Overall, this study provides evidences about how glycolytic enzymes affect 
tumorigenesis, which brings centain levels of explanations about why cancer cells prefer 
to glycolysis for Warburg effect.  
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CHAPTER 2 
PYRUVATE KINASE M2 PROMOTES CELL PROLIFERATION BY 
REGULATING GENE TRANSCRIPTION 
 
2.1 Abstract 
Alterations in metabolism may play a critical role in the transformation to 
malignancy during tumor progression. However, the ways by which the metabolism 
alterations affect tumor progression are not well understood. Here, we show that PKM2, 
a glycolysis enzyme, localizes to the cell nucleus. The nuclear PKM2 levels correlate 
with cell proliferation rates. Expression of PKM2 promotes cell proliferation. Nuclear 
PKM2 promotes cell proliferation by upregulating transcription of MEK5, a MAP kinase 
associated with cell proliferation. PKM2 regulates the MEK5 transcription by promoting 
stat3 phosphorylation at Y705 and facilitating stat3 binding to MEK5 promoter. Our 
studies reveal an important molecular link that connects metabolic alterations with gene 
expressions during tumor progression.  
 
2.2 Introduction 
Most cancer cells utilize aerobic pathways for glucose metabolism. Upon tumor 
progression, the oxidative phosphorylation in mitochondria is usually dramatically 
reduced even in the presence of oxygen (Warburg effects) (Warburg, 1956). Although it 
is still debatable whether the metabolic alteration is just a symptom of cell transformation 
or a causative factor in tumorigenesis, the evidence suggests that metabolic adjustments 
by tumor cells are necessary processes for tumorigenesis and tumor progression 
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(Deberardinis et al., 2008; Garber, 2006). It is generally believed that oncogenic products 
regulate the metabolic pathways (Matoba et al., 2006). Expression of oncogenes can 
result in substantial changes in composition of metabolism isoenzymes that regulate the 
flows of metabolites (Dang & Lewis, 1997; Elstrom et al., 2004; Semenza, 2007). 
However, it is not well understood whether, and how, metabolic changes during tumor 
progression will produce a feedback effect on cell proliferation. An important molecular 
signature of tumor development and progression is a shift in expression of pyruvate 
kinase isoenzymes. The tissue specific isoform (L, R, or M1) disappears and is replaced 
by pyruvate kinase isoenzyme type M2 (PKM2) in cancer cells (Elbers et al., 1991; 
Hacker et al., 1998). The glycolysis catalytically active PKM2 exists as a tetramer and 
associates with a glycolytic enzyme complex in normal cells (Altenberg & Greulich, 
2004; Dombrauckas et al., 2005; Zwerschke et al., 1999). In tumor cells, it is believed 
that PKM2 dominantly forms a dimer, and appears to be catalytically inactive for 
conversion of PEP to pyruvate (Ashizawa et al., 1991; Mazurek et al., 2005). The 
inactive PKM2 actually provides an advantage for metabolism as it helps to channel the 
carbon source from glycolytic intermediates to biosynthesis, especially syntheses of 
nucleic acids, lipids, and proteins, to meet the demands for tumor cell proliferation. 
Recent studies have suggested that PKM2 changes its catalytic activity, consequently 
facilitating cell proliferation by binding to tyrosine phosphor-proteins (Christofk et al., 
2008a; Christofk et al., 2008b). The observations suggest that growth signals regulate the 
flow of carbon sources from glucose.  
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2.3 Results 
2.3.1 Nuclear PKM2 Levels Correlate with Tumor Progression and Expression of 
PKM2 Promotes Cell Proliferation 
PKM2 is an enzyme that catalyzes the last step of glycolysis converting PEP to 
pyruvate. Several independent studies have revealed that the protein may localize to the 
cell nucleus (Hoshino et al., 2007; Schneider et al., 2002; Stetak et al., 2007). We further 
verified the nuclear localization of PKM2 in different cancer cells by immunostaining 
using antibody raised against a peptide spanning aa 399 – 412 of PKM2 (PabPKM2) (Fig. 
S1A). To understand the functional significance of nuclear localization of PKM2, we 
examined nuclear PKM2 levels in ten different cancer cell lines by immunoblot of 
nuclear extracts and whole cell lysates using the antibody PabPKM2. These ten different 
cell lines represented different cancer progression stages and are derived from cancers of 
different organs/tissue types. SW480 and SW620 are colon cancer cell lines derived from 
the same cancer patient. LN686 is a head-neck squamous cell carcinoma cell line while 
the M4C1 is derived from LN686 by selecting high metastatic and high proliferation sub-
lines in nude mice (Zhang et al., 2002). WM115 and WM266 are melanoma cell lines 
from the same patient. T98G and U87MG are cell lines of glioblastoma. H146 and H460 
are cell lines derived from lung cancer patients. Cell proliferation analyses demonstrated 
that M4C1, SW620, WM266, and H460 are more proliferated than their corresponding 
lines in the matched pairs (Fig. 2.1A). Immunoblot analyses indicated much higher 
nuclear levels of PKM2 in the more proliferated cancer cells than those in the 
corresponding less proliferated cells (Fig. 2.1B), The higher nuclear PKM2 levels were 
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not attributed to differences in PKM2 expression levels in different cells, as shown in 
figure 1B whereas no significant differences were observed in total PKM2 in cell lysates 
in all test cells. The detection of PKM2 in the nuclear extracts was not due to 
contamination of cytoplasmic proteins as demonstrated by lack of GAPDH in the 
immunoblot analyses of the nuclear extracts. 
We next investigated the effects of expression of PKM2 on cell proliferation with these 
ten different cell lines. HA-PKM2 was exogenously expressed in the cells using a 
commercially available Adeno-viral expression system. Quantization of PKM2 before 
and after exogenous expression revealed an approximately ~30% increase in cellular 
levels of PKM2 (Fig. 2.7 B). No significant differences in expression of HA-PKM2 were 
observed among the different cells (Fig. 2.1C). The expressed HA-PKM2 was distributed 
similarly to the endogenous PKM2 between the nucleus and the cytoplasm, as shown by 
immunoblot analyses using anti-HA antibody (Fig. 2.7C). It was evident that all cells that 
exogenously expressed HA-PKM2 experienced some degree of cell proliferation, with 
more proliferated cancer cells experiencing a higher proliferation rate increase than those 
of corresponding less proliferated cancer cells (Fig. 2.1D). The results suggested that 
expression of PKM2 promoted cell proliferation. To further test the role of PKM2 in 
promoting cell proliferation, we used a smartpool RNAi to knock down PKM2 in SW620 
and SW480 cells (Fig. 2.1E). The cell growth rate of the more proliferated SW620 was 
dramatically reduced by PKM2 knockdown, while the growth rate of the less proliferated 
SW480 cells was moderately reduced by PKM2 knockdown (Fig. 2.1E). Similar results 
were also observed with the pair of melanoma cell lines (WM115/WM266, Fig 2.1E). 
Thus, both PKM2 expression and knockdown experiments indicated that PKM2 plays a 
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role in promoting cell proliferation with stronger effects on the more proliferated cancer 
cells. The effects of expression of PKM2 in different cancer cells on cell proliferation 
correlated very well with nuclear levels of PKM2 in different cancer cells. 
 
2.3.2 PKM2 Activates Transcription of MEK5 
The observations that the nuclear PKM2 levels completely correlated with the cell 
proliferation and that the expression of HA-PKM2 promoted cell proliferation led us to 
believe that nuclear PKM2 plays an important role in promoting cell proliferation by 
action other than that in the glycolysis. One possibility is that nuclear PKM2 is involved 
in regulation of gene expressions. To explore this possibility, we carried out gene 
expression array analyses with SW620 cells that exogenously expressed HA-PKM2. 
Expressions of 350 genes were upregulated, and expressions of 359 genes were 
downregulated, by at least two fold under the expression of HA-PKM2 (Table S1). 
Among those affected genes, expression of MEK5 (also named MAP2K5), a MAP kinase 
closely associated with cell proliferation, was affected by over seven fold. The expression 
array analyses indicated that nuclear PKM2 may function as a regulator for gene 
transcription. Expression and activation of MEK5 plays a very important role in cell 
proliferation (Diaz-Meco & Moscat, 2001). Expression and activation of MEK5 have 
also been shown to closely associate with cancer progression, including prostate cancer 
and breast cancer (McCracken et al., 2008; Mehta et al., 2003; Song et al., 2004). Thus, 
we reasoned that upregulation of MEK5 may mediate, at least partially, the effects of 
nuclear PKM2 on promoting cell proliferation. To test this conjecture, we first verified 
the effects of expression of PKM2 on the expression of MEK5 by RT-PCR. Consistent 
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with the gene expression array analyses, RTPCR demonstrated a marginal increase in 
MEK5 expression in SW480 cells following the expression of PKM2. However, the 
changes in the MEK5 expression in SW620 cells were much more dramatic (Fig. 2.2A). 
Similar patterns were also observed with another pair of cell lines, WM115 and WM266. 
The effects on the expressions of MEK5 by the expression of PKM2 were further 
confirmed by immunoblot analyses of cellular MEK5. It was clear that the cellular 
MEK5 levels increased subsequent to expression of PKM2. The more aggressive cancer 
cells experienced more dramatic increases in MEK5 levels upon expression of PKM2 
(Fig. 2.2B). Interestingly, immunoblot of MEK5 using antibody against the 
phosphorylated MEK5 revealed a strong increase in the cellular levels of phosphorylated 
MEK5 (activated MEK5) in aggressive cancer cells compared to the less aggressive 
cancer cells upon exogenous expression of PKM2 (Fig. 2.2B). To further verify the role 
of PKM2 in transcriptional regulation of MEK5 gene, PKM2 was knocked down in 
SW620 and SW480 cells. Immunoblot analyses showed an approximately 80% PKM2 
knockdown efficiency (Fig. 2.2C). It was evident that MEK5 expression was slightly 
reduced in SW480. However, the reduction in cellular levels of MEK5 in SW620 cells 
was dramatic upon knockdown of PKM2 (Fig. 2.2C). Again, the phosphorylated MEK5 
experienced a sharp reduction in SW620 upon PKM2 knockdown, which was not 
observed in SW480 cells (Fig. 2.2C). We also analyzed the MEK5 mRNA levels in 
SW620 and WM266 cells upon PKM2 knockdown. Quantitative RT-PCR analyses 
demonstrated a strong reduction in cellular MEK5 mRNA in both PKM2 knockdown 
SW620 and WM266 cells (Fig. 2.2D). Thus, it is clear that PKM2 regulates the 
expression of MEK5. Expression of PKM2 appeared to also regulate MEK5 activation in 
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the more aggressive cancer cells. We further probed whether PKM2 regulates the 
transcription of the MEK5 gene directly, or if the regulatory effects were mediated 
through other cellular factor(s). To this end, we examined whether PKM2 interacted with 
the MEK5 promoter by chromatin immunoprecipitation (ChIP). We carried out the ChIP 
experiments with SW620 cells using the PCR primer pair that spanned the region of nt –
1,621 – -1,366 of MEK5 promoter. Our ChIP assays clearly demonstrated that PKM2 
indeed interacted with the MEK5 promoter (Fig. 2.2E), indicating that PKM2 most likely 
regulates the transcription of the MEK5 gene directly. The preceding experiments 
suggested that PKM2 plays an active role in regulating the transcription of the MEK5 
gene. We next sought to test whether up-regulation of MEK5 by PKM2 contributed to 
cell proliferation. We first knocked down MEK5 by RNAi in SW620 and WM266 cells. 
As a result, the cell proliferation rate was dramatically reduced (Fig. 2.3A). The 
proliferation rate increases stimulated by expression of HA-PKM2 in MEK5 knockdown 
SW620 and WM266 cells were also largely reduced (Fig. 2.3A), suggesting that up-
regulation of MEK5, at least partially, mediated the effects of HA-PKM2 overexpression 
on cell proliferation. Moreover, we analyzed the MEK5 expression levels and 
phosphorylation status in these ten different cancer cell lines. MEK5 was expressed in all 
ten cell lines, but there were substantially higher levels of MEK5 in the more proliferated 
cancer cells than in the less proliferated cancer cells. Strikingly, the levels of 
phosphorylated MEK5 were also consistently higher in more proliferated cancer cells 
than in less proliferated cancer cells (Fig. 2.3B). Clearly, there is a close correlation 
between cellular MEK5 expression levels, the MEK5 phosphorylation levels and nuclear 
PKM2 levels, and all were correlated closely with the cell proliferation status of the cells 
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(comparing Fig. 2.3B with Fig. 2.1B). We concluded from these studies that up-
regulation and activation of MEK5 by nuclear PKM2 contributed to cell proliferation. 
 
2.3.3 PKM2 Upregulates MEK5 Transcription by Activation of Stat3 
In searching for the proteins (possibly transcription factor) that may interact with 
nuclear PKM2, we noted that stat3 regulates transcription of MEK5 gene and the protein 
interacts with MEK5 promoter at -1776 nt – -1520 nt region by the ChIP assay (Song et 
al., 2004). Interestingly, PKM2 also interacts with MEK5 promoter at the same region by 
ChIP assay (Fig. 2.2E). Thus, we wondered whether PKM2 would interact with stat3 in 
the cell nucleus. To probe the interaction between PKM2 and stat3, we carried out co-
immunoprecipitation with nuclear extracts made from SW620 and SW480 cells. Clearly, 
stat3 co-precipitated with PKM2. As a control, stat3 was not precipitated using rabbit 
IgG as IP antibody (Fig. 2.3C). Consistent with our previous observations, there were 
substantially less PKM2 and stat3 co-immunoprecipitation in the nuclear extracts 
prepared from SW480 than in the extracts made from SW620 cells. The 
coimmunoprecipitation was also carried out using reversed IP and IB antibodies, and 
with exogenously expressed HA-PKM2 (Fig. 2.8 A&B). These co-immunoprecipitation 
experiments indicated that PKM2 indeed interacted with stat3 in the nuclear extracts. We 
next tested whether the activation of stat3 was required for the effects of PKM2 on 
upregulation of MEK5 transcription. To this end, we first knocked down stat3 using 
RNAi in SW620/SW480 and WM266/WM115 cells and subsequently HA-PKM2 was 
expressed in the stat3 knockdown cells. It was clear that expression of HA-PKM2 could 
no longer upregulate MEK5 gene transcription as measured by cellular levels of both 
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mRNA and protein of MEK5 (Fig. 2.4 A&B, C&D). To further test the role of stat3 in 
mediating the effects of PKM2 on upregulation of MEK5 transcription, we used a 
dominate-negative mutant stat3 (Y705F) (Xie et al., 2006). The wild-type or dominate 
negative mutant was co-expressed with HA-PKM2 in SW620/SW480 and 
WM266/WM115 cells. Expression of MEK5 in both mRNA and protein levels was 
examined. It was evident that expression of dominate-negative stat3 mutant largely 
diminished the effects of PKM2 on upregulating MEK5 transcription (Fig. 2.8 C&D, 
E&F). It is well documented that the activity of the active stat3 can be inhibited by 
specific inhibitor (Xu et al., 2008). We therefore tested the effects of a stat3 inhibitor on 
the upregulation of MEK5 by expression of HA-PKM2 in SW620 and WM266 cells. 
Treatment of the HA-PKM2 expressing cells with the inhibitor resulted in a decrease in 
MEK5 transcription (Fig. 2.8 G&H). Thus, we concluded that activation of stat3 
mediated the regulatory effects of PKM2 on MEK5 transcription. 
We further investigated whether expression of PKM2 affected the stat3 binding to 
its target DNA at the MEK5 promoter. We first carried out ChIP analyses with SW620 
cells using the PCR primer pair span the region -1621 nt - -1366 nt. Our ChIP assays 
showed that interaction of stat3 with the MEK5 promoter can be detected by this PCR 
primer pair (Fig. 2.9A). To probe whether knockdown or expression of PKM2 affected 
the interaction of stat3 with the MEK5 promoter, we performed ChIP experiments in 
SW620 cells in which the endogenous PKM2 was knocked down or HA-PKM2 was 
expressed. Clearly, the stat3 and MEK5 promoter interaction was strengthened by HA-
PKM2 expression and was weakened by PKM2 knockdown (Fig. 2.5A). To further 
analyze the effects of PKM2 on the interaction between stat3 and its target DNA, we 
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carried out gel mobility shift assays using a 32P-labled oligonucleotide duplex containing 
a stat3 binding sequence (Xie et al., 2006). The gel-shift experiments were carried out 
with nuclear extracts made from SW620 cells with/without PKM2 knockdown or 
with/without HA-PKM2 expression. Autoradiography indicated that a slow migration 
complex was assembled with the labeled oligonucleotide and addition of the antibody 
against stat3 or PKM2 resulted in a supershift complex (Fig. 2.5B). The supershift 
complexes clearly indicated the coexistence of both PKM2 and stat3 in the assembled 
oligo-protein complex. Interestingly, knockdown of PKM2 substantially decreased the 
assembly of the oligo-protein complex and assembly of stat3 in the complex (the weak 
supershift) (Fig. 2.5D), while expression of HA-PKM2 dramatically increased assembled 
complex and assembly of both stat3 and PKM2 in the complex (Fig. 2.5C). The gelshift 
and supershift experiments suggested that PKM2 and stat3 might participate in 
transcription complex at the same stat3 DNA binding site, and PKM2 facilitated stat3 
binding to its target DNA sequence. To further test this notion, we carried out ChIP/Re-
ChIP experiments with the MEK5 promoter using antibody against stat3 and the antibody 
PabPKM2. The ChIP/Re-ChIP experiment clearly indicated that both PKM2 and stat3 
interacted simultaneously with MEK5 promoter at the region of -1621 – -1366 nt (Fig. 
2.5E). Stat3 is a transcription activator that is activated by phosphorylation at Y705 
mainly by JAK or Src kinase. The phosphorylation increased the stat3 and DNA binding 
affinity (Sehgal, 2008). We observed the interaction between stat3 and PKM2 in the cell 
nucleus and PKM2 increased the stat3 binding to its target sequence both in vitro and in 
vivo. We suspected that PKM2 may play a role in stat3 phosphorylation at Y705. To test 
this conjecture, we analyzed the stat3 phosphorylation in SW620 cells in which the HA-
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PKM2 was exogenously expressed. The phosphorylation of stat3 at Y705 in the nuclear 
extracts was examined by immunoblot using antibody against the Y705 phosphorylated 
stat3. Clearly, a significant increase in Y705 phosphorylation of stat3 in the nuclear 
extracts was evident by the immunoblot, upon expression of HA-PKM2 in the cells. 
Examination of the cellular levels of stat3 by immunoblot indicated that the expression 
levels of stat3 were not affected by the PKM2 expression (Fig. 2.6A). We further 
examined the effects of knockdown of PKM2 on the phosphorylation of stat3. 
Immunoblot analyses demonstrated that the phosphorylation levels of stat3 were 
significantly reduced upon PKM2 knockdown. The cellular levels of stat3 were not 
affected by PKM2 knockdown (Fig. 2.6B). It is known that JAK2 and c-Src are the most 
common protein tyrosine kinases that phosphorylate stat3. We therefore probed whether 
JAK2 and c-Src were activated by the HA-PKM2 expression. We examined 
JAK2/activated JAK2 and c-Src/activated c-Src by immunoblot using antibodies against 
JAK2, the phosphorylated (Y1007/1008) JAK2 (activated), c-Src, and the phosphorylated 
c-Src (Y530) with the cell lysate made from SW620 cells with/without HA-PKM2 
expression. Clearly, JAK2 and c-Src were not activated upon the HAPKM2 expression 
(Fig. 2.6 C&D). The experiments suggested that expression of PKM2 promoted stat3 
phosphorylation (activation), and the phosphorylation was not due to activation of JAK2 
and c-Src. 
 
2.3.4 Expression of PKM2 did not Alter Production of Pyruvate and Lactate 
PKM2 is an enzyme that acts in the glycolysis pathway. We therefore analyzed 
production of lactate and pyruvate in two pairs of cells, SW620/SW480 and 
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WM266/WM115, in which the HA-PKM2 was exogenously expressed. Upon exogenous 
expression of HA-PKM2, there were no significant changes in cellular lactate and 
pyruvate for either WM266 or SW620 cells (the more proliferated cell lines). Cellular 
pyruvate and lactate increased slightly in SW480 and WM115 cells (the less proliferated 
cell lines), indicating a slight increase in glycolytic pyruvate kinase activity upon 
exogenous expression of HA-PKM2 in the less aggressive cancer cells, while expression 
of PKM2 did not lead to any changes in glycolytic pyruvate kinase activity in the more 
proliferated cancer cells. Overall, no substantial changes in cellular pyruvate and lactate 
were observed (Fig. 2.9 B-E), suggesting that the differences in stimulating cell 
proliferation by expression of HA-PKM2 in more proliferated and less proliferated 
cancer cells were not simply due to the effects on the carbohydrate metabolism. 
 
2.4 Discussion 
During tumor progression, growth signals stimulate the conversion of 
glycolytically active PKM2 to an inactive form of the enzyme, consequently regulating 
the glycolysis pathway to channel the carbon source from glucose for biosynthesis 
(Christofk et al., 2008a; Deberardinis et al., 2008; Garber, 2006; Mazurek & Eigenbrodt, 
2003). It is conceivable that tumor cells need to coordinate the metabolism alterations 
with expression of genes that are related to cell proliferation during tumor progression. 
PKM2 has long been recognized as a so-called ‘moonlight’ enzyme that plays a very 
important role in tumor progression (Sriram et al., 2005). Clearly, the activity of PKM2 
in transcription regulation is an important ‘moonlight’ activity of the protein. The 
functions of PKM2 in regulating expression of genes fulfill the role of feedback 
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signaling from metabolic alterations to gene regulation during tumor malignancy 
transformation (see model in Fig. 2.6E). It is intriguing that a glycolytic enzyme can 
translocate to the nucleus and act in gene transcription. Our co-immunoprecipitation 
experiments demonstrated that nuclear PKM2 coimmunoprecipitated with stat3, a 
transcription activator whose activations response to various growth factor and cytokines 
stimulations. PKM2 activates stat3 and increases the capability of the transcription 
activator binding to its target DNA, thus consequently activates transcription. This is a 
new pathway that leads to activation of stat3. Stat3 is a transcription activator that is 
activated in response to inflammatory cytokines, such as IL-6 (Gao et al., 2007; Watson 
& Neoh, 2008). Strikingly, activation of stat3 represents probably one of the most 
important molecular signatures involved in promoting cancer progression. It has been 
observed that activation of stat3 is detected in almost all cancer types (Frank, 2007; 
Groner et al., 2008; Huang, 2007; Kim et al., 2007). However, it is generally believed 
that activations of stat3 in response to growth factor and cytokines are usually transient. 
A long standing question is “How do the malignant cancer cells maintain constitutive 
activation of stat3?” Currently, mutation(s) that lead to constitutive activation of stat3 
have not been identified. Thus, activation of stat3 by PKM2 in malignant cancer cells 
potentially provides a very attractive explanation for this long-standing question. The 
increase in nuclear stat3 phosphorylation at Y705 by expression of PKM2 implies a 
possibility that PKM2 may function as a protein kinase in the cell nucleus. Consistent 
with this conjecture, it was observed that PKM2 purified from extracts of hepatoma cells 
could phosphorylate histone H1 in vitro (Ignacak & Stachurska, 2003). We attempted to 
test possible kinase activity of the recombinant PKM2 expressed in E. coli with a 
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commercial recombinant GST-stat3 in the presence of ATP. No phosphorylation of stat3 
was observed (data not shown). However, it is possible that PKM2 expressed in bacteria 
did not adapter the same structural or conformational properties. Alternatively, PKM2 
may interact with tyrosine phosphorylated stat3 and the interaction helps redistribution of 
the phosphorylated stat3 to the cell nucleus. PKM2 is demonstrated to interact with 
tyrosine-phosphor-peptide. It is believed that interaction of PKM2 with tyrosine 
phosphor-protein confers the functional role of PKM2 in promoting cell proliferation 
(Christofk et al., 2008a; Christofk et al., 2008b). However, the interaction of PKM2 with 
a particular tyrosine phosphorylated protein has not been identified. Here, we 
demonstrated an example that PKM2 targeted a cellular tyrosine phosphor-protein stat3. 
PKM2 interacts with the phosphorylated stat3 and aids the activity of the phosphorylated 
protein in gene transcription, which consequently confers the functional role of PKM2 in 
promoting cell proliferation. 
 
2.5 Materials and Methods 
2.5.1 Reagents, Cell lines, and Antibodies 
The KLH conjugated peptide spans aa 399 – 412 of PKM2 was synthesized by 
Global Peptide Services. PKM2 polycolonal antibody and anti-HA antibody was raised in 
the animal facility of Georgia State University. Antibodies against Lamin A/C, Histone 
2A, MEK5, MEK5(pSer311/Thr315), stat3, stat3(pY705), JAK2, JAK2(p-1007/1008), c-
Src, p-c-Src(pY530), and _-actin were purchased from Cell Signaling, Abnova, 
Invitrogen, SantaCruz, Abcam, and AnaSpec respectively. Recombinant GST-stat3 was 
purchased from Abcam. Cell lines LN686 and M4C1 were gifts from Dr. Georgia Chen, 
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Emory University. Cell lines SW480, SW620, WM115, WM266, T98G, U87MG, H146 
and H460 were purchased from ATCC and cultured by following the vendor’s 
instructions. The vector for expression of dominate negative stat3 (Y705F) was a kind 
gift from Dr. Suyan Huang, The University of Texas, M.D. Anderson Cancer Center (Xie 
et al., 2006). Stat3 inhibitor, Ethyl-1-(4-cyno-2,3,5,6-tetrafluorophenyl)-6,7,8-trifluoro-4-
oxo-1,4-dihydroquinoline-3-carboxylate (Xu et al., 2008) was purchased from 
Calbiochem and used without further purification. 
 
2.5.2 RNA Interference, Subcellular Extracts Preparation, Co-immunoprecipitation, 
immunoblot, Cell Proliferation Assays, and Chromatin immunoprecipitation (ChIP) 
The siRNA duplexes for PKM2, stat3, and MEK5, siGENOME ON-TARGETplus 
SMARTpool duplex, were purchased from Dharmacon RNA technologies. The 
experimental procedures for preparation of subcellular extracts, co-immunoprecipitation, 
RNA interference knockdown, immunoblot, cell proliferation assays, and chromatin 
immunoprecipitation (ChIP) were similar to that of our previous reports (Yang et al., 
2006; Yang et al., 2007b). Cell proliferations were measured using the commercial cell 
proliferation kit (Calbiochem) that monitors incorporation of BrdU (Yang et al., 2006; 
Yang et al., 2007a). 
 
2.5.3 Expression of PKM2 by Adenovirus Using Commercial AdEasy System 
The cDNA encoding PKM2 was purchased from OriGene Technologies. PKM2 
cDNA was cloned into a shuttle vector pAdEasy-1 with EcoRI and NotI restriction 
endonuclease sites. The resultant plasmid was digested with Pme1 and transformed into 
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competent AdEasier cells containing the adenovirail backbone plasmid pAdEasy-1 by 
electroporation (BJ5183-AD-1, Stratagene). Recombinants were selected for kanamycin 
resistance and further confirmed by restriction endonuclease analyses and DNA 
autosequencing. The confirmed plasmid with PKM2 cDNA was digested with PacI 
restriction endonuclease and transformed into HEK-293 cells expressing adenovirus E1 
(Stratagene). The production of recombinant adenoviruses in HEK-293 cells was 
examined under fluorescent microscope and collected in three weeks. The recombinant 
viruses were amplified three rounds in HEK-293 cells to increase virus titer (1x1013 
Pfu/ml). The viruses were collected by centrifugation and stored at -80oC. The cells were 
seeded in a 48 well plate to 70% – 80% confluence. Viruses stock (50 _l at 1x1013 
Pfu/ml) were added to each well and incubated for 3 – 5 hours following by changing 
fresh culture medium. The expression of HA-PKM2 was examined 48 hours after 
incubation. 
 
2.5.4 Cellular Pyruvate and Lactate 
Cellular pyruvate and lactate were analyzed by commercially available kits 
(BioVision). Cells (WM115, WM266, SW480, and SW620) were infected with adeno-
viruses for overexpression of 
HA-PKM2 or control vectors, and were lysed in lysis buffers that were included in the 
kits. The lysates were centrifuged at 13,000g to remove the precipitates. The prepared 
extracts (10 _l) were applied to the assay test. The standard curves were made using 
probes included with the kits. Pyruvate and lactate amounts were measured by following 
the vendor’s instructions. 
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2.5.5 Microarray Analyses of Gene Expressions 
Total RNA from cells expressing HA-tagged PKM2 or control was extracted with 
an RNeasy kit by following the vendor’s instructions (Qiagen). The total RNA 
concentration was determined by spectrometer reading at OD 280 nm. The isolated total 
RNA (10 _g) of each sample was used for synthesizing cDNA using the ImProm-II 
reverse transcription system (Promega). Synthesized cDNA was purified by phenol-
chloroform extraction and ethanol precipitation. The cDNA was labeled using the 
GeneChip® IVT Labeling Kit (Affymetrix). The labeled cDNA was fragmented in 
fragmentation buffer and hybridized to a GeneChip® Human Genome U133 Plus 2.0 
Array (Affymetrix). The arrays were scanned with the Affymetrix GeneChip 3000 
scanner. The data were analyzed by Affymetrix GeneChip Operating Software (GCOS) 
Version 1.0. The array data in table S1 obtained with SW620 cells in which PKM2 was 
exogenously expressed were subtracted from a reference array where the cells were 
infected with viruses carrying an empty vector. The same expression array experiments 
were repeated two times. 
 
2.5.6 Real Time PCR and RT-PCR 
Total RNA was extracted from the cells using RNeasy kit by following the 
manufacturer’s instruction (Qiagen). Reverse transcription process was performed with 
ImProm-II reverse transcription system (Promega). Subsequent Polymerase Chain 
Reactions were carried out with 1 μg of template cDNA mixed with the Fast SYBR green 
master mix in an Applied Biosystems Real-Time PCR 7500 system (Applied biosystems). 
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The PCR reactions using standard RT-PCR negative control primer set were performed 
as reference. The primer pairs, forward 5’-CATGTCCTTGGAAGAATTGC-3’, reverse 
5’-ATAGAATTCACCAGCTGAGTG-3’, that 
targeted exon 12 – exon 14/15 regions of the MEK5 gene was used in our RT-PCR 
experiments.The primer pair for PCR reaction in the ChIP with MEK5 promoter was, 
forward 5’-GTATGCAAATTTGGCAAATTGAG-3’ reverse 5’- 
CTTCAGATATTCTAGGAATTTCCC-3’, targeting nt -1,621 – -1,366 region. The 
primer pair for ChIP target exon 1 of MEK5 (nt 342– nt 542) was forward 5’-
CAGAGACCTTCACCATAGCG-3’ and reverse 5’-
AACAAGGGAATGGAGGATGAG-3’. The primer pair for PCR reaction in the ChIP 
withGAPDH gene was forward 5’-CAATTCCCCATCTCAGTCGT-3’, reverse 5’-
AGTAGCCGGGCCCTACTTT-3’ span region of -360 nt - -163 nt. 
 
2.5.7 Gel-Mobility Shift and Super-Shift Assays 
The mobility shift assays were carried out with oligonucleotide that harbors a stat3 
binding sequence 5’-GATCCTTCTGGGAATTCCTAGATC-3’ (Xie et al., 2006). The 
oligonucleotide was 5’-end 32P-labeled. The labeled oligonucleotide (100 pmole) was 
incubated with 15% nuclear extracts (20 _l) prepared from appropriate cells as indicated 
in the figure legends for 30 minutes at room temperature in the binding buffer (5% 
glycerol, 1mM MgCl2, 0.5mM EDTA, 0.5mM DTT, 50mM NaCl, 10mM Tris-HCl, 
0.05mg/ml poly(dI-dC)). The proteinoligonucleotide complexes were separated in 4% 
native polyacrylamide gel (acrylamide: polyacrylamide 59:1). For supershift analyses, a 
monoclonal antibody against stat3 (invitrogen) or the antibody PabPKM2 was added to 
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the oligonucleotide-nuclear extracts mixture and incubated for additional 45 minutes. The 
complexes in gel were transferred to a membrane and subjected to autoradiography. 
 
2.5.8 ChIP, Re-ChIP 
ChIP and Re-ChIP experiments were performed with a commercial ChIP/Re-ChIP 
kit (Activemotif) by following vendor’s instruction. Briefly, the first round of ChIP was 
carried out s described above. The DNA was recovered from the immunoprecipitates by 
elution with 1% SDS, and 90% of the eluted chromatin from the first round of 
immunoprecipation was diluted 10-fold with ChIP buffer. The second round of 
immunoprecipitation was then carried out with the recovered immunoprecipitates. DNA 
fragmentations, reverse crosslinking, and PCR reaction was subsequently performed with 
the second round of immunoprecipitation. 
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Figure 2.1 PKM2 Promotes Cell Proliferation 
(A) Cell proliferations of ten cancer cell lines (indicated) were measured using a 
commercial cell proliferation kit. The proliferation rates are presented as fold changes of 
BrdU incorporation of the same cultured cells before and after 48 hours culturing by 
defining the initial BrdU incorporation as 1. (B) Nuclear localization of PKM2 in 
different cancer cells. Immunoblot analyses of PKM2 using the antibody PabPKM2 
(IB:PKM2) in nuclear extracts (NE) and whole cell lysates (WCL) of ten different cell 
lines (indicated). Blots of lamin A/C and H2A are loading controls. (C) Exogenous HA-
PKM2 (HAPK) expression using the adeno-viral expression kit in ten different cell lines 
(indicated) were analyzed by immunoblot using anti-HA antibody (IB:HA). Immunoblot 
of _-actin (IB:_-actin) were loading controls. Vec were the cells infected with virus that 
carry an empty vector. (D) Cell proliferation rates of ten different cell lines (indicated) in 
which PKM2 was exogenously expressed using the adeno-viral expression kit were 
measured using the cell proliferation kit. Cell proliferations are presented as fold changes 
in BrdU incorporation of the same cultured cells before expression of PKM2 and 48 
hours after PKM2 expression. The BrdU incorporation of each cell line without PKM2 
expression is defined as 1. (E) (Top) Cell proliferations of SW480 and SW620 cells were 
measured using the cell proliferation kit. Cell proliferations were presented as fold 
changes in BrdU incorporation before and 48 hours after knockdown of PKM2 using a 
smart-pool RNAi (PK). NT represents the cells treated with non-target RNAi. The BrdU 
incorporation of each cell line before PKM2 knockdown was defined as 1. (Bottom) 
Immunoblot analyses of cellular PKM2 using the antibody PabPKM2 (IB:PKM2) 48 
hours after RNAi knockdown of PKM2 in different cells (indicated). Immunoblot of β-
actin (IB:β-actin) were loading controls. NT represents the cells treated with non-target 
RNAi. Error bars in (A), (D), and (E) are standard deviations for three independent 
experiments. 
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Figure 2.2 PKM2 Upregulates MEK5 Transcription 
(A) RT-PCR analyses of cellular MEK5 mRNA levels in two pairs of cancer cells 
(indicated) in which PKM2 was exogenously expressed using the adeno-viral expression 
kit. The results are presented as fold increase in PCR products before and 48 hours after 
PKM2 exogenous expression in the same cells. The level of PCR product from each cell 
line before PKM2 exogenous expression was defined as 1. (B) Expressions (IB:MEK5) 
and phosphorylation (IB:p-MEK5) of MEK5 in different cancer cells (indicated on top) 
were analyzed by immunoblot using antibodies against MEK5 and phosphorylated 
MEK5. HA-PKM2 was expressed (HAPK) in the cells using the adeno-viral expression 
kit (IB:HA). Vec were the cells infected with virus that carry the empty vector. (C) 
Expressions (IB:MEK5) and phosphorylation (IB:p-MEK5) of MEK5 in SW480 and 
SW620 cells (indicated) in which PKM2 was knocked down (PK) using the smart pool 
RNAi were analyzed by immunoblot using antibodies against MEK5 and phosphorylated 
MEK5. The cellular levels of PKM2 were analyzed by immunoblot of PKM2 (IB:PKM2). 
(D) (Bottom panel) RT-PCR analyses of cellular MEK5 mRNA levels in SW620 and 
WM266 cells (indicated) in which PKM2 was knocked down using a smart-pool RNAi 
(PK). NT represents the cells treated with non-target RNAi. The results are presented as 
fold changes in PCR products before and 48 hours after PKM2 knockdown in the same 
cells. The level of PCR products from each cell line that was treated with non-target 
RNAi was defined as 1. (Upper panel) Immunoblot analyses of cellular PKM2 in 
SW620 and WM266 cells (indicated) in which PKM2 was knocked down using a smart-
pool RNAi (PK). (E) ChIP of the MEK5 promoter (MEK5 promoter) using antibody 
against PKM2 in SW620 cells (_PK). ChIP using rabbit IgG was a negative control. ChIP 
using PCR primer pair targeting a region of exon 1 (MEK5 exon 1) of MEK5 gene (nt 
342 – nt 542) is a negative control. ChIP targeting GAPDH promoter (GAPDH promoter) 
using antibody against PKM2 was another negative control. The primer pair positions are 
indicated. Inputs were PCR products from DNA extracts without ChIP. In (B), (C), and 
(D), Immunoblot of β-actin (IB:β-actin) is a loading control. Error bars in (A) and (D) are 
standard deviations of three measurements 
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Figure 2.3 Expression of MEK5 Mediates the Effects of PKM2 in Cell Proliferation 
(A) (Upper panel) Cellular levels of MEK5 and exogenously expressed HA-PKM2 in 
WM266 and SW620 cells were analyzed by immunoblot using antibodies against MEK5 
(IB: MEK5) and HA (IB:HA). MEK5 in the cells was knocked down by RNAi (PK). 
PKM2 was exogenously expressed in the cells using the adeno-viral expression kit. 
(Bottom Panel) Cell proliferations of WM266 and SW620 cells were measured using the 
cell proliferation kit. Proliferations of WM266 (1 – 4) or SW620 (5 – 8) cells were 
measured under following conditions: 1) and 5) Open bars, HA-PKM2 expression and no 
MEK5 knockdown;. 2) and 6) Gray bars, HA-PKM2 was expressed and no MEK5 
knockdown; 3) and 7) Black bars, no PKM2 expression and MEK5 knockdown; and 4) 
and 8) Striped bars, PKM2 expression and MEK5 knockdown. The proliferations are 
presented as fold changes of BrdU incorporation before and after indicated treatments. 
NT represents the cells treated with non-target RNAi. Vec were the cells infected with 
virus that carry the empty vector. Error bars are standard deviations of three 
measurements. (B) Cellular MEK5 levels and phosphorylation of the protein in ten 
different cell lines (indicated at top) were examined by immunoblot of whole cell lysate 
using antibodies against MEK5 and phosphorylated MEK5. In (A) and (B) Immunoblot 
of β-actin (IB:β-actin) is a loading control. (C) Co-immunoprecipitation of PKM2 with 
stat3. PKM2 was immunoprecipitated from nuclear extracts prepared from SW620 and 
SW480 cells using the antibody PabPKM2 (IP: αPK). The immunoprecipitates were 
analyzed by immunoblot using antibodies against stat3 (IB: Stat3) or PKM2 (IB: PKM2). 
Ponceau S staining of IgG heavy chain (IgG HC) in the immunoprecipitates is the 
loading control. Immunoprecipitation using rabbit IgG (IP:IgG) was the control 
immunoprecipitation. 
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Figure 2.4 PKM2 Upregulates MEK5 Transcription via Activation of Stat3 
(A) & (C) Expressions of MEK5 (IB: MEK5) in SW620/SW480 (A) and 
WM115/WM266 cells (C) (indicated) were analyzed by immunoblot the cell lysate 
(WCL) prepared from the cells in which stat3 was knocked down by RNAi (stat3, 
IB:Stat3). HA-PKM2 was exogenously expressed in the stat3 knockdown cells (IB:HA). 
The blot of β-actin (IB: β-actin) are the loading controls. (B) & (D) RT-PCR analyses of 
cellular MEK5 mRNA levels in SW620/SW480 (B) and WM266/WM115 cells (D) 
(indicated) in which stat3 was knocked down by RNAi (stat3, IB:Stat3). HA-PKM2 was 
exogenously expressed in the stat3 knockdown cells (IB: HA). The results are presented 
as fold changes in PCR products before and 48 hours after stat3 knockdown and HA-
PKM2 expression in the same cells. The level of PCR products from each cell line that 
was treated with non-target RNAi was defined as 1. In (A), (B), (C), and (D), NT 
represents the cells treated with non-target RNAi. Vec were the cells infected with virus 
that carry the empty vector. Error bars in (B) and (D) are standard deviations of three 
measurements. 
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Figure 2.5 PKM2 Upregulates MEK5 Transcription by Promoting Stat3 DNA Interaction 
(A) (Upper panels) ChIP of the MEK5 promoter (MEK5 promoter) using antibody 
against stat3 in SW620 cells (αStat3). The cells were treated non-target RNAi (left, NT) 
or with RNAi target PKM2 (right, RNAi-PK), or HA-PKM2 was exogenously expressed 
in the cells (middle, HAPK). ChIP using rabbit IgG (IgG) was a negative control. Inputs 
were PCR products from DNA extracts without ChIP. The primer pair positions are 
indicated. (Lower panels) the cellular PKM2 (right) and HA-PKM2 (left) levels in 
SW620 cells that were treated with RNAi target PKM2 (PK) or with non-target RNAi 
(NT), or infected with virus that carry HA-PKM2 expression vector (HAPK) or vector 
alone (Vec). The blot of β-actin (IB:β-actin) is the loading control. (B) DNA-protein 
complex (Complex) assembled on a 32P-labeled oligonucleotide containing the stat3 
targeting sequence in nuclear extracts prepared from SW620 cells (left panel) was 
detected by gel-shift and autoradiography. Probe indicates the free 32P-labeled 
oligonucleotide probe without addition of nuclear extracts. The antibodies against PKM2 
(αPK), stat3 (αStat3), or no antibody (NoAb) was added to the complex to create 
supershift (Supershift) (right panel). (C) & (D) Supershift complex assembled with the 
32P-labeled oligonucleotide and antibodies (indicated) in the nuclear extracts prepared 
from SW620 cells in which (D) PKM2 was knocked down by RNAi (PK) or (C) HA-
PKM2 was exogenously expressed (HAPK) was detected by gel-shift and 
autoradiography. NT means the cells were treated with non-target RNAi. Vec means the 
cells were infected with virus that carried the empty vector. Probe only is the free probe 
without addition of nuclear extracts. The free probe (low exposure) is the loading control 
with 1/10 of exposure time in autoradiography. The quantification of the assembled 
complex and super shift complex were presented as percentage (Shifted/total x102) of 
probe in the shift complex calculated by Intensities of complex [complex (grey bars) or 
supershift (open bars)] divided by Intensities of total [free probe + complex + supershift). 
Immunoblots at bottom of each panel indicate cellular levels of HA-PKM2 (IB:HA) and 
endogenous PKM2 (IB:PKM2). Immunoblot of β-actin is the loading control. (E) ChIP 
and Re-ChIP of the MEK5 promoter (MEK5 promoter) in SW620 cells. The antibody is 
against stat3 (αStat3) was used as the first ChIP antibody (ChIP). The antibody 
PabPKM2 (αPK) was used as Re-ChIP antibody (Re-ChIP). ChIP and Re-ChIP using 
rabbit IgG (IgG) were the negative control experiments. The primer pair targeting the 
same region (-1621 nt – -1366 nt) was used in ChIP and Re-ChIP assays. 
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Figure 2.6 PKM2 Phosphorylates Stat3 
(A) & (B) The levels of Y705 phosphorylated stat3 (IB:p-Tyr-Stat3) in the cell nucleus 
were analyzed by immunoblot of nuclear extracts (NE) prepared from SW620 cells in 
which HAPKM2 was expressed (A. HAPK) or endogenous PKM2 was knocked down 
using the smartpool RNAi (B, PK). The total cellular stat3 levels were analyzed by 
immunoblot analyses of stat3 (IB:Stat3) in whole cell lysate (WCL). In (A), immunoblot 
of HA-tag (IB:HA) indicates the HA-PKM2 expression levels in the cells. In (B), 
immunoblot of PKM2 (IB:PKM2) represents cellular PKM2 levels in the cells. 
Immunoblot of lamin A/C and β-actin are the loading controls. (C) & (D) Activation 
JAK2 (B) or c-Src (C) in SW620 cells in which HA-PKM2 was expressed (HAPK) was 
analyzed by immunoblot of cytoplasmic extracts (Cyto) using antibody against 
phosphorylated JAK2 (B, IB:p-JAK2) or antibody against phosphorylated c-Src (C, IB:p-
c-Src). Vec means the cells were infected by virus carry the empty vector. Immunoblots 
of JAK2 (IB: JAK2) in (B) and c-Src (IB:Src) in (C) are loading control. Immunoblot of 
β-actin is another loading control. The expression levels of HA-PKM2 were examined by 
immunoblot of HA-tag. (E) A hypothetic model for the role of PKM2 in promoting cell 
proliferation. 
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Figure 2.7 Expression PKM2 in Cancer Cells 
(A) Immunostaining of PKM2 using the antibody PabPKM2 in SW480, SW620, and 
T98G cells (indicated). The red signal represents staining of PKM2 in the cells (a). The 
blue signal represents DAPI staining of DNA (b). (c) is the overlay of PKM2 antibody 
staining and DAPI staining. (B) Cellular levels of PKM2 in WM115, WM266, SW480, 
and SW620 cells (indicated) before and 48 hours after infection of the cells with viruses 
that carry PKM2 expression vector (HAPK) or empty vector (Vec) were analyzed by 
immunoblot of PKM2 (IB:PKM2) in cell lysate using the antibody PabPKM2. The 
exogenously expressed HA-PKM2 was examined by immunoblot using anti-HA antibody. 
The right panel is quantization of immunoblot signals of IB:PKM2 by defining the IB 
signal before HA-PKM2 expression as 1 in each cell line. Error bars are standard 
deviations of three measurements. (C) Levels of exogenously expressed HA-PKM2 
(HAPK) in the cell nucleus (NE) and the cytoplasm (Cyto) in WM115, WM266, SW480, 
and SW620 cells (indicated) were analyzed by immunoblot using anti-HA antibody 
(IB:HA). Vec were the cells infected with virus carrying an empty vector. In (B) and (C), 
immunoblot of β-actin (IB: β-actin) and lamin A/C (IB:Lamin A/C) were loading 
controls. 
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Figure 2.8 PKM2 Interacts with Stat3 to Regulate MEK5 Gene Transcription 
(A) & (B) Co-immunoprecipitations of endogenous PKM2 (A) and exogenous HAPKM2 
(B) with stat3 were analyzed by immunoprecipitation using antibody against stat3 (IP: 
αstat3 in A) and anti-HA antibody (IP:HA in B) from nuclear extracts prepared from 
SW620 and SW480 cells. The immunoprecipitates were analyzed by immunoblot using 
antibodies against stat3 (IB:Stat3) or PKM2 (IB:PKM2). Ponceau S staining of IgG 
heave chain (IgG HC) in the immunoprecipitates is the loading control. 
Immunoprecipitation using rabbit IgG (IP:IgG) was the control immunoprecipitation. In 
(B), the immunoblot using anti-HA antibody was an additional loading control. (C) & 
(E), Expressions of MEK5 (IB:MEK5) in SW620/SW480 (C) and WM115/WM266 (E) 
cells were analyzed by immunoblot the whole cell lysate (WCL) prepared from the cells 
in which a stat3 dominant negative mutant (DNST) and HA-PKM2 (HAPK) were 
expressed. Immunoblot of HA-Stat3DN (IB:HA (stat3DN) and HA-PKM2 (IB:HAPK) 
indicated the exogenous expression levels. The cellular levels of phosphorylated MEK5 
were also examined by immunoblot using the antibody against phosphorylated MEK5 
(IB:p-MEK5). (D) & (F) RT-PCR analyses of cellular MEK5 mRNA levels in 
SW620/SW480 (D) and WM266/WM115 (F) cells in which a stat3 dominant negative 
mutant (DNST) and HAPKM2 (HAPK) were expressed. The results are presented as fold 
changes in PCR products before and 48 hours after the dominant negative stat3 mutant 
and HA-PKM2 expression in the same cells. The level of PCR products from each cell 
line that was infected with virus that carry the empty vector (Vec) and no stat3 mutant 
expression was defined as 1. (G) Expressions of MEK5 (IB: MEK5) in SW620/WM266 
cells (indicated) were analyzed by immunoblot the whole cell lysate (WCL) prepared 
from the cells in which HA-PKM2 was exogenously expressed (HAPK) and that were 
treated with the stat3 inhibitor (Inhibitor). Cells treated with DMSO (the same amounts 
as used in inhibitor treatments as solvent for dissolve the inhibitor) are the control 
treatments. (H) RT-PCR analyses of cellular MEK5 mRNA levels in SW620/WM266 
cells. The results are presented as fold changes in PCR products before and 48 hours after 
the dominant negative stat3 mutant and HA-PKM2 expression in the same cells. The 
level of PCR products from each cell line that was infected with virus that carry the 
empty vector (Vec) and no stat3 mutant expression was defined as 1. In (C), (E), and (G), 
immunoblot of β-actin (IB: β-actin) is the loading control. Error bars in (D), (F), and (H) 
are standard deviations of three measurements. 
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Figure 2.9 PKM2 is Associated with Stat3 Promoter Region  
(A) ChIP of the MEK5 promoter (MEK5 promoter) using antibody against stat3 in 
SW620 cells (αStat3). ChIP using rabbit IgG (IgG) was a negative control. ChIP using 
PCR primer pair targeting a region of exon 1 (MEK5 exon 1) of MEK5 gene (nt 342 – nt 
542) is a negative control. ChIP targeting GAPDH promoter (GAPDH promoter) using 
antibody against stat3 was another negative control. The primer pair positions are 
indicated. Inputs were PCR products from DNA extracts without ChIP. (B-E) The 
cellular levels of lactate (B, C) and pyruvate (D, E) in WM115/WM266 (B, D), and 
SW480/SW620 (C, E) cells (indicated) were analyzed using commercial pyruvate and 
lactate analyses kits. The results were presented as fold changes before and 48 hours after 
exogenous expression of HA-PKM2 using the adeno-viral system. The cellular levels of 
pyruvate and lactate measured by the kits in the cells before exogenous expression of 
HA-PKM2 were defined as 1. 
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Table 1 List for gene expressions regulated by PKM2 overexpression in SW480 cells 
Gene ID Gene Name 
Expression 
Fold 
Change 
(up-
regulated) 
Description 
10862691 ACVR1B 2.02 Homo sapiens activin A receptor, type IB (ACVR1B), transcript variant 2, mRNA 
5901887 ADAMTS5 2.04 Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 
349268 ADCY1 3.51 Human fetal brain adenylyl cyclase mRNA, 3 end. 
3139026 AF10 2.09 Homo sapiens type V AF10 protein (AF10) Mrna 
4502050 ALOX12 2.31 Homo sapiens arachidonate 12-lipoxygenase (ALOX12) 
10190675 ANKRD3 2.85 Homo sapiens ankyrin repeat domain 3 (ANKRD3) 
2210410 AP1S2 2.24 adaptor-related protein complex 1, sigma 2 subunit 
28771 APOA1 3.65 Human mRNA for apolipoprotein AI (apo AI) 
13937840 ATM 2.19 Homo sapiens, Similar to ataxia telangiectasia mutated (includes complementation groups A, C and D), clone MGC:12371 
3849111 ATP6H 2.38 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 9kD 
13603411 B29 2.67 Homo sapiens B29 mRNA, complete cds.  
13111840 BART1 2.18 binder of Arl Two  
3307010 BCAA 2.98 RBP1-like protein 
219494 BGP 3.14 Human mRNA for biliary glycoprotein, complete cds 
19756424 BIRC5 2.46 baculoviral IAP repeat-containing 5 (survivin) 
9945321 BNPI 2.11 Homo sapiens brain-specific Na-dependent inorganic phosphate cotransporter (BNPI) 
10437300 C14orf85 2.88 Homo sapiens cDNA: FLJ21234 fis, clone COL00841 
5361475 C21ORF23 2.20 chromosome 21 open reading frame 23 
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4188559 CALR 3.05 calreticulin 
3049661 CALR 3.07 calreticulin 
9966860 CATX-8 2.07 Homo sapiens CATX-8 protein (CATX-8), mRNA.  
5450397 CCND1 2.50 cyclin D1 (PRAD1: parathyroid adenomatosis 1) 
11141862 CLDN6 2.63 Homo sapiens claudin 6 (CLDN6), mRNA 
18141077 CNK2 2.03 Homo sapiens connector enhancer of KSR2A mRNA 
5393570 CNN3 2.15 calponin 3, acidic 
4503086 CSN2 2.39 Homo sapiens casein, beta (CSN2), mRNA 
6807697 DKFZp434A1014 2.36 Homo sapiens mRNA; cDNA DKFZp434A1014 (from clone DKFZp434A1014) 
5912137 DKFZp434H168 2.22 hypothetical protein 
12053074 DKFZp434N1817 2.98 Homo sapiens mRNA; cDNA DKFZp434N1817 (from clone DKFZp434N1817) 
4884089 DKFZp564C196 3.88 Homo sapiens mRNA; cDNA DKFZp564C196 (from clone DKFZp564C196) 
13183072 DKFZP586K0717 2.48 Homo sapiens multi-PDZ-domain-containing protein mRNA 
10823629 DLG5 2.00 discs, large (Drosophila) homolog 5 
2046909 EIF5A 3.36 eukaryotic translation initiation factor 5A 
10729178 EPS15R 2.20 epidermal growth factor receptor substrate EPS15R 
6505954 ETV5 2.28 ets variant gene 5 (ets-related molecule) 
7455945 ETV5 2.16 ets variant gene 5 (ets-related molecule) 
11006648 FBXL7 2.67 f-box and leucine-rich repeat protein 7  
11056051 FCGR2A 2.24 Homo sapiens Fc fragment of IgG, low affinity IIa, receptor for (CD32) (FCGR2A) 
4758357 FGD1 2.03 Homo sapiens faciogenital dysplasia (Aarskog-Scott syndrome) (FGD1), 
9622332 FGF5 2.12 Homo sapiens fibroblast growth factor 5 short variant (FGF5), alternatively spliced 
13186264 FGFR2 3.72 Homo sapiens fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor 
814986 FLJ10154 2.32 hypothetical protein FLJ10154 
10941605 FLJ10287 2.33 hypothetical protein 
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5855915 FLJ10342 2.43 hypothetical protein FLJ10342 
3483211 FLJ11193 2.27 Homo sapiens full length insert cDNA clone YP41C12 
1483671 FLJ13195 2.22 hypothetical protein FLJ13195 similar to stromal antigen 3 
22749176 FLJ36779 2.31 Homo sapiens hypothetical protein FLJ36779 (FLJ36779) 
27734816 FLJ39058 2.00 Homo sapiens hypothetical protein FLJ39058 (FLJ39058) 
1228635 FLRT3 2.40 fibronectin leucine rich transmembrane protein 3  
4503734 FOXC1 2.02 forkhead box C1 
3416539 FOXD1 2.30 forkhead box D1 
6912371 FOXD3 4.64 Homo sapiens forkhead box D3 (FOXD3), mRNA 
8393383 G8 2.52 Homo sapiens G8 protein (G8), mRNA. 
1754748 GABAA receptor gamma 3 subunit 2.11 GABAA receptor gamma 3 subunit (human, fetal brain, mRNA Partial, 1536 nt) 
20202213 GAD2 3.17 glutamate decarboxylase 2 (pancreatic islets and brain) 
4406347 GCAP3 3.59 Homo sapiens guanylate cyclase activating protein 3 splice variant (GCAP3) mRNA 
4758433 GHSR 3.33 Homo sapiens growth hormone secretagogue receptor (GHSR) 
3400047 GLP 2.71 golgin-like protein 
28269674 GPR126 3.40 G protein-coupled receptor 126 
6006002 GRIN2A 4.39 Homo sapiens glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A) 
6005773 GUCA2B 5.02 Homo sapiens guanylate cyclase activator 2B (uroguanylin) (GUCA2B), mRNA 
9867563 H41 2.02 hypothetical protein 
13549111 HBB 2.33 Homo sapiens beta globin chain variant (HBB) mRNA, complete cds. 
5928292 HDAC3 2.28 histone deacetylase 3 
1597725 HLA-DRB4 2.48 Homo sapiens HLA class II DRB4 null antigen (HLA-DRB4) pseudogene mRNA, null allele HLA-DRB4*0201N 
13489076 HOXA6 2.24 Homo sapiens homeo box A6 (HOXA6), mRNA. 
3461865 HSPA1L 2.09 Heat shock protein 70 testis variant 
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7019420 HUMBINDC 2.54 Homo sapiens DNA binding protein for surfactant protein B (HUMBINDC), mRNA. 
4504590 IFNA14 2.98 Homo sapiens interferon, alpha 14 (IFNA14), mRNA 
10835102 IFNA4 2.71 Homo sapiens interferon, alpha 4 (IFNA4), mRNA. 
4504706 INPP4B 2.32 Homo sapiens inositol polyphosphate-4-phosphatase, type II, 105kD (INPP4B), mRNA 
13050848 INSIG1 2.03 insulin induced gene 1 
4072135 ITGB5 2.13 integrin, beta 5 
6912441 KCNE1L 2.08 Homo sapiens potassium voltage-gated channel, Isk-related family, member 1-like (KCNE1L) 
7657246 KCNIP1 2.23 Homo sapiens Kv channel-interacting protein 1 (KCNIP1), mRNA 
1193698 KIAA0256 2.09 KIAA0256 gene product 
3327077 KIAA0632 2.33 Homo sapiens mRNA for KIAA0632 protein, partial cds. 
10828334 KIAA0644 2.14 KIAA0644 gene product 
11445251 KIAA0847 2.25 KIAA0847 protein 
9792490 KIAA0964 2.24 KIAA0964 protein 
10940593 KIAA1096 2.02 KIAA1096 protein 
1552995 KLF1 2.76 Human erythroid-specific transcription factor EKLF mRNA, complete cds. 
6007796 Kv4.3 3.38 Homo sapiens voltage gated potassium channel Kv4.3 short splice variant (Kv4.3)  
8923829 LEP503 2.24 Homo sapiens lens epithelial protein (LEP503), mRNA. 
4150402 LOC145622 3.45 hypothetical protein LOC145622 
21687187 LOC146325 2.63 Homo sapiens similar to hypothetical protein FLJ13841 (LOC146325) 
16553309 LOC149086 3.30 Homo sapiens cDNA FLJ33000 fis, clone THYMU1000191. 
24270838 LOC283403 2.29 Homo sapiens, clone IMAGE:5268545, mRNA. 
3923425 LOC284889 4.76 hypothetical protein LOC284889 
13277527 LOC51065 2.07 Homo sapiens, Similar to 40S ribosomal protein S27 isoform, clone MGC:12175 
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10911294 LOC286411 2.97 hypothetical protein LOC286411 
12770474 LOC55884 2.10 CS box-containing WD protein 
1720456 LOC56851 2.65 chromosome 11 hypothetical protein ORF3 
5394758 LOC56993 2.46 mitochondrial import receptor Tom22 
19913482 LOC57821 2.38 Homo sapiens, Similar to hypothetical protein LOC57821, clone MGC:26487 
4523295 LOC57863 2.77 hypothetical protein FLJ10698 
4505016 LRP6 2.67 Homo sapiens low density lipoprotein receptor-related protein 6 (LRP6), mRNA
11081627 LSP1 2.50 lymphocyte-specific protein 1 
3387766 m6b1 2.02 glycoprotein M6B /DEF=Homo sapiens m6b1 mRNA, complete cds. 
1616780 MAP2K5 5.04 Human MAP kinase kinase MEK5c mRNA, complete cds. 
4885476 MB 2.05 Homo sapiens myoglobin (MB), mRNA 
4337095 MEGT1 2.25 Homo sapiens MSH55 gene, partial cds; and CLIC1, DDAH, G6b, G6c, 
219881 MS4A1 2.23 Homo sapiens mRNA for IgE receptor beta subunit, complete cds. 
12803920 MS4A2 2.11 Homo sapiens, membrane-spanning 4-domains, subfamily A, member 2, clone MGC:3969 
5031926 MUSK 2.05 Homo sapiens muscle, skeletal, receptor tyrosine kinase (MUSK), mRNA 
4505376 NEUROD1 3.53 Homo sapiens neurogenic differentiation 1 (NEUROD1), mRNA. 
6133390 NOLA2 2.24 nucleolar protein family A, member 2 (HACA small nucleolar RNPs) 
11452542 NOV 2.01 nephroblastoma overexpressed gene 
7669529 NRG2 2.07 Homo sapiens neuregulin 2 (NRG2), transcript variant 3, mRNA 
18087816 NY-REN-41 2.03 Homo sapiens NY-REN-41 antigen (NY-REN-41) 
5110327 OGT 2.16 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypep) 
21104485 OKSW-cl.92 2.55 Homo sapiens OKSW-cl.92 mRNA, complete cds. 
11545886 OT7T022 2.45 Homo sapiens neuropeptide FF 1; RFamide-related peptide receptor (OT7T022), mRNA. 
7524355 PAX3 2.81 Homo sapiens paired box gene 3 (Waardenburg syndrome 1) (PAX3), transcript variant PAX3B 
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6679187 P-B 3.92 Homo sapiens salivary proline-rich protein (P-B), mRNA. 
4406228 PPIE 2.09 Homo sapiens peptidyl-prolyl cis-trans isomerase E (PPIE) mRNA, alternatively spliced 
4989070 PPM1A 2.30 protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform 
4328589 PRO1073 2.25 PRO1073 protein 
7662589 PRO1073 2.22 Homo sapiens PRO1073 protein (PRO1073), mRNA. 
7770170 PRO2214 2.25 Homo sapiens PRO2214 mRNA 
7770218 PRO2706 2.12 Homo sapiens PRO2706 mRNA 
2552941 PSMB4 2.61 proteasome (prosome, macropain) subunit, beta type, 4 
726735 RAD23B 2.43 RAD23 (S. cerevisiae) homolog B 
6691625 RAGE 3.15 Homo sapiens RAGE mRNA for advanced glycation endproducts receptor 
4506420 RARB 3.81 Homo sapiens retinoic acid receptor, beta (RARB), mRNA 
1072311 RGN 2.14 Human mRNA for SMP-30 (senescence marker protein-30) 
13097176 RPL10 2.06 ribosomal protein L10  
4489788 RPL23A 2.52 ribosomal protein L23a 
9130191 RPL27 2.52 ribosomal protein L27 
10151019 RPL27A 4.56 ribosomal protein L27a 
10372131 RPL37A 2.92 ribosomal protein L37a 
6712816 RPL38 2.14 ribosomal protein L38 
13529169 RPLP2 2.50 ribosomal protein, large P2 
11954150 RPS11 6.10 ribosomal protein S11 
12652562 RPS19 4.07 Homo sapiens, ribosomal protein S19, clone MGC:1630 
6642739 RPS20 2.12 Homo sapiens clone FLB0708 mRNA sequence. 
11683880 RREB1 2.09 ras responsive element binding protein 1 
4678742 RS1 3.47 retinoschisis (X-linked, juvenile) 1  
1052870 SCCA2 2.12 Human squamous cell carcinoma antigen 2 (SCCA2)  
11493551 SCD 2.73 Homo sapiens PRO1933 mRNA, complete cds. 
820298 SEC14L2 2.96 SEC14 (S. cerevisiae)-like 2 
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10031679 SEL1L 2.58 sel-1 (suppressor of lin-12, C.elegans)-like 
306441 SLC3A1 2.47 Homo sapiens amino acid transport protein  
10940859 SMURF2 2.38 E3 ubiquitin ligase SMURF2 
6569554 SNRPG 3.46 small nuclear ribonucleoprotein polypeptide G 
10863910 SPINK2 4.24 Homo sapiens serine protease inhibitor, Kazal type, 2 (acrosin-trypsin inhibitor) (SPINK2) 
4557870 TF 2.67 Homo sapiens transferrin (TF), mRNA 
10820568 TGFB2 2.54 transforming growth factor, beta 2 
12407428 TRIM14 2.32 Homo sapiens tripartite motif protein TRIM14 alpha (TRIM14) mRNA, alternatively spliced. 
3153858 TXN delta 3 2.25 Homo sapiens thioredoxin delta 3 (TXN delta 3) mRNA, partial cds. 
3056223 UBE2H 2.16 ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8) 
6457377 VIL2 3.64 Homo sapiens cytovillin 2 (VIL2) mRNA, partial cds 
4991221 WNT5A 2.83 wingless-type MMTV integration site family, member 5A 
22477810  2.40 Homo sapiens, Similar to RIKEN cDNA 4930442L21 gene, clone MGC:34773 
18478590  2.58 Homo sapiens prostate-specific KLK2 mRNA, complete cds, alternatively spliced 
21750477  2.12 Homo sapiens cDNA FLJ34667 fis, clone LIVER2000769 
3017252  2.20 Homo sapiens mRNA; cDNA DKFZp564M243 (from clone DKFZp564M243) 
16553266  3.37 Homo sapiens cDNA FLJ32963 fis, clone TESTI2008405. 
652989  3.96 Homo sapiens cDNA FLJ34653 fis, clone KIDNE2018287. 
21750410  2.51 Homo sapiens cDNA FLJ34611 fis, clone KIDNE2014112. 
21706985  3.61 Homo sapiens cDNA FLJ33147 fis, clone UTERU2000218 
3483352  2.19 Homo sapiens full length insert cDNA clone YU66F10. 
5111893  2.16 Homo sapiens cDNA FLJ37762 fis, clone BRHIP2024347, weakly similar to GALECTIN-3. 
18089211  2.29 Homo sapiens, clone IMAGE:4732650, mRNA 
13283225  2.05 Human mRNA upregulated during camptothecin-induced apoptosis of U937 
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cells. 
9325152  2.08 Homo sapiens full length insert cDNA clone ZD79H04 
15943770  2.94 Homo sapiens, clone IMAGE:5404026, mRNA 
2265537  2.03 Homo sapiens cDNA FLJ36460 fis, clone THYMU2014801. 
27694447  2.48 Homo sapiens, clone IMAGE:6155889, mRNA. 
21391489  2.13 Homo sapiens D21S2088E mRNA sequence. 
4895021  2.55 Homo sapiens clone IMAGE:120631 mRNA sequence. 
21752222  2.00 Homo sapiens cDNA FLJ36051 fis, clone TESTI2018083. 
23138779  4.45 Homo sapiens, clone IMAGE:4799886, mRNA. 
23271185  2.54 Homo sapiens, clone IMAGE:4723617, mRNA. 
22749602  2.52 Homo sapiens, clone IMAGE:5167209, mRNA. 
24659364  2.17 Homo sapiens, clone IMAGE:5762932, mRNA. 
10717930  2.84 chromosome 14 open reading frame 70 
10719117  2.02 Homo sapiens, clone IMAGE:4732650, mRNA 
16553158  2.11 Homo sapiens cDNA FLJ32886 fis, clone TESTI2004255. 
15080371  2.42 Homo sapiens, clone IMAGE:4541510, mRNA. 
562424  2.34 Homo sapiens cDNA FLJ33351 fis, clone BRACE2005063. 
15929454  6.42 Homo sapiens, clone IMAGE:3885734, mRNA. 
27370602  2.60 Homo sapiens, clone IMAGE:5272850, mRNA. 
21755882  2.16 Homo sapiens cDNA FLJ39080 fis, clone NT2RP7018197. 
23273407  2.09 Homo sapiens, clone IMAGE:4821940, mRNA. 
21707002  2.29 Homo sapiens, clone IMAGE:4838775, mRNA, partial cds. 
15492406  2.15 Homo sapiens, clone IMAGE:5288527, mRNA 
4761757  2.18 Homo sapiens full length insert cDNA clone YP51C12. 
16551907  2.99 Homo sapiens cDNA FLJ31929 fis, clone NT2RP7006160. 
26251840  3.10 Homo sapiens, clone IMAGE:5270242, mRNA. 
23138689  2.01 Homo sapiens, clone IMAGE:5284251, mRNA. 
27695778  2.00 Homo sapiens, clone IMAGE:5287262, mRNA. 
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9368862  5.02 Homo sapiens mRNA; cDNA DKFZp547B124 (from clone DKFZp547B124). 
22789247  2.21 Homo sapiens, clone IMAGE:5284619, mRNA. 
23243297  2.44 Homo sapiens, Similar to hypothetical protein FLJ1066 
26251897  2.45 Homo sapiens, clone IMAGE:5744232, mRNA 
15929532  2.93 Homo sapiens, clone IMAGE:4272661, mRNA 
21733910  3.02 Homo sapiens mRNA; cDNA DKFZp451E068 (from clone DKFZp451E068). 
27693443  5.55 Homo sapiens, clone IMAGE:5297745, mRNA. 
21748888  2.02 Homo sapiens cDNA FLJ33360 fis, clone BRACE2005253. 
18645132  2.38 Homo sapiens, clone IMAGE:4106638, mRNA, partial cds 
18490345  2.24 Homo sapiens, clone IMAGE:4280848, mRNA. 
13543960  2.03 Homo sapiens, clone IMAGE:3505629, mRNA, partial cds 
7998994  2.28 Human mucin mRNA, partial CDS 
19048193  2.56 Homo sapiens, clone IMAGE:4838884, mRNA 
27469480  2.46 Homo sapiens, clone IMAGE:5303725, mRNA 
21707013  3.17 Homo sapiens, clone IMAGE:5278245, mRNA. 
21733665  2.06 Homo sapiens mRNA; cDNA DKFZp451E0119 (from clone DKFZp451E0119). 
9880662  3.25 Homo sapiens trapped 3 terminal exon, clone B2D7 
23138784  2.14 Homo sapiens, clone IMAGE:4815137, mRNA. 
1314791  3.24 Human oral cancer candidate gene mRNA, clone T9, 3 end. 
3245917  3.30 Homo sapiens, clone IMAGE:4828827, mRNA 
22773448  2.16 Homo sapiens, clone IMAGE:4798439, mRNA. 
12872929  2.28 Homo sapiens, clone IMAGE:4295896, mRNA 
18266902  2.06 Homo sapiens, clone IMAGE:3920449, mRNA. 
19387911  2.13 Homo sapiens, clone IMAGE:4876018, mRNA. 
17315156  2.22 Homo sapiens, clone IMAGE:4622909, mRNA. 
23138810  2.05 Homo sapiens, clone IMAGE:5285294, mRNA. 
23025744  2.09 Homo sapiens, Similar to hypothetical protein MGC5149, 
15214740  2.54 Homo sapiens, clone IMAGE:4708704, mRNA. 
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23272857  2.61 Homo sapiens, clone IMAGE:5583231, mRNA. 
21955461  3.82 Homo sapiens, clone IMAGE:4824334, mRNA. 
22382161  3.48 Homo sapiens, clone IMAGE:4770655, mRNA. 
19387889  2.74 Homo sapiens, clone IMAGE:4544545, mRNA. 
18204260  2.21 Homo sapiens, Similar to zinc finger protein 
22902336  2.34 Homo sapiens, clone IMAGE:4475530, mRNA. 
22658409  2.32 Homo sapiens, clone IMAGE:5106435, mRNA. 
14713658  2.43 Homo sapiens, clone IMAGE:4290767, mRNA. 
18988609  2.07 Homo sapiens, clone IMAGE:3936226, mRNA 
21961399  2.05 Homo sapiens, clone IMAGE:4401081, mRNA. 
13543476  2.18 Homo sapiens, hyaluronoglucosaminidase 3, clone MGC:14472 
897614  2.17 Homo sapiens transmembrane tyrosine kinase mRNA, complete cds. 
5053998  2.05 Human BRCA2 region, mRNA sequence CG011 
6698300  2.10 Homo sapiens cDNA: FLJ21771 fis, clone COLF7779 
9368876  2.22 Homo sapiens mRNA; cDNA DKFZp547N074 (from clone DKFZp547N074) 
10435808  2.10 Homo sapiens cDNA FLJ13712 fis, clone PLACE2000394. 
7947076  2.28 Human soluble CD44 (CD44) mRNA, with exon v9 extension, partial cds 
10432666  2.35 Homo sapiens cDNA FLJ11412 fis, clone HEMBA1000876 
527579  3.28 H.sapiens mRNA for ribosomal protein L18a homologue 
7328007  2.30 Homo sapiens mRNA; cDNA DKFZp434H0229  
10440237  2.11 Homo sapiens cDNA: FLJ23519 fis, clone LNG04908  
6197723  2.32 ESTs, Weakly similar to ALUF_HUMAN  
10810430  2.35 ESTs, Weakly similar to AF208855 1 BM-013  
4874618  2.64 ESTs, Highly similar to T-box-containing transcriptional activator 
12005981  2.06 Homo sapiens DC37 mRNA, complete cds. 
11493436  2.41 Homo sapiens clone FLB8034 PRO2158 mRNA, complete cds 
6983841  2.73 Homo sapiens mRNA for tomoregulin, complete cds 
12006208  3.44 Homo sapiens DC48 mRNA, complete cds.  
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13623316  3.46 Homo sapiens, clone MGC:10724, mRNA, complete cds 
13603378  2.59 Homo sapiens 5-nucleotidase I mRNA, complete cds 
1126361  2.40 ESTs 
4610307  2.89 Homo sapiens cDNA: FLJ21410 fis, clone COL03938 
7246662  2.95 ESTs, Weakly similar to KIAA1204 protein (H.sapiens) 
9867611  2.91 ESTs, Weakly similar to ALU7 
5448126  2.71 Homo sapiens cDNA: FLJ21042 fis, clone CAE11204 
4997672  2.68 ESTs 
11263724  2.00 ESTs 
10030244  2.33 ESTs 
5854418  2.30 ESTs 
11130642  2.18 Homo sapiens mRNA; cDNA DKFZp586J0720  
5054233  2.89 ESTs 
2874383  2.56 Homo sapiens cDNA FLJ10500 fis, clone NT2RP2000369 
10825381  2.23 ESTs 
5513942  2.67 ESTs, Highly similar to I38945 melanoma ubiquitous mutated protein  
9704374  2.14 Homo sapiens cDNA FLJ12936 fis, clone NT2RP2005018 
10585982  2.42 ESTs 
2898542  2.17 ESTs 
2878893  2.40 Homo sapiens cDNA: FLJ21715 fis, clone COL10287, highly similar to AF071569 multifunctional  
10301536  2.40 ESTs 
11593563  2.40 ESTs 
7799136  3.00 Homo sapiens EST from clone 208499, full insert  
11007502  2.50 Homo sapiens cDNA FLJ12030 fis, clone HEMBB1001868 
11016719  2.01 Homo sapiens cDNA FLJ10941 fis, clone OVARC1001243 
2261986  2.25 Homo sapiens HSPC106 mRNA, partial cds 
10433162  2.02 Homo sapiens cDNA FLJ11814 fis, clone HEMBA1006381. 
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10438582  4.22 Homo sapiens cDNA: FLJ22266 fis, clone HRC03089. 
10432694  2.51 Homo sapiens cDNA FLJ11437 fis, clone HEMBA1001226  
6808434  2.99 Homo sapiens mRNA; cDNA DKFZp434E145  
5912099  2.83 Homo sapiens mRNA; cDNA DKFZp566O1624 
11008881  2.42 Homo sapiens cDNA FLJ12212 fis, clone MAMMA1000979 
10433290  2.04 Homo sapiens cDNA FLJ11919 fis, clone HEMBB1000274. 
4406668  5.86 Homo sapiens clone 24894 mRNA sequence. 
4884225  3.26 Homo sapiens mRNA; cDNA DKFZp564B032  
3766130  3.41 Homo sapiens PAC clone RP4-669B10 from 7q33-q35 
10439146  2.25 Homo sapiens cDNA: FLJ22668 fis, clone HSI08585. 
10439819  4.20 Homo sapiens cDNA: FLJ23208 fis, clone ADSE01253. 
4500031  3.26 Homo sapiens mRNA; cDNA DKFZp564I103  
876413  2.59 ESTs 
4070155  2.10 ESTs 
7247381  2.22 ESTs 
10822124  2.05 ESTs 
4311165  2.55 ESTs 
5741187  2.73 ESTs 
4738586  2.23 ESTs 
3898470  2.39 ESTs 
696583  2.01 ESTs, Weakly similar to alternatively spliced product using exon 13A  
4896021  3.37 ESTs 
6702839  4.08 ESTs 
10939000  2.66 ESTs 
3052775  2.23 ESTs 
2782919  3.11 ESTs 
8909427  2.65 ESTs 
9703764  2.68 ESTs 
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1227643  2.37 ESTs 
10301882  2.08 ESTs 
9869489  2.25 ESTs 
1225259  2.38 ESTs 
11592084  2.11 ESTs 
697122  4.68 ESTs 
4985432  2.32 ESTs 
7148710  2.35 ESTs 
1505796  2.32 ESTs 
8156739  2.64 ESTs 
3109118  2.90 ESTs 
11547763  2.04 ESTs 
8888160  5.14 ESTs 
8157795  2.75 ESTs, Weakly similar to AF108460 1 ubinuclein 
5340596  2.20 ESTs 
2006798  2.38 ESTs 
6496811  2.39 ESTs 
6496811  2.43 ESTs 
9179366  2.26 ESTs 
11600065  2.20 ESTs 
3427699  3.24 ESTs 
5111876  2.56 ESTs 
8905208  2.09 ESTs 
13340980  2.36 ESTs 
2052997  2.25 ESTs 
5054311  3.72 ESTs 
4083674  3.16 ESTs 
7457491  2.76 ESTs 
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817755  2.66 ESTs 
648511  2.04 ESTs 
5054307  2.96 ESTs 
6661498  2.04 ESTs 
11598629  2.54 ESTs 
6444844  2.12 ESTs 
8007397  2.56 ESTs 
8472949  2.23 ESTs, Moderately similar to pyruvate dehydrogenase E1-alpha subunit precursor 
10032681  3.27 ESTs, Weakly similar to ALUA_HUMAN  
9867191  2.11 ESTs 
5887371  2.04 ESTs, Weakly similar to CYA6_HUMAN ADENYLATE CYCLASE, TYPE VI 
12057724  4.64 ESTs 
821774  2.19 ESTs 
6087291  2.06 ESTs 
867415  2.03 ESTs 
5768395  2.56 ESTs 
3143651  2.05 ESTs 
11599277  2.20 ESTs 
12512341  2.22 ESTs 
3959771  2.00 ESTs 
3041371  2.05 ESTs 
12356555  2.26 ESTs 
5393539  2.64 ESTs 
3412614  5.54 ESTs 
1484744  2.37 ESTs 
4147560  2.09 ESTs 
2910255  2.40 ESTs 
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9792941  3.15 ESTs 
Gene ID Gene Name 
Expression 
Fold 
Change 
(down 
regulated) 
Description 
10321660 ACP1 -4.00 Acid phosphatase 1, soluble 
5901889 ADAMTS8 -2.06 Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 8 (ADAMTS8), mRNA 
4501922 ADCYAP1R1 -2.05 Homo sapiens adenylate cyclase activating polypeptide 1 (pituitary) receptor type I (ADCYAP1R1) 
5453538 ADE2H1 -2.24 Homo sapiens multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase (ADE2H1) 
11061448 ADIR -2.78 Homo sapiens mRNA for ATP-dependant interferon response protein 2 (ADIR gene) 
1306665 AGA -2.77 aspartylglucosaminidase 
2155239 AGPAT2 -2.15 Human lysophosphatidic acid acyltransferase-beta mRNA 
5529662 ANXA2 -2.14 annexin A2 
11038642 AP2S1 -2.90 Homo sapiens adaptor-related protein complex 2, sigma 1 subunit (AP2S1), transcript variant AP17delta, 
5848763 APLP2 -2.02 Amyloid beta (A4) precursor-like protein 2 
7662085 ARHGEF11 -2.72 Homo sapiens Rho guanine exchange factor (GEF) 11 (ARHGEF11), mRNA 
5031602 ARL4 -2.31 Homo sapiens ADP-ribosylation factor-like 4 (ARL4), mRNA 
2094740 ARNTL -2.26 Homo sapiens mRNA for BMAL1e, complete cds 
4757779 ARRB2 -2.47 Homo sapiens arrestin, beta 2 (ARRB2), mRNA 
12275865 ATDC -2.74 Homo sapiens tripartite motif protein TRIM29 beta mRNA, complete cds 
5437188 AXIN2 -2.34 Axin 2 (conductin, axil) 
13569945 BA108L7.2 -2.46 Homo sapiens similar to rat tricarboxylate carrier-like protein (BA108L7.2), mRNA 
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12751138 BAL -2.48 Homo sapiens B aggressive lymphoma long isoform (BAL) mRNA, complete cds 
4757837 BAX -2.19 Homo sapiens BCL2-associated X protein (BAX), mRNA 
4502380 BCL2L1 -3.30 Homo sapiens BCL2-like 1 (BCL2L1), mRNA 
13112010 BENE -3.90 Homo sapiens, clone MGC:4419, mRNA, complete cds 
9878618 BIG2 -3.68 brefeldin A-inhibited guanine nucleotide-exchange protein 2 
17511794 bioref -2.28 Homo sapiens, clone MGC:31940 IMAGE:4553653, mRNA, complete cds 
16359168 BITE -2.24 Homo sapiens, Similar to p10-binding protein, clone MGC:22949 IMAGE:4858367, mRNA 
2778778 BLVRA -4.31 biliverdin reductase A 
686012 BRPF3 -2.27 bromodomain and PHD finger containing, 3 
3739598 C11ORF15 -2.87 chromosome 11 open reading frame 15 
10287071 CALM3 -2.41 calmodulin 3 (phosphorylase kinase, delta) 
4086141 CALR -3.46 Calreticulin 
12056961 CAST -3.12 Homo sapiens calpastatin mRNA, complete cds 
4826664 CCS -2.15 Homo sapiens copper chaperone for superoxide dismutase (CCS), mRNA 
1137068 CD74 -2.63 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antig 
12923866 CDS2 -2.02 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 
15126732 CGI-18 -2.26 Homo sapiens, Similar to CGI-18 protein, clone MGC:8735 IMAGE:3858865 
1230376 CGI-56 -2.41 beta-parvin 
4885104 CHAF1B -4.70 Homo sapiens chromatin assembly factor 1, subunit B (p60) (CHAF1B), mRNA
1905899 CKAP1 -2.03 Homo sapiens DNA from chromosome 19-cosmid f24590 containing CAPNS and POL2RI 
4502876 CLDN4 -2.63 Homo sapiens claudin 4 (CLDN4), mRNA 
6005734 COPE -3.15 Homo sapiens coatomer protein complex, subunit epsilon (COPE), mRNA 
3641620 CPD -2.04 Homo sapiens mRNA for gp180-carboxypeptidase D-like enzyme, complete cds 
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12751066 CRI1 -2.15 Homo sapiens PNAS-26 mRNA, complete cds 
15341933 CRYZL1 -2.10 Homo sapiens, clone MGC:8826 IMAGE:3870188, mRNA, complete cds 
6397524 CTL1 -2.24 Transporter-like protein 
11591983 CTRL -2.56 chymotrypsin-like 
18482479 CXADR -2.46 Homo sapiens coxsackie-adenovirus-receptor isoform CAR37 (CXADR) 
3551833 DAGK1 -2.09 Homo sapiens clone 24 diacylglycerol kinase alpha (DAGK1) mRNA, complete cds 
4503318 DGUOK -3.66 Homo sapiens deoxyguanosine kinase (DGUOK), mRNA 
7108341 DHPS -2.35 Homo sapiens deoxyhypusine synthase (DHPS), transcript variant 1, mRNA 
12053302 DKFZp434E229 -3.00 Homo sapiens mRNA; cDNA DKFZp434E229 (from clone DKFZp434E229) 
12053188 DKFZp434M182 -2.07 Homo sapiens mRNA; cDNA DKFZp434M182 (from clone DKFZp434M182) 
6807975 DKFZp434P072 -3.36 Homo sapiens mRNA; cDNA DKFZp434P072 (from clone DKFZp434P072) 
12804040 DKFZP564J0123 -2.69 Homo sapiens, Similar to nuclear protein E3-3 orf1, clone MGC:10527, mRNA 
4929614 DKFZP566C134 -3.09 Homo sapiens CGI-73 protein mRNA, complete cds 
12053344 DKFZp586H1320 -2.82 Homo sapiens mRNA; cDNA DKFZp586H1320 
12053358 DKFZp586H1322 -2.90 Homo sapiens mRNA; cDNA DKFZp586H1322 
13276648 DKFZp761J1523 -2.86 Homo sapiens mRNA; cDNA DKFZp761J1523 
8393263 DLL3 -2.87 Homo sapiens delta (Drosophila)-like 3 (DLL3), mRNA 
11493772 EHF -2.77 Homo sapiens ETS-family transcription factor EHF (EHF) mRNA 
10832596 ENSA -3.67 endosulfine alpha 
11594983 EPB41L2 -2.07 Erythrocyte membrane protein band 4.1-like 2 
10439354 FANCA -2.68 Homo sapiens cDNA: FLJ22829 fis, clone KAIA4075, highly similar to HSCH 
5031692 FBRNP -2.89 Homo sapiens heterogeneous nuclear protein similar to rat helix destabilizing protein (FBRNP), mRNA 
10438969 FBXO5 -2.55 Homo sapiens cDNA: FLJ22544 fis, clone HSI00219 
13186237 FGFR1 -2.54 Homo sapiens fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) (FGFR1), transcript variant 5, Mrna 
2078479 FHL-1 -2.28 Human heart protein with four and a half LIM domains (FHL-1) mRNA 
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10436956 FJH1 -2.96 Homo sapiens cDNA: FLJ20982 fis, clone ADSU02018 
11056001 FKSG2 -2.55 Homo sapiens apoptosis inhibitor (FKSG2), mRNA 
12408251 FKSG30 -2.64 Homo sapiens FKSG30 (FKSG30) mRNA, complete cds 
13327692 FLII -2.13 Flightless I (Drosophila) homolog 
8922343 FLJ10308 -2.28 Homo sapiens homolog of rat nadrin (FLJ10308), mRNA 
8922412 FLJ10415 -3.95 Homo sapiens hypothetical protein FLJ10415 
8922425 FLJ10450 -3.29 Homo sapiens hypothetical protein FLJ10450 
8922643 FLJ10751 -2.25 Homo sapiens hypothetical protein FLJ10751 
8922715 FLJ10851 -2.78 Homo sapiens hypothetical protein FLJ10851 
13280012 FLJ10903 -2.05 Hypothetical protein FLJ10903 
12892919 FLJ11126 -2.01 hypothetical protein FLJ11126 
11967980 FLJ12538 -3.89 Homo sapiens hypothetical protein FLJ12538 similar to ras-related protein RAB17 
12597646 FLJ12572 -2.35 Homo sapiens hypothetical protein FLJ12572 (FLJ12572), mRNA 
13376722 FLJ12584 -3.18 Homo sapiens hypothetical protein FLJ12584 (FLJ12584), mRNA 
13376330 FLJ12618 -3.18 Homo sapiens hypothetical protein FLJ12618 (FLJ12618), mRNA 
13529205 FLJ12644 -3.21 Homo sapiens, hypothetical protein FLJ12644, clone MGC:12483 
13376670 FLJ13087 -2.91 Homo sapiens hypothetical protein FLJ13087 (FLJ13087), mRNA 
11968026 FLJ13258 -2.38 Homo sapiens hypothetical protein FLJ13258 similar to fused toes (FLJ13258), mRNA 
13376616 FLJ14038 -3.14 Homo sapiens hypothetical protein FLJ14038 (FLJ14038), mRNA 
12654818 FLJ20071 -3.16 Homo sapiens, Similar to hypothetical protein FLJ20071, clone MGC:4975 
8923113 FLJ20113 -3.10 Homo sapiens hypothetical protein FLJ20113 (FLJ20113), mRNA 
13581300 FLJ20335 -2.47 hypothetical protein FLJ20335 
9134345 FLJ20452 -2.24 Hypothetical protein FLJ20452 
10435257 FLJ20542 -3.09 Homo sapiens cDNA FLJ13294 fis, clone OVARC1001232 
6228478 FLJ20580 -2.85 Hypothetical protein FLJ20580 
13376618 FLJ21168 -2.21 Homo sapiens hypothetical protein FLJ21168 (FLJ21168), mRNA 
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12232416 FLJ22059 -2.01 Homo sapiens hypothetical protein FLJ22059 (FLJ22059), mRNA 
12759062 FLJ22313 -2.00 hypothetical protein FLJ22313 
22749272 FLJ35954 -2.14 Homo sapiens hypothetical protein FLJ35954 (FLJ35954), mRNA 
5803018 FSHPRH1 -2.74 Homo sapiens FSH primary response (LRPR1, rat) homolog 1 (FSHPRH1), mRNA 
4503800 FUBP1 -2.02 Homo sapiens far upstream element (FUSE) binding protein 1 (FUBP1), mRNA 
4503870 GABRR2 -2.14 Homo sapiens gamma-aminobutyric acid (GABA) receptor, rho 2 (GABRR2), mRNA 
2459950 GART -2.08 Homo sapiens GARS-AIRS-GART mRNA, partial cds 
4503942 GCDH -2.26 Homo sapiens glutaryl-Coenzyme A dehydrogenase (GCDH), nuclear gene encoding mitochondrial protein, transcript variant 1 
5729839 GCP2 -2.36 Homo sapiens gamma-tubulin complex protein 2 (GCP2), mRNA 
9970082 GFPT1 -2.21 glutamine-fructose-6-phosphate transaminase 1 
4557626 GLE1L -2.94 Homo sapiens GLE1 (yeast homolog)-like, RNA export mediator (GLE1L), mRNA 
4504036 GNA11 -2.69 Homo sapiens guanine nucleotide binding protein (G protein), alpha 11 (Gq class) (GNA11), mRNA 
4504184 GSTT1 -2.07 Homo sapiens glutathione S-transferase theta 1 (GSTT1), mRNA 
2687868 GTBP -2.38 Homo sapiens GTBP mRNA for GTBP-ALT, complete cds 
4504200 GTF2H4 -2.32 Homo sapiens general transcription factor IIH, polypeptide 4 (52kD subunit) (GTF2H4), mRNA 
595266 HADHA -2.09 Human 78 kDa gastrin-binding protein mRNA, complete cds 
8118720 HDAC8 -2.66 Homo sapiens class I histone deacetylase (HDAC8) mRNA, complete cds 
5001538 HIBADH -2.39 Homo sapiens BAC clone GS1-98E2 from 7p11.2-p21 
5855963 HKE2 -2.07 HLA class II region expressed gene KE2 
1575443 HLA-Cw*1701 -2.30 Homo sapiens HLA class I heavy chain (HLA-Cw*1701) mRNA, complete cds 
17736799 hMCLC-3 -2.30 Homo sapiens hMCLC-3 mRNA for Mid-1-related chloride channel 3, complete 
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cds 
16416450 hMtCCA -3.47 Homo sapiens hMtCCA mRNA for tRNA-nucleotidyltransferase, complete cds 
10434948 HN1L -3.17 Hypothetical protein similar to mouse HN1 (Hematological and Neurological expressed sequence 1) 
10365758 HNRPC -2.36 Heterogeneous nuclear ribonucleoprotein C (C1C2) 
5031752 HNRPH1 -2.07 Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (H) (HNRPH1), mRNA 
11875212 HPC2 -2.98 Homo sapiens putative prostate cancer susceptibility protein (HPC2), mRNA 
11291478 HPIP -3.35 Hematopoietic PBX-interacting protein 
2853276 HPRP4 -2.66 Homo sapiens WD splicing factor Hprp4p (HPRP4) mRNA, complete cds 
5110914 HRB -2.38 HIV-1 Rev binding protein 
12006357 HRIHFB2122 -2.02 Homo sapiens Tara mRNA, complete cds 
10703387 HRMT1L1 -2.44 HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 
5579469 HSPA1A -2.29 Homo sapiens heat shock 70kD protein 1A (HSPA1A), mRNA 
7661727 HSPC003 -2.19 Homo sapiens HSPC003 protein (HSPC003), mRNA 
7661735 HSPC018 -3.53 Homo sapiens HSPC018 protein (HSPC018), mRNA 
7661741 HSPC023 -3.60 Homo sapiens HSPC023 protein (HSPC023), mRNA 
7661793 HSPC134 -2.02 Homo sapiens HSPC134 protein (HSPC134), mRNA 
12654148 HSPC154 -2.77 Homo sapiens, HSPC154 protein, clone MGC:4897, mRNA, complete cds 
7106781 HSPC196 -2.56 Homo sapiens HSPC196 mRNA, complete cds 
5031770 HSPF2 -3.11 Homo sapiens heat shock 40kD protein 2 (HSPF2), mRNA 
4617892 ICAM1 -2.40 Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 
7542379 IDS -2.14 Homo sapiens normal control W-IDS fusion transcript, mRNA sequence 
9970542 IGHG3 -3.69 immunoglobulin heavy constant gamma 3 (G3m marker) 
4826773 ISG15 -2.31 Homo sapiens interferon-stimulated protein, 15 kDa (ISG15), mRNA 
11252643 ITGB4 -3.82 integrin, beta 4 
4504808 JUNB -2.79 Homo sapiens jun B proto-oncogene (JUNB), mRNA 
577300 KIAA0090 -2.45 Human mRNA for KIAA0090 gene, partial cds 
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7661901 KIAA0095 -4.69 Homo sapiens KIAA0095 gene product (KIAA0095), mRNA 
10439023 KIAA0197 -2.39 Homo sapiens cDNA: FLJ22583 fis, clone HSI02596 
11286290 KIAA0273 -2.41 KIAA0273 gene product 
832234 KIAA0285 -2.29 KIAA0285 gene product 
5113513 KIAA0414 -2.37 KIAA0414 protein 
2887434 KIAA0432 -2.36 Homo sapiens KIAA0432 mRNA, complete cds 
1686271 KIAA0470 -2.05 KIAA0470 gene product 
7023392 KIAA0713 -2.05 Homo sapiens cDNA FLJ10999 fis, clone PLACE1002529 
18256839 KIAA0826 -3.92 Homo sapiens, clone MGC:25069 IMAGE:4498553, mRNA, complete cds 
7662331 KIAA0844 -2.11 Homo sapiens KIAA0844 protein (KIAA0844), mRNA 
4665833 KIAA0872 -3.88 KIAA0872 protein 
12784477 KIAA1150 -2.05 KIAA1150 protein 
11546048 KIAA1247 -4.09 Human DNA sequence from clone RP5-1049G16 on chromosome 20q12-13.2 
10434518 KIAA1250 -2.06 Likely homolog of rat kinase D-interacting substance of 220 kDa; KIAA1250 protein 
7959294 KIAA1514 -2.95 Homo sapiens mRNA for KIAA1514 protein, partial cds 
10047238 KIAA1582 -2.63 Homo sapiens mRNA for KIAA1582 protein, partial cds 
12697944 KIAA1700 -2.08 Homo sapiens mRNA for KIAA1700 protein, partial cds 
1928356 KNS2 -2.14 Kinesin 2 (60-70kD) 
2588629 LOC51666 -2.81 Human BAC clone GS1-303P24 from 7q21-22 
10435318 LOC51729 -4.73 Homo sapiens cDNA FLJ13336 fis, clone OVARC1001879 
9910351 LOC56904 -3.13 Homo sapiens SH3-containing protein SH3GLB2 (LOC56904), mRNA 
12768600 M11S1 -2.10 Membrane component, chromosome 11, surface marker 1 
5454183 MAP3K12 -2.58 Homo sapiens mitogen-activated protein kinase kinase kinase 12 (MAP3K12), mRNA 
4505098 MAP4 -3.16 Homo sapiens microtubule-associated protein 4 (MAP4), mRNA 
795931 MFAP3 -2.70 microfibrillar-associated protein 3 
13128987 MGC3103 -3.01 Homo sapiens hypothetical protein MGC3103 
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22749020 MGC39558 -2.52 Homo sapiens hypothetical protein MGC39558 
5803089 MLN64 -2.25 Homo sapiens steroidogenic acute regulatory protein related 
7019460 MLX -2.15 Homo sapiens MAX-like bHLHZIP protein (MLX), mRNA 
6006024 MPP1 -2.02 Homo sapiens membrane protein, palmitoylated 1 (55kD) 
13549066 MST4 -3.78 Homo sapiens serinethreonine protein kinase MST4 (MST4) mRNA 
5174602 MYRL2 -2.57 Homo sapiens myosin regulatory light chain 2, smooth muscle isoform (MYRL2), mRNA 
9502399 MYRL2 -2.70 Homo sapiens chromosome 19, BAC CIT-HSPC_204F22 (BC228680) 
6912523 NARF -2.28 Homo sapiens nuclear prelamin A recognition factor (NARF), mRNA 
1480645 NCOA1 -2.51 Human steroid receptor coactivator-1 F-SRC-1 mRNA, complete cds 
4826853 NDUFB8 -3.68 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8 (19kD, ASHI) 
4505370 NDUFS8 -2.17 Homo sapiens NADH dehydrogenase (ubiquinone) Fe-S protein 8 (23kD) (NADH-coenzyme Q reductase) 
506817 NFE2 -2.75 Human leucine zipper mRNA, complete cds 
17391108 NFS1 -2.14 Homo sapiens, Similar to nitrogen fixation gene 1 (S. cerevisiae, homolog) 
1669493 NFYC -2.36 Human transcription factor NF-YC subunit mRNA 
10864008 NLI-IF -2.07 Homo sapiens nuclear LIM interactor-interacting factor (NLI-IF) 
4534208 NMT1 -2.24 N-myristoyltransferase 1 
12803666 NR2F6 -2.81 Homo sapiens, nuclear receptor subfamily 2, group F, member 6, clone MGC:4277, mRNA, complete cds 
4505274 NUDT1 -2.25 Homo sapiens nudix (nucleoside diphosphate linked moiety X)-type motif 1 (NUDT1), mRNA 
7019476 OMI -3.11 Homo sapiens HtrA-like serine protease (OMI), mRNA 
5663957 OSBP -2.59 Oxysterol binding protein 
13699862 OTRPC4 -2.47 Homo sapiens vanilloid receptor-related osmotically activated channel; OTRPC4 protein (OTRPC4) 
4505548 P2RX4 -2.67 Homo sapiens purinergic receptor P2X, ligand-gated ion channel, 4 (P2RX4), 
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mRNA 
12906073 PHB -2.07 Prohibitin 
10824430 PICALM -2.23 Phosphatidylinositol binding clathrin assembly protein 
10818329 PICALM -2.35 Phosphatidylinositol binding clathrin assembly protein 
1743874 PIP5K1A -2.08 Human 68 kDa type I phosphatidylinositol-4-phosphate 5-kinase alpha mRNA, clone PIP5KIa3 
9966876 PIST -3.33 Homo sapiens PIST (PIST), mRNA 
10742618 PL6 -2.08 PL6 protein 
12654620 PMP24 -2.30 Homo sapiens, 24 kDa intrinsic membrane protein, clone MGC:1213 
4505944 POLR2E -2.12 Homo sapiens polymerase (RNA) II (DNA directed) polypeptide E (25kD) 
10435912 PPFIA3 -2.42 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 3 
4505990 PPIC -2.09 Homo sapiens peptidylprolyl isomerase C (cyclophilin C) (PPIC), mRNA 
5031988 PPP3CC -2.71 Homo sapiens protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma) 
13699864 PRO1853 -2.21 Homo sapiens hypothetical protein PRO1853 (PRO1853), mRNA 
12771232 PRO2706 -2.08 Hypothetical protein PRO2706 
6807722 PRO2730 -3.71 Homo sapiens mRNA; cDNA DKFZp434C0814 
8924201 PRO2801 -2.47 Homo sapiens hypothetical protein PRO2801 (PRO2801), mRNA 
4506192 PSMB1 -2.08 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 1 (PSMB1), mRNA 
11445036 PSMD11 -2.48 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 
16580750 PTBLP -3.47 Homo sapiens PTBLP mRNA for PTB-like protein S, complete cds 
4506278 PTMS -2.18 Homo sapiens parathymosin (PTMS), mRNA 
4506310 PTPRF -3.22 Homo sapiens protein tyrosine phosphatase, receptor type 
2281288 PTPRN2 -4.50 Human tyrosine phosphatase IA-2beta mRNA, complete cds 
13376819 PUS1 -5.14 Homo sapiens pseudouridine synthase 1 (PUS1), mRNA 
4896040 RASA3 -3.20 RAS p21 protein activator (GTPase activating protein) 3 (Ins(1,3,4,5)P4-
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binding 
9256633 RASSF1 -3.54 Homo sapiens Ras association (RalGDSAF-6) domain family 1, mRNA 
8400719 RBMS1 -3.09 Homo sapiens RNA binding motif, single stranded interacting protein 1, transcript variant MSSP-3 
6677700 RE2 -2.50 Homo sapiens G-protein coupled receptor 
6677722 RFC5 -2.79 Homo sapiens replication factor C (activator 1) 5 (36.5kD), mRNA 
5231227 RNASE6PL -2.39 Homo sapiens ribonuclease 6 precursor 
12656362 RNF6 -2.47 Homo sapiens RNF6 protein, alternatively spliced 
10811717 RP42 -3.57 RP42 homolog 
13528944 RPA3 -2.08 Homo sapiens, replication protein A3 (14kD), clone MGC:12305 
4506680 RPS11 -2.48 Homo sapiens ribosomal protein S11 
4506690 RPS16 -2.09 Homo sapiens ribosomal protein S16 
4506762 S100A3 -3.22 Homo sapiens S100 calcium-binding protein A3 
13540474 SAA2 -2.51 Homo sapiens serum amyloid A2 
758680 SAA2 -2.10 Homo sapiens serum amyloid A2-alpha mRNA, complete cds 
5730024 SAD1 -3.08 Homo sapiens SnRNP assembly defective 1 homolog, mRNA 
10584719 SAT -2.06 Spermidinespermine N1-acetyltransferase 
7023794 SEC15L -3.77 Homo sapiens cDNA FLJ11251 fis, clone PLACE1008813 
7661681 SENP3 -2.05 Homo sapiens sentrinSUMO-specific protease 3 (SENP3), mRNA 
7021892 SENP3 -2.49 Homo sapiens cDNA FLJ10061 fis, clone HEMBA1001413. 
15430748 SEPTIN6 -2.92 Homo sapiens SEPTIN6 type IV (SEPTIN6) mRNA, complete cds 
11141876 SIGIRR -2.69 Homo sapiens single Ig IL-1R-related molecule 
5803168 SIPA1 -2.69 Homo sapiens signal-induced proliferation-associated gene 1 
5436769 SLC12A4 -2.49 solute carrier family 12 (potassiumchloride transporters), member 4 
4759111 SLC16A3 -2.12 Homo sapiens solute carrier family 16 (monocarboxylic acid transporters), member 3 
4507006 SLC25A12 -2.01 Homo sapiens solute carrier family 25 (mitochondrial carrier, Aralar), member 12 
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4826715 SLC29A1 -2.52 Homo sapiens solute carrier family 29 (nucleoside transporters), member 1 
4507022 SLC4A2 -2.80 Homo sapiens solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1) 
10946127 SMARCA4 -2.03 SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 
10432598 SMARCB1 -2.63 SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 
21739263 Spir-1 -2.91 Homo sapiens mRNA; cDNA DKFZp434O034 
11127696 SSXTSSX4v fusion -2.28 Homo sapiens SYTSSX4v fusion protein (SSXTSSX4v fusion) mRNA 
7305524 ST7 -2.85 Homo sapiens potential tumor suppressor (ST7), mRNA 
2443360 STATI2 -3.19 Homo sapiens mRNA for STAT induced STAT inhibitor-2, complete cds 
12893045 STIP1 -2.11 Stress-induced-phosphoprotein 1 (Hsp70Hsp90-organizing protein) 
6991686 SYK -2.50 spleen tyrosine kinase 
5454101 TACC3 -3.67 Homo sapiens transforming, acidic coiled-coil containing protein 3 (TACC3), mRNA 
10439398 TAF1B -2.67 Homo sapiens cDNA: FLJ22868 fis 
2961148 TASR1 -2.13 Homo sapiens TLS-associated protein TASR mRNA, complete cds 
4507372 TBCC -2.99 Homo sapiens tubulin-specific chaperone c (TBCC), mRNA 
4507384 TCEA2 -3.12 Homo sapiens transcription elongation factor A (SII), 2 (TCEA2), mRNA 
5886115 TCF7 -2.24 transcription factor 7 (T-cell specific, HMG-box) 
529172 TCF8 -2.20 Human zinc finger homeodomain protein mRNA, complete cds 
339577 TGM2 -2.66 Human transglutaminase mRNA, complete cds 
13097680 TGM2 -2.20 Similar to transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase), clone MGC:1193 
11024699 TIMM13B -2.02 Homo sapiens translocase of inner mitochondrial membrane 13 (yeast) homolog B (TIMM13B) 
5802826 TIMM8B -2.38 Homo sapiens DDP-like protein mRNA, complete cds 
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9257247 TIMP2 -2.04 Homo sapiens tissue inhibitor of metalloproteinase 2 (TIMP2), mRNA 
2460248 TNNC1 -4.61 Homo sapiens cardiac ventricular troponin C mRNA, complete cds 
7706580 TOK-1 -2.25 Homo sapiens cdk inhibitor p21 binding protein (TOK-1), mRNA 
5032188 TP53BP1 -3.39 Homo sapiens tumor protein p53-binding protein, 1 (TP53BP1), mRNA 
14010353 TPM3 -2.15 Homo sapiens tropomyosin 4-anaplastic lymphoma kinase fusion protein minor isoform mRNA 
12803958 TPM4 -2.03 Homo sapiens, tropomyosin 4, clone MGC:3641, mRNA, complete cds 
7317562 TPP2 -2.84 Tripeptidyl peptidase II 
4759277 U5-100K -2.62 Homo sapiens prp28, U5 snRNP 100 kd protein (U5-100K), mRNA 
13376853 UBXD1 -3.48 Homo sapiens UBX domain-containing gene 1 (UBXD1) 
13506764 UCK1 -3.84 Homo sapiens uridine-cytidine kinase 1 (UCK1) mRNA, complete cds 
4557872 UROS -2.24 Homo sapiens uroporphyrinogen III synthase (congenital erythropoietic porphyria) (UROS), mRNA 
2735306 VDAC3 -2.27 Human voltage dependent anion channel form 3 mRNA, complete cds 
2881843 VDUP1 -2.40 Upregulated by 1,25-dihydroxyvitamin D-3 
5454161 VDUP1 -2.01 Homo sapiens upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA 
2631843 VIL2 -3.19 Villin 2 (ezrin) 
11141864 VPS11 -3.06 Homo sapiens vacuolar protein sorting 11 (yeast homolog) (VPS11), mRNA 
5730119 YKT6 -3.21 Homo sapiens SNARE protein (YKT6), mRNA 
4096984 YWHAE -2.86 Human epsilon isoform 14-3-3 protein mRNA, complete cds 
6005977 ZNF258 -2.19 Homo sapiens zinc finger protein 258 (ZNF258), mRNA 
23510456 ZNF41 -3.10 Homo sapiens zinc finger protein 41 (ZNF41), transcript variant 1, mRNA 
11129064  -2.09 ESTs 
405730  -3.23 H.sapiens protein-serinethreonine kinase gene, complete CDS 
824338  -2.04 ESTs 
13623280  -2.80 Homo sapiens, hypothetical protein FLJ10647, clone MGC:11318, mRNA, complete cds 
12385360  -2.24 ESTs 
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12749776  -2.49 ESTs 
405744  -2.55 H.sapiens protein-serinethreonine kinase gene, complete CDS 
1265017  -5.13 Homo sapiens cDNA, 3  end 
5769385  -2.86 ESTs, Moderately similar to zinc finger protein (H.sapiens) 
10736104  -2.10 ESTs 
3308527  -2.91 Homo sapiens clone 25129 mRNA sequence 
3178040  -2.77 ESTs 
11008259  -4.12 Homo sapiens cDNA FLJ11985 fis, clone HEMBB1001356 
1437008  -3.17 ESTs 
13281338  -4.03 Homo sapiens, clone IMAGE:3908672, mRNA, partial cds 
2457916  -4.31 Homo sapiens cDNA FLJ30840 fis, clone FEBRA2002442 
4174746  -2.94 ESTs 
16553977  -2.14 Homo sapiens cDNA FLJ25255 fis, clone STM03941 
6506313  -2.13 ESTs 
13591689  -2.30 Homo sapiens PUMAJFY1 protein mRNA, complete cds 
10821160  -2.58 Homo sapiens cDNA: FLJ23031 fis, clone LNG01932 
27469755  -2.24 Homo sapiens, clone IMAGE:5310953, mRNA 
15930214  -3.10 Homo sapiens, clone IMAGE:3884761, mRNA 
1849639  -2.24 ESTs 
4072178  -2.05 ESTs, Weakly similar to T12540 hypothetical protein DKFZp434J214.1 
3430180  -2.18 Homo sapiens cDNA: FLJ21781 fis, clone HEP00223 
3451333  -5.58 Homo sapiens chromosome 19, cosmid F22162 
1641998  -2.29 ESTs 
10836767  -3.44 ESTs 
19731133  -2.51 Homo sapiens cDNA FLJ31833 fis, clone NT2RP6000130 
18255994  -2.89 Homo sapiens, clone MGC:30053 IMAGE:5139119, mRNA, complete cds 
22800482  -3.19 Homo sapiens, clone IMAGE:4552615, mRNA. 
3085925  -2.53 ESTs 
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2984582  -2.13 Homo sapiens chromosome 9, P1 clone 11659 
8331754  -2.22 Homo sapiens X28 region near ALD locus containing DUSP9, ribosomal protein L18a 
5232294  -2.97 ESTs 
20362593  -2.18 Homo sapiens cDNA FLJ38785 fis, clone LIVER2001329 
12661587  -2.75 ESTs 
4188996  -2.06 ESTs 
21734157  -2.01 Homo sapiens mRNA; cDNA DKFZp686F0137 
9513134  -2.31 ESTs 
22477667  -2.24 Homo sapiens, clone IMAGE:5223521, mRNA 
10951966  -2.48 Human clone JkA8 mRNA induced upon T-cell activation, 3 end. 
2012170  -2.61 ESTs 
4888084  -2.48 ESTs, Weakly similar to WASP-family protein 
1278185  -2.02 Homo sapiens cDNA, 5  end 
10914577  -2.38 ESTs 
1422999  -2.27 Homo sapiens cDNA, 3  end 
10434882  -2.15 Homo sapiens cDNA FLJ13049 fis, clone NT2RP30014 
13575205  -2.06 Homo sapiens cDNA FLJ11901 fis, clone HEMBA1007347 
11683355  -2.15 ESTs, Weakly similar to S69890 mitogen inducible gene mig-2 
13045294  -2.60 ESTs 
1301533  -3.37 Homo sapiens 14q32 Jagged2 gene, complete cds 
4703703  -2.31 ESTs 
770394  -2.07 ESTs 
11100686  -2.24 ESTs, Weakly similar to KIAA0681 protein 
12654762  -3.48 Homo sapiens, clone MGC:982 IMAGE:3354306, mRNA, complete cds 
5037961  -2.66 Homo sapiens mRNA; cDNA DKFZp434C1714 
11009912  -2.90 Homo sapiens cDNA FLJ12532 fis, clone NT2RM4000200 
3808147  -2.25 Homo sapiens ASMTL gene 
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5924742  -2.27 Homo sapiens, clone IMAGE:4642241, mRNA 
405728  -2.38 H.sapiens protein-serinethreonine kinase gene, complete CDS 
7921055  -2.65 Homo sapiens chromosome 14 BAC 98L12 
5854235  -2.72 ESTs 
12917064  -2.14 ESTs 
10456093  -3.75 Homo sapiens partial mRNA for FUSCHOP chimaeric fusion protein (type 9 transcript variant) 
12669922  -2.38 ESTs 
4664062  -2.09 ESTs 
4884256  -2.28 Homo sapiens mRNA; cDNA DKFZp564O222 
4738836  -2.71 Homo sapiens cDNA, 3  end 
1869771  -2.32 Human DNA sequence from PAC 296K21 on chromosome X contains cytokeratin exon, delta-aminolevulinate synthase (erythroid) 
13477192  -2.64 Homo sapiens, Similar to CG5078 gene product, clone MGC:12945, mRNA, complete cds 
21040444  -2.87 Homo sapiens, Similar to syndecan binding prote 
12384240  -2.09 ESTs 
2839126  -2.20 Homo sapiens mRNA; cDNA DKFZp434F0217 
10348509  -2.13 ESTs, Moderately similar to T43492 hypothetical protein DKFZp434A219.1 (H.sapiens) 
9812380  -3.48 ESTs 
10151243  -2.06 Homo sapiens cDNA: FLJ22482 fis, clone HRC10859 
5657550  -2.08 ESTs, Moderately similar to ADHUA fructose-bisphosphate aldolase (H.sapiens) 
6656370  -2.44 ESTs 
2094759  -2.38 Human beta-cytoplasmic actin (ACTBP9) pseudogene 
4002364  -2.45 Homo sapiens clone 24627 mRNA sequence 
12654408  -2.16 Homo sapiens, Similar to phosphatidylinositol glycan, class O, clone 
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MGC:3079 
6143075  -2.09 Homo sapiens cDNA: FLJ22807 fis, clone KAIA2887 
10964796  -2.56 Homo sapiens mRNA; cDNA DKFZp564N1272 
13663829  -2.12 Human mRNA for heat shock protein 90kDa, 5UTR 
1470308  -2.34 Phosphoglycerate kinase {alternatively spliced} 
 
 
Note* For up-regulated genes, totally 359 genes were up-regulated and 153 genes were named.  
For down-regulated genes, totally 360 genes were down-regulated and 273 genes were named.
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CHAPTER 3 
NUCLEAR PYRUVATE KINASE M2 IS A PROTEIN KINASE 
 
3.1 Abstract 
Pyruvate kinase isoform M2 (PKM2) is a glycolysis enzyme catalyzing 
conversion of phosphoenolpyruvate (PEP) to pyruvate with transferring a phosphate from 
PEP to ADP. We report here that PKM2 is also a protein kinase using PEP as phosphate 
donor. The protein substrate is bound at the ADP binding site. Our experiments suggest 
that PKM2 dimer is an active protein kinase, while the tetramer is an active pyruvate 
kinase. Binding of the tyrosyl phosphorylated proteins at the FBP binding site converts 
the tetrameric PKM2 to a dimer, and reciprocally regulates the pyruvate kinase and 
protein kinase activities of PKM2. Expression a PKM2 mutant that exists as a dimer 
promotes cell proliferation. Growth factor stimulations significantly increase the 
dimer/tretramer PKM2 ratio in cells. Thus, our study reveals that the regulation of 
pyruvate kinase and protein kinase activities of PKM2 by growth signals plays an 
important role in promoting cell proliferation. 
 
3.2 Introduction 
An important molecular feature of tumor development is the expression of 
pyruvate kinase isoenzyme M2 (PKM2) (Elbers, van Unnik et al. 1991; Hacker, 
Steinberg et al. 1998). The glycolysis catalytically active PKM2 exists as a tetramer and 
associates with a glycolytic enzyme complex in normal cells (Dombrauckas, 2005; 
Zwerschke, 1999; Altenberg, 2004). In tumor cells, it is believed that PKM2 dominantly 
forms a dimer, and appears to be catalytically inactive for conversion of PEP to pyruvate 
(Ashizawa, McPhie et al. 1991; Mazurek, Boschek et al. 2005). It is believed that the 
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inactive PKM2 actually provides growth advantage for tumor progression as it helps to 
channel the carbon source from glycolytic intermediates to biosynthesis, especially 
syntheses of nucleic acids, lipids, and proteins, to meet the demands for tumor cell 
proliferation. Recent studies have suggested that PKM2 changes its pyruvate kinase 
activity, consequently facilitating cell proliferation by binding to tyrosine phosphor-
peptide (Christofk, Vander Heiden et al. 2008; Christofk, Vander Heiden et al. 2008), 
indicating that growth signals regulate the activity of PKM2 in glucose metabolism.  
 
3.3 Results 
3.3.1 PKM2 is a Protein Kinase   
 We previously reported that nuclear PKM2 upregulated the MEK5 gene 
transcription by activating the transcription co-activator stat3. We showed that expression 
of PKM2 increased stat3 phosphorylation at Y705 (Gao, et.al. Oncogene revision 2009). 
We questioned whether PKM2 could act as a protein kinase that directly phosphorylated 
stat3. However, an in vitro phosphorylation using both the E. coli expressed recombinant 
PKM2 (rPKM2) and the protein purified from nuclear extracts of mammalian cancer 
cells in the presence of ATP did yield phosphorylation of a commercially available GST-
stat3. Since PKM2 use PEP as phosphate donor to phosphorylate ADP in the glycolysis, 
we reasoned that the protein may use the same phosphate donor to phosphorylate a 
protein substrate. Thus, we replaced ATP by PEP in our in vitro phosphorylation 
reaction. Immunoblot using a commercially available antibody against Y705 
phosphorylated stat3 demonstrated that the GST-stat3 was phosphorylated by both the 
rPKM2 and a HA-tagged PKM2 (HA-PKM2) immunopurified from nuclear extracts of 
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SW620 cells in the presence of PEP. As observed previously, stat3 was not 
phosphorylated in the presence of ATP (Fig. 3.1 A&B). These experimental results 
indicated that PKM2 is a protein kinase using PEP as the phosphate donor. 
 
3.3.2 Dimeric PKM2 is the Active Protein Kinase 
We and others previously reported that PKM2 localized to the cell nucleus 
(Hoshino, Hirst et al. 2007), Gao,et.al. Oncogene revision, 2009). In addition, we 
observed that the kinase activity of the nuclear HA-PKM2 in phosphorylation of stat3 
was substantially higher than that of the rPKM2 expressed in E. coli. We therefore sought 
to compare the protein kinase activity of the nuclear PKM2 and the cytoplasmic PKM2. 
We immunopurified the HA-PKM2 from nuclear or cytoplasmic extracts prepared from 
SW620 cells. The same in vitro phosphorylation reactions using the GST-stat3 as 
substrate were carried out with the immunopurified HA-PKM2 in the presence of PEP or 
ATP. It was evident that both the HA-PKM2 purified from the nuclear extracts and the 
cytoplasmic extracts were active in phosphorylating stat3. However, it was also clear that 
the HA-PKM2 purified from the nuclear extracts had much higher activity in 
phosphorylating stat3 than that of protein purified from the cytoplasmic extracts (Fig. 3.1 
C&D). 
It was reported that the catalytically active tetramer and inactive dimer of PKM2 
co-exist in cells with high proliferation rate (Mazurek et al., 2005). Fructose-1,6-
bisphosphate (FBP) and tyrosine phosphorylation by viral oncogenic products were 
identified as the regulators for the conversion between these two forms (Ashizawa, 
McPhie et al. 1991; Mazurek, Boschek et al. 2005). We therefore questioned whether the 
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differences in the protein kinase activity of nuclear/cytoplasmic PKM2 and the rPKM2 
expressed in E. coli. were due to dimer or tetramer of the protein. To investigated 
whether PKM2 is a dimer or a tetramer both in the nucleus and in the cytoplasm, we first 
fractioned the nuclear extracts and cytoplasmic extracts of SW620 cells by size exclusion 
chromatography. Non-specific protein-protein interactions were disrupted by treatment of 
the extracts with 600 mM 6-aminocaproic acid (6-AcA). The levels of PKM2 in each 
chromatography fraction were examined by immunoblot using the antibody PabPKM2. 
Nuclear PKM2 was only detected in fractions 14 – 16, while cytoplasmic PKM2 was 
mainly detected in fractions 10 – 16 with the highest concentrations in fractions 10 – 12. 
According to the molecular weight calibration standard (Fig. 3.6 A&B), fraction 11 co-
elutes with a molecular weight near 240 kDa, while fraction 14 co-elutes with a 
molecular weight near 120 kDa (Fig. 3.1E). The gel-filtration chromatography 
experiments suggested that nuclear PKM2 was completely dimer (120 kDa), while the 
cytoplasmic PKM2 existed in both dimer and tetramer with a higher population of 
tetramers. The same chromatography procedure was also employed to analyze whether 
the rPKM2 is a dimer or tetramer. It was evident that the rPKM2 was detected in the 
fractions 11 – 14, which indicates that the bacterially expressed rPKM2 is mostly 
tetramer with very small amount of dimer (Fig. 3.2B). To further probe the 
dimer/tetramer status of nuclear and cytoplasmic PKM2, nuclear extracts and 
cytoplasmic extracts made from SW620 cells were separated by a non-denaturing PAGE 
(8% acrylamide:bis-acrylamide = 40:1) and subjected to immunoblot analyses using the 
antibody PabPKM2. The extracts were also treated with 600 mM 6-AcA prior to 
electrophoresis. It was clear that the nuclear PKM2 migrated slightly faster than the BSA 
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dimer (132 kDa). Conversely, the majority of the cytoplasmic PKM2 approximately co-
migrated with Urease (272 kDa) (Fig. 3.6C). Thus, both non-denaturing gel 
electrophoresis and size exclusion chromatography results strongly suggested a division 
of PKM2 between a dimer form in the nucleus and mainly a tetramer form in the 
cytoplasm. The bacterially expressed rPKM2 mainly exist as tetramer. Based on the 
proceeding experimental observations, we speculated that the dimer form of PKM2 is the 
active protein kinase, while tetramer is an active pyruvate kinase. Closely examination of 
the crystal structure of the tetramer human PKM2 (Dombrauckas, Santarsiero et al. 2005) 
reveals that a positive charged residue R399 may plays a critical role in forming the 
tetramer of PKM2. It is notable that the R399 forms stable charge-charge interactions 
with residues E418, D357, and E396 of PKM2 located on the other dimer of the tetramer 
PKM2 (Fig. 3.2A). We therefore created a mutant R399E to disrupt the charge-charge 
interaction. Size exclusion chromatography analyses of the wt rPKM2 and the R399E 
mutant demonstrated that the wild-type rPKM2 existed most as a tetramer with residue 
amounts of dimer, while the R399E mutant was mostly dimer (Fig. 3.2B). We reasoned 
that the dimeric R399E mutant would be more active in phosphorylating stat3 compared 
to the wild-type rPKM2. Thus, the in vitro phosphorylation reactions were carried out 
with the wild-type rPKM2 and the R399E mutant. It was evident that the protein kinase 
activity of the R399E mutant was substantially higher than that of the wild-type rPKM2 
(Fig. 3.2C), while the pyruvate kinase activity of the mutant was dramatically lower than 
that of the rPKM2 (Fig. 3.2D). The results supported our speculation that dimeric PKM2 
is the active protein kinase.  
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To further verify the phosphorylation of stat3 by PKM2, we prepared [32P]-
labeled PEP according to the methods described by Roossien FF. and co-workers 
(Roossien, Brink et al. 1983). The same in vitro phosphorylation reaction was carried out 
with the rPKM2, the rPKM1, and the R399E mutant using the [32P]-labeled PEP. The 
phosphorylation reaction mixture was separated by SDS-PAGE and subjected to 
autoradiography. It was clear that the GST-stat3 was phosphorylated by the R399E 
mutant. The phosphorylation of the GST-stat3 by the rPKM2 was very weak (can only be 
visualized by a substantial overexposure in autoradiograph). The GST-stat3 was not 
phosphorylated by the recombinant PKM1 in the presence of the [32P]-PEP (Fig. 3.6D). 
No phosphorylation can be detected even under very high overexposure in the 
autoradiograph. 
 
3.3.3 Binding Tyrosyl Phosphor-protein at the FBP Site Converts the Tetramer 
PKM2 to the Dimmer and Reciprocally Regulates the Protein Kinase and Pyruvate 
Kinase Activities 
 
Christofk and co-workers reported that PKM2 interacts with phosphor-tyrosine 
peptide and the interaction plays an important role in promoting cell proliferation 
(Christofk et al., 2008a; Christofk et al., 2008b), suggesting a possible pathway that 
growth signals promotes proliferation via protein tyrosine phosphorylation and 
subsequent action on PKM2. Nevertheless, the interaction between PKM2 and a 
particular cellular tyrosine phosphor-protein is not revealed. We previously demonstrated 
that P68 RNA helicase is phosphorylated in cancer cells, and tyrosine phosphorylation of 
p68 correlates with cancer progression (Yang, Lin et al. 2005). Phosphorylation of p68 at 
Y593 promotes EMT (Yang, Lin et al. 2006), while phosphorylation of p68 at Y593 and 
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Y595 mediated resistance to apoptotic-induction (Yang, Lin et al. 2007). In an effort to 
probe interacting protein with the tyrosyl phosphorylated p68, we used a 14 amino acid 
sequence segment that includes the Y593 or Y593/595 phosphorylation site (aa 587 to 
600). The peptides either carried no phosphorylation (Ref to as PepY593), Y593 
phosphorylation (Ref to as PhosPepY593), or Y593/595 double phosphorylations (Ref to 
as D-PhosPepY593). We also used another control peptide that span different region of 
p68 (aa 561 – 574) with Y567 phosphorylation (Ref to as PhosPepY567). The peptides 
were conjugated to agarose beads. Precipitation experiments from nuclear extracts made 
from T98G cells demonstrated that the DPhosPepY593 pulled-down a nuclear protein 
that migrated at ~60 kDa (Fig. 3.7A). The interacting protein was identified by MALDI 
(tof/tof) as PKM2 (pyruvate kinase type M2) (Fig. 3.7A right panel). To verify the 
interaction of p68 with PKM2, the precipitates by the phosphorylated/non-
phosphorylated p68 peptides were examined by immunoblot assay using a polyclonal 
antibody developed against PKM2. It was clear that the ~60 kDa protein precipitated by 
the tyrosine phosphorylated p68 peptide was recognized by the PKM2 antibody (Fig. 
3.7B). The interaction between p68 and PKM2 was also verified by reciprocal pull-down 
with the nuclear extracts made from T98G cells using recombinant PKM2 as bait (Fig. 
3.7C). PKM2 is a glycolysis enzyme that predominantly localizes in the cytoplasm. Thus, 
we asked whether p68 also interacts with PKM2 in the cytoplasm. To this end, PKM2 
was immunoprecipitated from both the cytoplasmic extracts and nuclear extracts made 
from T98G cells. Co-imunoprecipitation of p68 with PKM2 was examined by 
immunoblot using the antibody p68-RGG. It was evident that p68 co-immunoprecipitated 
with PKM2 both in the cytoplasmic extracts and the nuclear extracts (Fig. 3.7D right 
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panel). Similar co-immunoprecipitation results were also observed with exogenously 
expressed HA-PKM2 (Fig. 3.7D, left panel). To further verify that PKM2 and p68 
interaction is the p68 phosphorylation dependent, we carried out co-immunoprecipitation 
experiment with the nuclear extracts of T98G cells in which HA-p68, wt or Y593F (a p68 
mutant that can not be phosphorylated), was expressed. It was clear that wt HA-p68 co-
precipitated with PKM2, while the Y593F mutant did not (Fig. 3.7E), suggesting that p68 
tyrosine phosphorylation is required for PKM2 and p68 interaction.  
We questioned whether the interaction of PKM2 with the tyrosine phosphor-p68 
might promote the conversion of PKM2 from tetramer to the dimer form, To test this 
conjecture, we employed three phosphorylated/unphosphorylated peptides, the double 
tyrosine phosphorylated peptide D-PhosPepY593, the peptide that spans different region 
of p68 PhosPepY567, and the PepY593. We first examined the interaction of the selected 
phosphor/unphosphor-peptides with the rPKM2 by monitoring the Trp fluorescence 
changes of the rPKM2 upon interaction with the peptides. It was clear that the D-
PhosPepY593 interacted with the rPKM2 with Kd around 30 μM, while the 
PhosPepY567 and the PepY593 did not (Fig. 3.8 A, B, and C). It was demonstrated that 
the tyrosine phosphor-peptide interacts with PKM2 at FBP binding site (Christofk, 
Vander Heiden et al. 2008). To test whether the phosphor-tyrosine peptide interact with 
the rPKM2 at FBP binding site, we examined the interaction between the peptide D-
PhosPepY593 with the rPKM2 in the presence of excessive amounts of FBP. It was clear 
that FBP competed with the D-PhosPepY593 for binding to the rPKM2 (Fig. 3.8 A, B, 
and C). The competition of FBP with p68 for binding to PKM2 was also revealed by co-
immunoprecipitation experiment. It was clear that coimmunoprecipitation of p68 with 
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HA-PKM2 in T98G cell extracts decreased by supplementing the extracts with different 
concentrations of FBP (Fig. 3.8D). The similar coimmunoprecipitation experiment was 
also carried out with the rPKM2 and the HA-p68 immunopurified from T98G cell 
extracts in the presence of various concentrations of FBP. High concentration of FBP 
decreased the HA-p68 and the rPKM2 interaction (Fig. 3.8E). It is reported that W515–
G520 located at the activating loop of C-terminal of PKM2 is critical for the FBP binding 
(Dombrauckas, Santarsiero et al. 2005). Thus, we created a truncation mutant with 
deletion of W515 – G531. The interaction of the phosphor-p68 with the PKM2 truncation 
was examined by the co-immunoprecipitation procedure. It was evident that the deletion 
of the FBP binding activating loop abolished the interaction between p68 and PKM2 
(Fig. 3.8F). Meanwhile, a mutation (K270M) that affects the glycolytic substrate binding 
(Dombrauckas, 2005) did not affect the interaction between p68 and PKM2 (Fig. 3.8F). 
These results are consistent with the observations by Christofk and co-workers 
(Christofk, Vander Heiden et al. 2008; Christofk, Vander Heiden et al. 2008), indicating 
the phosphor-peptides D-PhosPepY593 and phosphor-p68 interact with PKM2 at the 
FBP binding site. 
To examine the effects of binding the phosphor-peptides on the tetramer and 
dimmer formation, we used the same size exclusion chromatography method to analyze 
the molecular sizes of the rPKM2 in the presence or absence of the three tyrosine 
phosphor/unphosphorpeptides and compared to the chromatography profile of molecular 
size standard. It was evident that there were substantially more dimeric PKM2 in the 
presence of phosphor-peptides, DPhosPepY593, while the tetramer and dimer ratio of the 
rPKM2 was not affected in the presence of the phosphor-peptide PhosPepY567 and non-
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phosphor-peptide PepY593 (Fig. 3.3A). The experiments apparently suggested that 
binding the tyrosyl phosphor-protein converts tetramer PKM2 to a dimeric form. 
We further questioned whether binding of the tyrosyl phosphor-protein/peptide 
would activate the protein kinase activity and inactive pyruvate kinase activity of PKM2. 
To this end, the in vitro phosphorylation reactions were carried out with the rPKM2 in 
the presence of different tyrosine phosphor/unphosphor-peptide. Examination of 
phosphorylation of stat3 by the immunoblot using the anti-phospho-stat3 antibody 
indicated that phosphorylation of stat3 at Y705 by the rPKM2 was dramatically increased 
in the presence of phosphor-peptide DPhosPepY593 (Fig. 3.3B). The phosphorylations of 
stat3 by the rPKM2 were not affected in the presence of the peptide PepY593 without 
tyrosine phosphorylation. The phosphorylation of stat3 was also not affected in the 
presence of another tyrosine phosphor-peptide PhosPepY567 that did not bind to PKM2 
(Fig. 3.3B). We next tested whether indeed presence of phosphor-p68 would activate the 
protein kinase activity of PKM2. To this end, we immunopurified HA-p68 from nuclear 
extracts prepared from T98G cells. Phosphorylation of GST-stat3 by the rPKM2 in the 
presence or absence of the immunopurified HA-p68 was examined. Clearly, stat3 was 
much strongly phosphorylated by the rPKM2 in the presence of the purified HA-p68 
compared to that in the absence of the purified HA-p68 (Fig. 3.3C). The results support 
the notion that binding of the tyrosyl phosphor-protein activates the protein kinase 
activity of PKM2.  
PKM2 is a glycolysis enzyme. It is believed that the tetramer form of the protein 
is catalytic active in catalyzing the conversion of PEP to pyruvate in the glycolysis. Since 
the binding of the tyrosine phosphor-protein promoted the conversion from tetramer to 
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dimer, we reasoned that binding the tyrosine phosphor-protein/peptide to PKM2 should 
result in protein that is less active in catalyzing the conversion of PEP to pyruvate. We 
used the method similar to that is described by Christofk and coworkers (Christofk, 
Vander Heiden et al. 2008; Christofk, Vander Heiden et al. 2008) to monitor the pyruvate 
kinase activity of the rPKM2 in the presence of the tyrosine phosphor-peptides. The 
rPKM2 catalytic activity was dramatically reduced in the presence of D-PhosPepY593, 
while the activity was not affected in the presence of the peptides PhosPepY567 and 
PepY593 (Fig. 3.3D), which indicate that binding of PKM2 to the tyrosine phosphor-
proteins converted the protein to dimer and consequently reduced the glycolytic enzyme 
activity. The notion was further supported by the experiments that the enzymatic activity 
of the R399E in converting PEP to pyruvate was dramatically decreased compared to that 
of recombinant wild-type (Fig. 3.2D). 
 
3.3.4 PKM2 Kinase Substrates Bind to the ADP Binding Site for Phosphorylation 
 PKM2 directly phosphorylates stat3. One interesting question is how the protein 
substrate is bound to PKM2. Our results showed that PEP was used as phosphate donor 
by PKM2 in phosphorylation of a protein substrate. It is established that in the catalysis 
of ADP phosphorylation in glycolysis, PKM2 binds phosphate donor PEP at one site and 
substrate ADP at the other. Thus, a very logic assumption based on this knowledge is that 
the protein substrate may bind to the ADP site. To test this conjecture, we carried out 
competition binding analyses. Co-immunoprecipitation was carried out to detect the 
interaction between PKM2 and Stat3 mutant in the presence of ADP. The results showed 
that ADP competed the interaction between Stat3 and PKM2. The interaction between 
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Stat3 and PKM2 mutants were also probed. Co-IP results showed that the mutant at 
glycolytic substract binding site, K270M, abolished the interaction between Stat3 and 
PKM2 (Fig. 3.4B). Our experiments thus far demonstrate that tyrosine phosphor-p68 
interacts with PKM2 at the FBP site and strengthen the protein kinase activity of the 
protein. We therefore predict a three ways interaction among the phosphor-p68, PKM2, 
and GST-stat3. To test this possible protein interaction, we carried out the GST-pull 
down using the GST-stat3. Immunoblot demonstrated that both recombinant PKM2 and 
p68 purified from cell extracts of T98G cells were co-precipitated with GST-stat3 (Fig. 
3.4C). 
  
3.3.5 PKM2 Protein Kinase Substrates Bind to the ADP Binding Site 
PKM2 directly phosphorylates stat3. One interesting question is how the protein 
substrate is bound to PKM2. Our results showed that PEP was used as phosphate donor 
by PKM2 in phosphorylation of a protein substrate. It is established that in the catalysis 
of ADP phosphorylation in the glycolysis, PKM2 binds phosphate donor PEP at one site 
and substrate ADP at the other. Thus, a very logic assumption based on this knowledge is 
that the protein substrate may bind to the ADP site. To test this conjecture, we carried out 
competition binding analyses. The R399E mutant and stat3 interaction was analyzed in 
the presence and absence of ADP, PEP, and FBP. The GST-stat3 was immobilized on the 
glutathione-agarose beads. Recombinant R399E in mixing with buffer, ADP, PEP, or 
FBP were incubated with the beads. Binding of R399E to the immobilized GST-stat3 was 
then analyzed by SDS-PAGE followed by immunoblot of R399E and stat3. It was very 
clear that the interaction of R399E with stat3 was not affected in the presence of 5 mM 
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FBP, while the interaction was almost not detectable in the presence of 5 mM ADP. The 
R339E and stat3 interaction was also weakened in the presence of 5 mM of PEP. This 
was most likely due to phosphorylation of stat3, as the reduction in stat3 and R399E 
interaction was not PEP concentration dependent, while the R399E and GST-stat3 
interaction showed a clear ADP concentration dependent reduction (Fig. 3.3E), indicating 
the competition of ADP with stat3 in binding R399E. Our experiments thus far 
demonstrate that tyrosine phosphor-p68 interacts with PKM2 at the FBP site and 
strengthen the protein kinase activity of the protein. We therefore predict a three ways 
interaction among the phosphor-p68, PKM2, and stat3. To test this possible protein 
interaction, we carried out the GST-pull down using the GST-stat3. Immunoblot 
demonstrated that both the HA-PKM2 and p68 purified from cell extracts of T98G cells 
were co-precipitated with GST-stat3 (Fig. 3.3F). The three ways interaction was also 
probed by co-immunoprecipitation experiments using anti-HA antibody. The rPKM2 and 
GST-stat3 were co-precipitated with HA-p68 that was immunopurified from cellular 
extracts of T98G cells (Fig. 3.9A). These results provided additional support for the 
notion that PKM2 protein kinase substrate binds to the ADP binding site. The notion that 
protein kinase substrate is bound at the ADP binding site of PKM2 was also supported by 
our early observations that addition of ADP decreased the activity of PKM2 in 
phosphorylation of stat3, while addition of FBP did not (see Fig. 3.1C and 3.2C). 
 
 
3.3.6 Expression of R399E Increased Stat3 Phosphorylation in Cells and Promoted 
Cell Proliferation 
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We employed a PKM2 mutant R399E. Our experiments showed that the 
recombinant R399E existed mostly as a dimer and the mutant exhibited strong activity in 
phosphorylation of GST-stat3. We therefore questioned whether the R399E mutant 
would be active in phosphorylation of stat3 in cells. To this end, the HA-R399E was 
exogenously expressed in SW480 cells. Immunoblot examination of the phosphor-stat3 
in the nuclear extracts indicated a significantly increase in the levels of Y705 
phosphorylated stat3. This increase was not due to increase in cellular levels of stat3 as 
immunoblot of cell lysate indicated very similar stat3 levels in cells with/without 
expression of the R399E or wt PKM2 (Fig. 3.4A). The exogenously expressed HA-
R399E was subsequently immunopurified from cell lysate. Size exclusion 
chromatography experiments showed that, unlike the exogenously expressed wild-type 
HAPKM2, the HA-R399E was almost completely dimer in cell lysate (Fig. 3.4B) In vitro 
phosphorylation assays indicated that the immunopurified HA-R399E phosphorylated 
GST-stat3 (Fig. 3.4B). We previously observed that expression of PKM2 led to up-
regulation of MEK5 and cell proliferation (Gao et.al., Oncogene 2009 revision). Thus, 
we tested here if exogenous expression of R399E in SW480 cells would lead to MEK5 
up-regulation and cell proliferation. RT-PCR analyses clearly demonstrated that the 
cellular levels of mRNA of MEK5 increased significantly (Fig. 3.4C). Examination of 
cell proliferation using a commercial kit that monitoring the cooperation of BrdU 
demonstrated that expression of R399E led to a strong increase in cell proliferation (Fig. 
3.4D). 
 
3.3.7 Growth Factor Stimulations Result in Increase in Dimeric PKM2 in Cells 
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It is well documented that stimulation of cells by growth factors and cytokines 
results in activation of various protein tyrosine kinases that subsequently phosphorylates 
many protein substrates at tyrosine residue (Hunter and Cooper 1985). For instance, we 
previously demonstrated that PDGF or EGF stimulation led to tyrosine phosphorylation 
of p68 RNA helicase (Yang, Lin et al. 2005; Yang, Lin et al. 2006). Presently our 
experiments demonstrated that binding to tyrosine phosphor-protein converted PKM2 
from tetramer to dimer therefore activated the protein kinase activity of the protein. We 
reason whether treatment of cells with growth factors would affect PKM2. Thus, SW480 
cells were treated with EGF. The same chromatography procedure used for detecting the 
PKM2 tetramer vs dimer in crude cell extracts was employed here to analyze the tetramer 
and dimer ratio of PKM2 in cells under the stimulation of EGF. It was clear that the 
levels of dimer PKM2 in growth factor stimulated cells were significantly higher than 
that in corresponding unstimulated cells (Fig. 3.5A). Immunoblot analyses of PKM2 in 
nuclear and cytoplasmic extracts suggested that growth factor stimulation led to increase 
in nuclear PKM2 levels (Fig. 3.5B). Analyses of protein tyrosine phosphorylation and 
p68 tyrosine phosphorylation revealed that there was a substantial increase in protein 
tyrosine phosphorylation and tyrosine phosphorylation of p68 at tyrosine residue (Fig. 
3.5C). These experiments suggested that indeed there is a clear correlation between the 
levels of protein tyrosine phosphorylations and dimeric PKM2 in cells, which is 
inducible by growth factors and cytokines. 
 
 
3.4 Discussion 
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During tumor progression, growth signals stimulate the conversion of 
glycolytically active PKM2 to an inactive form, consequently regulating the glycolysis 
pathway to channel the carbon source from glucose for biosynthesis (Deberardinis, 2008; 
Garber, 2006; Mazurek, 2003; Christofk, 2008). It is conceivable that tumor cells need to 
coordinate the metabolism alterations with expression of genes that are related to cell 
proliferation during tumor progression. Thus, at the same token, the growth signals will 
also activates protein kinase activity of PKM2, which subsequently target transcription 
factor and activate transcription of genes that closely associated with cell proliferation. 
PKM2 has long been recognized as a so-called ‘moonlight’ enzyme that plays a very 
important role in tumor progression (Sriram, 2005). Clearly, the protein kinase activity of 
PKM2 and subsequent activity in transcription regulation is an important ‘moonlight’ 
activity of the protein. The functions of PKM2 in regulating expression of genes fulfill 
the role of feedback signaling from metabolic alterations to gene regulation during tumor 
malignancy transformation (see model in Fig. 3.5D). 
It is intriguing that a glycolytic enzyme can function as a protein kinase and 
translocate to the nucleus acting on gene transcription. Our studies suggested a molecular 
base for the activity conversion (Fig. 3.5D). Growth signal (growth factors or cytokines) 
stimulations lead to activation of protein tyrosine kinases, which phosphorylate a number 
of downstream targets. A number of tyrosine phosphor-proteins subsequently act on 
PKM2 by interacting with the protein at the FBP binding site. The tyrosine phosphor-
protein and PKM2 interaction results in the conversion of PKM2 from tetramer to a 
dimer, which consequently lead to decrease in pyruvate kinase activity and increase in 
protein kinase activity. It was revealed from x-ray crystallography structural analyses of 
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the tetramer PKM2 that the ADP binding site is formed by a large hydrophobic hole, 
indicating a great flexibility for nucleotide binding (Muirhead, Clayden et al. 1986; 
Dombrauckas, Santarsiero et al. 2005). The large hydrophobic hole at the nucleotide 
binding site is almost completely buried in a tetramer structure, while it would be 
completely accessible with the dimeric form. Thus, it is conceivable that the nucleotide 
binding site may be able to accommodate a protein substrate when PKM2 is converted to 
a dimer. Alternatively, binding the tyrosine phosphor-protein to the FBP site would 
results in a significant conformation change that will allow PKM2 to accommodate a 
protein substrate binding. Stat3 is a transcription activator that is activated in response to 
inflammatory cytokines, such as IL-6 (Gao, 2007; Watson, 2008). Strikingly, activation 
of stat3 represents probably one of the most important molecular signatures involved in 
promoting cancer progression. It has been observed that activation of stat3 is detected in 
almost all cancer types (Frank 2007; Huang, Qiu et al. 2007; Kim, Chan et al. 2007; 
Groner, Lucks et al. 2008). However, it is generally believed that activations of stat3 in 
response to growth factor and cytokines are usually transient. A long standing question is 
“How do the malignant cancer cells maintain constitutive activation of stat3?” Currently, 
mutation(s) that lead to constitutive activation of stat3 have not been identified. Thus, 
activation of stat3 by PKM2 in malignant cancer cells potentially provides a very 
attractive explanation for this long-standing question. Whether stat3 is the only PKM2 
substrate for its protein kinase activity is an open question. PKM2 interacts with several 
other proteins (Garcia-Gonzalo, Cruz et al. 2003; Lee, Kim et al. 2008; Spoden, 
Morandell et al. 2009). It was also reported that PKM2 purified from hepatoma tumour 
cells can phosphorylate histone H1 in vitro (Ignacak and Stachurska 2003). Thus, it will 
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be very interested to identify other PKM2 protein kinase substrates and uncover the 
putative cellular function of the corresponding protein phosphorylations. 
 
3.5 Materials and Methods 
3.5.1 Reagents, Cell lines, and Antibodies 
The KLH conjugated peptide spans aa 399 – 412 of PKM2 
(IYHLQLFEELRRLAPI) was synthesized by Global Peptide Services. PKM2 
polycolonal antibody and anti-HA antibody was raised in the animal facility of Georgia 
State University. The peptides, D-PhoPepY593, PepY593, and PhosPepY567, were 
synthesized by AnaSpec. Antibodies against stat3, stat3 (pY705), HA-tag, GAPDH, 
Lamin A/C, and β-actin were purchased from Cell Signaling, Abnova, SantaCruz, 
Abcam, and AnaSpec respectively. Recombinant GST-stat3 was purchased from Abcam. 
Cell lines SW480, SW620, T98G were purchased from ATCC and cultured by following 
the vendor’s instructions. 
 
3.5.2 Plasmids Construction 
Human full length cDNA of PKM2 and PKM1 were purchased from OriGene 
Technologies. The cDNA of PKM2 and PKM1 was subcloned into bacteria expression 
vector pET30a (+) as well as mammalian expression vectors pHM6. The PKM2 or its 
mutants were fused at the C-terminal of HA protein tag in pHM6 mammalian expression 
vector. Site directed mutagenesis were performed using QuikChange® Multi Site-
Directed Mutagenesis Kit (Stratagene). All the DNA clones and mutations were verified 
by auto-DNA sequencing at GSU. The HA-tagged full length p68 (wild type, Y593F 
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mutant) expression plasmids were constructed in pHM6 vectors as indicated in the 
previous papers from our lab (Yang, Lin et al. 2006).  
 
3.5.3 Expression and Purification of Recombinant PKM2 
Recombinant 6×his-PKM2, 6xhis-PKM1, or 6xhisPKM2 mutants was expressed 
in bacterial BL21-CodonPlus (DE3)-RIPL. The recombinant protein was expressed and 
accumulated in the bacterial inclusion body. After extensive washes, the bacterial 
inclusion bodies were dissolved into 8 M Urea pH = 7.5. The protein was then purified 
over a HiTrap® his-affinity column. The purified recombinant PKM2, PKM1, and PKM2 
mutants was then refold by slow dilution into 10 folds refolding buffer (10 mM tris 
pH=7.5, 20% glycerol, 0.1 M KCl, 0.1 M EDTA, 1 mM DTT) and dialysis against 
refolding buffer. Purified protein was verified by immunobloting using antibody against 
PKM2.  
 
3.5.4 Transfection and RNA Interference, Subcellular Extracts Preparation, 
Immunoprecipitation and Immuno Blots, and PCR and RT-PCR   
The experimental procedures for transfection, cellular extracts preparation, 
immunoprecipitation and immuno blots, and PCR and RT-PCR were similar to our 
previous reports (Yang, Lin et al. 2006; Yang, Lin et al. 2007). The primer pairs used in 
present study were, for RT-PCR analyses of MEK5 gene expression, forward 5’-
CATGTCCTTGGAAGAATTGC-3’, reverse 5’-ATAGAATTCACCAGCTGAGTG-3’, 
targeted exon 12 – exon 14/15 regions of the MEK5 gene.  
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3.5.5 Size-exclusion Chromatography and Non-denaturing Gel Electrophoresis  
Size exclusion chromatograph was performed with a Superdex 200 10/300GL 
column using Akta purifier 100 FPLC system. The samples of cytoplasmic extracts, 
nuclear extract, the rPKM2, the recombinant PKM2 mutants, and the immunopurified 
HA-PKM2/HA-R399E were prepared in tris-HCl buffer (50 mM tris, 0.15 M NaCl pH 
7.2). 6-AcA (600 mM) was added to the protein samples to disrupt the non-specific 
protein-protein interactions. For the crude cellular extracts, the samples were prepared in 
5 – 7 mg/ml of total protein. For the recombinant or the immunopurified proteins, the 
samples were prepared in concentration of 15 µM. 100 µl of prepared sample was loaded 
into the Superdex 200 10/300GL column and eluted with elution buffer (50 mM 
phosphate, 0.15M NaCl pH7.2). The fraction of 300 µl was collected, and 50 µl of each 
fraction was analyzed by 10 % SDS-PAGE and followed by immunoblot using 
appropriate antibody. A size exclusion chromatograph calibration kits was purchased 
from GE Healthcare. The protein standard samples (six high MW proteins) were 
dissolved in the same buffer with 600 mM AcA at concentrations instructed by the 
manufacture. Proteins were eluted with the same elution buffer. The fractions (300 µl) 
were collected with the same FPLC system and conditions. The elution profile was 
recorded based on the absorbance of elution fractions at 280 nm. The elution profile was 
plotted against LogMW according to vendor’s instructions.  
The treated cytoplasmic or the nuclear extracts (6 µl) were loaded on an 8% non-
denaturing polyacrylamide gel (40:1 – acrylamide:bis-acrylamide). The gel was subject 
to immunoblot using the antibody PabPKM2. The molecular weight markers, BSA and 
Urease (Sigma), were loaded on the same gel and were visualized by ponceau S staining. 
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3.5.6 PKM2 and Peptide Interaction 
Interactions between the rPKM2 and its derived mutants were analyzed by 
monitoring the changes of tryptophan fluorescence of the recombinant protein PKM2 or 
the mutants (λex =285 nm, λem =310-410 nm). The binding analyses were carried out 
with protein concentration 4 µM in the reaction buffer (50 mM tris, pH7.5, 100 mM 
KCl). Different peptides (100 µM) were titrated into the protein solution. All spectra 
were recorded at ambient temperature using a PTI spectrofluorimeter with a 1 cm path 
length cuvette. FBP was added in the protein solution with a final concentration of 2 mM. 
 
3.5.7 In vitro Protein Kinase and Pyruvate Kinase Assays  
 The bacterially expressed recombinant rPKM2/R399E or HA-PKM2/HA-R399E 
immunopurified from cellular extracts (10 µg/ml) were incubated with GST-stat3 (10 
µg/ml) under various conditions (indicated in the figure legends) with kinase buffer (50 
mM Tris-HCl pH = 7.5, 100 mM KCl, 50 mM MgCl2, 1 mM Na3VO4, 1 mM PMSF, and 
1 mM DTT) in 100 µl at room temperature for 1 hours. The phosphorylation reactions 
were carried out in the presence either 5 mM ATP or 5 mM PEP. The phosphorylation 
reactions were terminated by addition of 20 µl of 4 x SDS-PAGE loading buffer and 
heated to 100 °C for 8 minutes. The reaction mixtures were then subjected to 10% SDS-
PAGE separation and subsequent analyses. 
 Pyruvate kinase activity was analyzed by following the experimental procedure 
similar to that was described by Christofk and co-workers (Christofk, Vander Heiden et 
al. 2008). Briefly, the rPKM2 or the mutant R399E (at 1 µM) was incubated with the 
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buffer (100 mM Tris-HCl, pH=7.5, 100 mM KCl, 5 mM MgCl2) containing 1 mM ADP 
and 0.5 mM PEP. The reaction also contained 200 µM NADH and 10 µM FBP. After 
incubation at room temperature for 30 minutes, 8 units of LDH (Calbiochem) were added 
to the reaction. The reactions were then subsequently analyzed by measuring the 
absorbance at 340 nm. The pyruvate kinase activity was presented as relative pyruvate 
kinase activity by define the activity of the rPKM2 as 100.  
 
3.5.8 Peptide Pull Down and Protein Identification by Mass Spectroscopy 
The peptides, PepY593 CGMNQQAYAYPATAA, PhosPepY593 
CGMNQQA[pY]AYPATAA, D-PhosPepY593 CGMNQQA[pY]A[pY]PATAA, and 
PhosPepY567 CGNPTGT[pY]QNGYDST were purchased from Anaspec Inc. The 
peptides were conjugated to agarose beads using AminoLink Plus Immobilization kit 
(Pierce). The peptide-conjugated beads were incubated with 3 mg (total protein) fresh 
nuclear extract in NETs buffer (150 mM NaCl, 50 mM tris, pH 7.5, 5 mM EDTA, 0.1% 
NP-40) overnight at 4 °C. The next day, the beads were separated and washed with NETs 
buffer five times. The proteins precipitated with the peptide beads were separated in 10% 
SDS-PAGE and stained with GelCode blue stain (Pierce) or silver staining. After 
destaining, the identified protein bands were excised from the gel and digested with 
trypsin. The digested peptides were extracted from gel with Trypsin Profiel IGD kit 
(Sigma). The samples were concentrated with vacuum centrifugation and desalted with 
ZipTip C18 pipette tips (Millipore). After ZipTip purification, the peptides were eluted 
from the ZipTip with 50% acetonitrile (ACN)/0.1% trifluoroacetic (TFA) and spotted 
directly onto a wax-coated MALDI target plates. The peptides were analyzed by 
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TOF/TOF-MS analysis in Applied Biosystems 4700 Proteomics Analyzer. Peptides with 
“ion scores” above 30 were considered significant. The MS/MS data was searched in the 
NCBInr database (Mascot; All Taxa, Human). 
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Fig 3.1 PKM2 Phosphorylates GST-stat3 
Phosphorylation of GST-stat3 by the rPKM2 (A) and HA-PKM2 immunopurified from 
nuclear extracts of SW620 cells (B) in the presence of 5 mM ATP (ATP) or 5 mM of 
PEP (PEP) was revealed by immunoblot assays using antibody against Y705 
phosphorylated stat3 (IB:pY-stat3). Immunoblot analyses using antibody against stat3 
(IB:Stat3) indicates the amounts of GST-stat3 used in each phosphorylation reaction. The 
bottom panels in (A) & (B) are the quantitative analyses of immunoblot signals. The 
error bars represent the standard deviations of four measurements. Phosphorylation of 
GST-stat3 by the HA-PKM2 (HA-PK) immunopurified from the nuclear (C) and the 
cytoplasmic (D) extracts of SW620 cells in the presence of 5 mM ATP (ATP) or 5 mM 
of PEP (PEP) was revealed by immunoblot assays using antibody against Y705 
phosphorylated stat3 (IB:pY-stat3). The phosphorylation reactions were also carried out 
in the presence/absence of 5 mM of FBP (FBP), or 5 mM of ADP (ADP). The 
immunoblot of HA (IB:HA) indicates the amounts of HA-PKM2 used in each reaction. 
IgG HC is the ponceau S stain of antibody heavy chain, representing the amounts of 
antibody used in immunopurification of HA-PKM2 from the extracts. Coomassie blue 
staining (CBS) indicates the amounts of GSTstat3 and BSA used in each phosphorylation 
reaction. Vec were the cells infected with virus that carry an empty vector. (E) Size 
exclusion chromatography fractionation of nuclear (NE) and cytoplasmic (Cyto) extracts 
(100 μl) from SW620 cells. The fractions were collected using a FPLC at 300 μl per 
fraction. The collected fractions 6 to 17 from cytoplasmic extracts and fraction 9 to 18 
from nuclear extracts were immunoblotted using the antibody PabPKM2. Fraction 11 
(F11) co-eluted with 240 kDa and fraction 14 (F14) co-eluted with 120 kDa on the same 
column under identical conditions determined by size exclusion chromatography 
molecular weight calibration standard (see on-line supplementary Fig. S1 B&C). 
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Fig 3.2 Dimeric PKM2 is Active Protein Kinase 
(A) Part of x-ray crystal structure of human PKM2. The structure was obtained from 
PDB bank DOI: 10.1021/bi0474923. The residue R399 and its interactive residues E418, 
D357, and E396 are high lighted in color. (B) Size exclusion chromatography 
fractionation of the wild-type rPKM2 and R399E mutant. The recombinant proteins 100 
μl in 1.5 μM were loaded onto column. The chromatography fractions F10 – F18 were 
collected using a FPLC at 300 μl per fraction. The collected fractions were analyzed by 
immunoblot using the antibody PabPKM2 (IB:PKM2). (C) Phosphorylation of GST-stat3 
by the rPKM2 (10 μg/ml) (lower panel) and R399E mutant (10 μg/ml) (upper panel) in 
the presence of 5 mM ATP (ATP), 5 mM of PEP (PEP), 5 mM of FBP (FBP), and/or 5 
mM ADP (ADP) was revealed by immunoblot assays using antibody against Y705 
phosphorylated stat3 (IB:pY-stat3). Immunoblot analyses using antibody against stat3 
(IB:Stat3) indicates the amounts of GST-stat3 used in each phosphorylation reaction. (D) 
Pyruvate kinase activity of the rPKM2 or R399E mutant (5 μg/ml) was analyzed by the 
method described by Christofk and co-workers. The pyruvate kinase activity was 
expressed as relative pyruvate kinase activity by define the activity in the rPKM2 as 100. 
The error bars represent the standard deviations of four measurements. 
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Figure 3.3 Tyrosine Phosphor-peptide Converts Tetramer PKM2 to a Dimer and 
Activates Protein Kinase Activity 
(A) Size exclusion chromatography fractionation of the wild-type rPKM2 in the presence 
of different peptides (3 μM) D-phosPepY593 (lower panel), PepY593 (upper panel), and 
phosPepY567 (middle panel). The rPKM2 100 μl in 1.5 μM were loaded onto column. 
The chromatography fractions F10 – F18 were collected using a FPLC at 300 μl per 
fraction. The collected fractions were immunoblotted using the antibody PabPKM2 
(IB:PKM2). (B) Phosphorylation of GST-stat3 by the rPKM2 (10 μg/ml) and the R399E 
mutant (10 μg/ml) in the presence of different peptides (3 μM) D-PhosPepY593, 
PepY593, and PhosPepY567 was revealed by immunoblot assays using antibody against 
Y705 phosphorylated stat3 (IB:pY-stat3). (C) Phosphorylation of GST-stat3 by the 
rPKM2 (10 μg/ml) or the rPKM1 (10 μg/ml) in the presence of HA-p68 that was 
immunopurified from nuclear extracts of T98G cells and 5 mM of PEP was revealed by 
immunoblot assays using antibody against Y705 phosphorylated stat3 (IB:pY-stat3). In 
some phosphorylation reactions, 5 mM of FBP (FBP) or 5 mM ADP (ADP) was added to 
the reaction. Immunoblots of stat3 (IB:Stat3), HA-p68 (IB:HA), and PKM2 (IB:PKM2) 
indicate the amounts of GST-stat3, HA-p68, and the rPKM2 used in each 
phosphorylation reaction. (D) Pyruvate kinase activity of the rPKM2 (5 μg/ml) in the 
presence of different peptides (2 μM) D-PhosPepY593, PepY593, PhosPepY567, or 
buffer was analyzed by the method described by Christofk and co-workers. The pyruvate 
kinase activity of the rPKM2 was expressed as relative pyruvate kinase activity by define 
the activity in the presence of Buffer as 100. The error bars represent the standard 
deviations of four measurements. (E) Interaction of GST-stat3 and R399E mutant in the 
presence of FBP (5 mM), PEP (5 mM), or various concentrations of ADP (10, 100, 1000 
and 5000 μM) was analyzed by GST-pull-down using the glutathione beads. The co-
precipitation of R399E with GST-stat3 was detected by immunoblot using the antibody 
against PKM2 (IB:PKM2). Immunoblots of precipitates using antibody against stat3 
(IB:Stat3) indicate the amounts of GST-stat3 that was pulled-down by the glutathione 
beads. (F) Interaction of GST-stat3, the bacterially expressed rPKM2, and the HAp68 
immunopurified from T98G cells was analyzed by GST-pull-down using the glutathione 
beads. The GST-stat3 (2 μg/ml), the rPKM2 (2 μg/ml), and the HA-p68 were incubated 
in 500 μl at room temperature. The GST-stat3 was precipitated by the GST beads. Co-
precipitations of the HA-p68 and the rPKM2 from the mixture were analyzed by 
immunoblot using antibodies against p68 (IB:p68) and PKM2 (IB:PKM2). The strip blot 
using anti-phosphor-tyrosine indicates the tyrosine phosphorylation of the precipitated 
HA-p68. Immunoblot of stat3 (IB:Stat3) indicates the amounts of GST-stat3 that were 
precipitated by GST beads.  
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Fig 3.4 The R399E Mutant Phosphorylates Stat3 in Cells and Expression of the Mutant 
Promotes Cell Proliferation  
(A) Phosphorylation of stat3 in SW480 cells was examined by immunoblot analyses of 
the nuclear extracts (NE) using antibody against the Y705 phosphorylated stat3 (IB:pY-
Stat3). PKM2 wild-type (HAPK) or the R399E (R399E) mutant was expressed in the 
cells by transient transfection. Immunoblots using anti-HA antibody (IB:HA) and anti-
stat3 antibody (IB:Stat3) in the nuclear extracts and whole cell lysate (WCL) indicate the 
levels of stat3 and HA-PKM2/HAR399E in the nuclear extracts and whole cell lysate. 
(B) Phosphorylation of GST-stat3 by the HA-p68 and the HA-R399E mutant that were 
immunopurified from cell lysate of SW480 cells in the presence of 5 mM of PEP was 
revealed by immunoblot analyses using antibody against the Y705 phosphorylated stat3 
(IB:pY-Stat3). The phosphorylation reactions were also carried out in the 
presence/absence of 5 mM of FBP (FBP), or 5 mM of ADP (ADP). The immunoblot of 
HA (IB:HA) indicates the amounts of HA-PKM2 or HA-R399E used in each reaction. 
IgG HC is the ponceau S stain of antibody heavy chain, representing the amounts of 
antibody used in immunopurification of the HA-PKM2 or the HA-R399E mutant from 
the extracts. (C) Expression of MEK5 mRNA in SW480 cells was analyzed by RT-PCR 
HA-PKM2 (HAPK) or HA-R399E (R399E) was exogenously expressed in the cells. The 
results are presented as fold changes in PCR products before and 48 hours after HA-
PKM2 or HA-R399E expression. (D) Cell proliferations of SW480 cells were measured 
using the cell proliferation kit. Cell proliferations were presented as fold changes in BrdU 
incorporation before and 48 hours after HA-PKM2 (HAPK) or HA-R399E (R399E) 
expression. The BrdU incorporation of the cells that were transfected with the empty 
vector (Vec) was defined as 1. Error bars in (C) and (D) are standard deviations of three 
independent measurements. Vec in (A), (B), (C), and (D) are the cells transfected with 
the empty vector. 
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Fig 3.5 Growth Factor Stimulation Leads to Tetramer to Dimer Conversion of PKM2 
(A) Size exclusion chromatography fractionation of cell lysate prepared from SW480 
cells that were treated/untreated by 25 ng/ml EGF for 8 hours. The cell lysate (100 μl) 
were loaded onto the column. The chromatography fractions F9 – F20 were collected 
using a FPLC at 300 μl per fraction. The collected fractions were immunoblotted using 
the antibody against PKM2 (IB:PKM2). (B) The PKM2 levels in the nuclear extracts 
(NE) of SW480 cells that were treated with EGF (25 ng/ml) at different time points 
(indicated) were examined by immunoblot of the nuclear extracts using antibody against 
PKM2 (IB:PKM2). Immunoblot analyses of PKM2 (IB:PKM2) in the whole cell lysate 
(WCL) indicate the cellular levels of PKM2. Immunoblot of β-actin (IB:β-actin) and 
lamin A/C (IB:Lamin A/C) were the loading controls. (C) Tyrosine phosphorylation of 
p68 in the in the nuclear extracts (NE) of SW480 cells that were treated with EGF (25 
ng/ml) at different time points (indicated) were examined by immunoblot analyses of p68 
that was immunoprecipitated (IP:68) from the extracts using the anti-phosphor-tyrosine 
antibody (IB:pY20). Immunoblot analyses of p68 (IB:p68) in the whole cell lysate 
(WCL) indicate the cellular levels of PKM2. Immunoblot of β-actin (IB:β-actin) was the 
loading control. (D) A hypothetic model that illustrates the functions of PKM2 in the 
glycolysis and gene expression, and the regulation between protein kinase or pyruvate 
kinase active of the protein. 
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Figure 3.6 Nuclear PKM2 is a Dimeric Form  
(A) Chromatographic elution profile of the molecular weight calibration kit proteins 
(indicated) on the Superdex 200 10/300GL column. The x-axis is the elution volume. The 
y-axis is the absorbance of the elution at 280 nm. (B) The standard curve of elution of the 
molecular weight calibration kit proteins on the Superdex 200 10/300GL column. The 
elution volumes were plotted against LogMW. (C) Immunoblot analyses of PKM2 in the 
cytoplasmic (Cyto) and nuclear (NE) extracts of SW620 cells. The extracts (6 µl) were 
treated (as described in methods) and loaded on an 8% non-denaturing gel 
electrophoresis. The gel was subjected to immunoblot using the antibody PabPKM2 
(IB:PKM2). The molecular weight markers, BSA (dimer) and Urease (trimer), were 
loaded on the same gel and were visualized by ponceau S staining (ponceau S stain). (D) 
Phosphorylation of GST-stat3 by the rPKM2 (10 µg/ml), the rPKM1 (10 µg/ml), or the 
R399E mutant (10 µg/ml) in the presence of 32P-PEP (~0.002 µCi) and unlabeled PEP (5 
mM). The reaction mixture were separated by 10 SDS-PAGE and subjected to 
autoradiograph 
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Figure 3.7 Tyrosine-phosphorylated p68 RNA Helicase Interacts with PKM2 both in 
vivo and in vitro   
(A) (Left panel) GelCode staining SDS-PAGE analyses of proteins pulled down from 
nuclear extracts of T98G cells by different peptides coupled to agarose beads. The 
peptides used are: Non-p is the peptide PepY593, Y593-p is the peptide PhosPepY593, 
Y593/595-p is the peptide D-PhosPepY593, and Y567-p is the peptide PhosPepY567. 
The arrow indicates the protein band that was cut out and subjected to trypsin digestion 
followed by MALDI-tof/tof analyses. M is molecular weight markers. (Right panel) The 
amino acid sequence of PKM2. The bold and underlined sequence indicates the peptide 
fragments identified by MALDI-tof/tof. (B) Interaction of the peptides Non-p and 
Y593/595-p with recombinant PKM2 (rPKM2). The recombinant PKM2 pull-downs 
(PD) by the peptides were examined by immunoblot using antibody against PKM2 
(IB:PKM2). Beads are the control pull-down using agarose beads alone. (C) Pull-down 
(PD) of p68 from nuclear extracts (NE) of T98G cells by recombinant PKM2 (rPKM2) 
was examined by immunoblot using antibody p68-RGG (IB:p68-RGG). The tyrosine 
phosphorylation of p68 was indicated by strip-blot of the pull-down using antibody 
against phospho-tyrosine (IB:PY20). Beads is the control pull-down using agarose beads 
alone. (D) (Left panel) Co-immunoprecipitations of p68 with exogenously expressed HA-
PKM2 from nuclear (NE) and cytoplasmic (Cyto) extracts of T98G cells were examined 
by immunoblot with antibody p68-RGG (IP:HA, IB:p68-RGG). IBs of HA-PKM2 
indicate the immunoprecipitateded HA-PKM2 from the extracts. (Right panel) Co-
immunoprecipitations of p68 with endogenous PKM2 from nuclear (NE) and cytoplasmic 
(Cyto) extracts of T98G cells were examined by immunoblot with antibody p68-RGG 
(IP:PKM2, IB:p68-RGG). IBs of GAPDH (IB:GAPDH) and lamin A/C (IB:Lamin A/C) 
are the loading controls. (E) Co-immunoprecipitations of exogenously expressed HA-
p68s (WT and Y593F, Vec is vector alone) with endogenous PKM2 from nuclear 
extracts (NE) of T98G cells were examined by immunoblot with anti-HA (IP:PKM2, 
IB:HA). IBs of the nuclear extracts using anti-HA indicate the expression of HA-p68 
(IB:HA). IBs of histone 2A (IB:H2A) are the loading controls. 
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Figure 3.8 p68 RNA Helicase Interacts with PKM2 at Its FBP Binding Site  
(A) Trp fluorescence emission spectrum of the rPKM2 (4 µM) with the titration of 
various different concentrations (indicated) of peptide D-PhosPepY593. Binding of the 
peptide to the rPKM2 was indicated by the decrease in fluorescence intensity at 334 nm. 
(B) Trp fluorescence emission intensity of the rPKM2 at 334 nm in the presence of 
various peptides (2 µM) D-PhosPepY593 (red circles), PepY593 (blue crosses), 
PhosPepY567 (green diamonds), and D-PhosPepY593 + 2 mM FBP (black squares). Y-
axis is the flurescence intensity at 334 nm. X-axis is peptide concentrations. (C) The 
dissociation constant (Kd) of the rPKM2 with the peptides D-PhosPepY593, PepY593, 
and PhosPepY567 were determined by the data fitting to langmuir equation (assume 1:1 
binding). The Kds were determined based on data fitting on three independent 
measurements. (D) Co-immunoprecipitation of p68 (IP:p68) with exogenously expressed 
HA-PKM2 in cellular extracts of T98G cells supplementary with various concentrations 
of FBP was examined by immunoblot using the anti-HA antibody (IB:HA). IgG HC is 
the ponceau S stain of antibody heavy chain, representing the amounts of antibody used 
in immunopurification of p68. (E) Pull-down of the rPKM2 by the HA-p68 
immunopurified from T98G cellular extracts (PD:HA-p68) was analyzed by immunoblot 
using antibody against PKM2 (IB:PKM2). The Pull-down experiments were performed 
in the presence of various concentrations of FBP (indicated in figure). IgG HC is the 
ponceau S stain of antibody heavy chain, representing the amounts of antibody used in 
immunopurification of HA-p68. IB:p68 indicate amounts of HA-p68 used in the pull-
down. (F) Co-immunoprecipitation of p68 with the exogenously expressed HA-PKM2 
and mutants (indicated) in the cellular extracts prepared from T98G cells. In (upper 
panel), the antibody p68-RGG was used as immunoprecipitation antibody (IP:p68). Co-
immunoprecipitations of HA-PKM2 and mutants with p68 were examined by 
immunoblot using antibody against PKM2. Immunoblot of p68 (IB:p68) indicated 
amounts of p68 that was immunoprecipitaed down. In (lower panel), the anti-HA 
antibody was used as immunoprecipitation antibody (IP:HA). Co-immunoprecipitations 
of p68 with HA-PKM2 and mutants were examined by immunoblot using antibody 
against p68 (IB:p68). IgG HC is the ponceau S stain of antibody heavy chain, 
representing the amounts of antibody used in immunoprecipitations. 
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Figure 3.9 PKM2, Stat3 and p68 Forms a Protein Complex  
(A) Co-immunoprecipitations of PKM2 and stat3 with HA-p68 in the cellular extracts of 
T98G cells. The exogenously expressed HA-p68 was immunoprecipitated using anti-HA 
antibody. The amounts of p68 precipitated from the extracts were examined by 
immunoblot using antibody against p68. The co-precipitation of PKM2 and stat3 were 
probed by immunblot using antibodies against PKM2 (IB:PKM2) and against stat3 
(IB:Stat3). IgG HC is the ponceau S stain of antibody heavy chain, representing the 
amounts of antibody used in immunoprecipitation of HA-p68 from the extracts. (B) Size 
exclusion chromatography fractionation of the wild-type HA-PKM2 (wtPKM2) or HA-
R399E (R399E) that were immunopurified from SW480 cell lysate. The HA-PKM2 or 
HA-R399E (100 µl in 0.4 µg/µl) was loaded onto the column. The chromatography 
fractions F9 – F18 were collected using a FPLC at 300 µl per fraction. The collected 
fractions were immunoblotted using the anti-HA antibody (IB:HA). 
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CHAPTER 4: NUCLEAR PKM2 REGULATES CDC14A EXPRESSION TO 
INDUCE MULTINUCLEUS 
 
4.1 Abstract 
The mammalian cell cycle is tightly regulated by multiple protein kinases and their 
phosphorylation substrates. Exit from anaphase is controlled by anaphase promoting 
complexes (APC). Cdc14A is a key regulator for cell to exit from anaphase. 
Overexpression of Cdc14A induces formation of multi-nuclei in cancer cells. The 
regulatory mechanism governoning the gene Cdc14A transcription is not well defined, 
yet. We demonstrated here that PKM2 and p68 RNA helicase co-regulated the 
transcription of Cdc14A gene in less aggressive cancer cells, such as SW480, T98G and 
LN686. Chromatin immunoprecipitation analysis indicated that the nuclear PKM2 and 
p68 RNA helicase associated with the Cdc14A promoter. Expression nuclear localization 
of PKM2 induced formation of multi-nuclei cells. Our experiments suggested that 
regulation of Cdc14A may mediate the effects of PKM2 expression on the inducation of 
multi-nuclei cells.    
 
4.2 Introduction 
In Saccharomyces cerevisiae, exit from mitosis is regulated by a cascade of signals 
named Cdc Fourteen Early Anaphase Release (FEAR) and Mitosis Exit Network (MEN) 
(Jensen and Johnston 2002; Bowerman 2004). In anaphase, Cdc14, is induced to export 
from the nucleolus into the cytoplasm (Bowerman 2004). Cdc14, a serine/tyrosine 
phosphatase, dephosphorylates and inactivates cyclin B–dependent kinase (Cdk), which 
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allows the exit from mitosis to continue into a new G1 phase (Bembenek and Yu 2003; 
de Bettignies and Johnston 2003; Kipreos 2004; Toth, Queralt et al. 2007). In budding 
yeast, Cdc14 is located in the nucleolus during interphase and is blocked by inhibitors 
Cfi1/Net1 until metaphase and released into the cytosol in late anaphase (Pereira, 
Manson et al. 2002; Buonomo, Rabitsch et al. 2003; Bloom and Cross 2007).  
In mammalian cells, Cdc14 has two orthologs: Cdc14A and Cdc14B, encodedg by 
two distinct genes. Cdc14A and Cdc14B have distinct cellular localizations during 
different stages of the cell cycle. The cellular localization of Cdc14A depends on cell 
cycle progression. The protein resides in the centrosome during interphase while Cdc14B 
locates in the nucleolus. During the process of mitosis, Cdc14A is released into the 
cytoplasm. As an important physiological regulator for cell cycle processes, expression 
of either Cdc14A or Cdc14B affects genomic stability (Mailand, Lukas et al. 2002). 
Studies show that Cdc14A overexpression induces the formation of multi-nuclei in 
mammalian cells by disrupting the process of separation of centrosomes, as well as 
blocking cytokinesis (Mailand, Lukas et al. 2002). Meanwhile, the depletion of Cdc14B 
in mammalian cells results in amplification of centrioles (Wu, Cho et al. 2008). Although 
the biological functions of Cdc14A have been well studied, so far, the molecular 
mechanism that governs Cdc14A transcription is not well defined.  
Pyruvate kinase is an enzyme acting in the glycolysis process. There are four 
isoforms of pyruvate kinases in mammals: type L, R, M1 and M2. L and R types are 
generated from one gene with different transcriptional start sites. During tumorigenesis 
M1 type expression is replaced by M2 type. The replacement of M1 type by M2 type 
changes the glycolysis rate to produce more phosphoryl intermediates for cell 
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proliferation. Besides its well-known glycolytic function in the cytosol, little is known for 
its function in the nucleus. Under the stimulation of interleukin 3 (IL-3), more PKM2 
localizes the nucleus to regulate cell proliferation in the IL-3-dependent hematopoietic 
cell line, Ba/F3 (Hoshino, Hirst et al. 2007). It is reported that PKM2 interacts with Oct-
4, an important transcription factor for regulating the pluripotence of embryonic stem 
cells (Lee, Kim et al. 2008). Interestingly, the N-terminal (a.a.1–348) of PKM2, interacts 
together with the SUMO-E3 ligase PIAS3 (inhibitor of activated STAT3) in the nucleus 
of cell of many cell lines, such as NIH3T3 and U-2 OS (Spoden, Morandell et al. 2009). 
A, Somatosatin, anti-cancer analogue TT-232 interacts with pyruvate kinase in cos-7 
cells. The interaction induces nuclear accumulation of PKM2 from the cytosol to trigger 
caspase-independent apoptosis (Stetak, Veress et al. 2007). PKM2 also plays a role in 
regulating virus replication. PKM2 interacts with NS5B, the Hepatitis C virus (HCV) 
RNA-dependent RNA polymerase, in the HCV replicon 9B cells (Wu, Zhou et al. 2008). 
The downregulation of PKM2 by shRNA in n HCV replicon 9B cells reduces the 
replication of HCV (Wu, Zhou et al. 2008).  
P68 RNA helicase belongs to the DEAD-box family of RNA helicase and has 
multiple physiological functions in diverse cellular processes, such as cell proliferation, 
epithelial-mesenchymal transition (EMT) and pre-mRNA splicing. Evidences show that 
p68 RNA helicase plays an important role in regulating gene transcription by interacting 
with a number of transcription factors as a co-activator (Warner, Bhattacherjee et al. 
2004; Fuller-Pace, Jacobs et al. 2007). P68 interacts with p53 at the C-terminal region of 
p53 to regulate p53 targeted genes, such as p21, Fas, PIG3 and mdm2 (Bates, Nicol et al. 
2005). P68 RNA helicase is reported to be recruited to the pS2 gene promoter, a 
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downstream target of estrogen receptor alpha (ERα), to regulate pS2 transcription 
(Watanabe, Yanagisawa et al. 2001). Neither the ATPase activity nor the RNA helicase 
activity of p68 is required for the function. P68 also interacts with CBP in the C-terminal 
of CBP to enhance CBP-mediated transcription (Rossow and Janknecht 2003). P68 RNA 
helicase interacts with Smad3 at the MH2 domains, to form an active transcription 
regulator complex (Warner, Bhattacherjee et al. 2004). Recently, it was reported that p68 
RNA helicase interacts with the androgen receptor (AR) in the nucleus and regulate gene 
transcription as a co-activator for androgen-dependent and androgen-independent gene 
expression in malignant prostate cancer cells (Clark, Coulson et al. 2008).  
In prsent study, we demonstrated that nuclear PKM2 and p68 RNA helicase 
induced the formation of multi-nuclei by upregulating Cdc14A expression in cancer cells. 
Nuclear PKM2 and p68 interacted with the promoter region of Cdc14A to regulate its 
transcription. 
 
4.3 Results 
4.3.1 Exogenous Overexpression of PKM2 and p68 RNA Helicase Induces Multi-
nuclei in Cancer Cells 
To understand functions of PKM2 in the cell cycle, we analyzed the morphology 
changes in SW480 cells overexpressing HA-PKM2. Staining nuclear DNA revealed the 
formation of multinuclei in SW480 cell expressing HA-PKM2 (Fig1A). Statistical 
analysis indicated that 34% of transfected cells had non-identical double nuclei. 9% of 
transfected cells had triple nuclei, and 4% of transfected cells showed more than triple 
nuclei (Fig1B). Very similar phenomenon was also observed with T98G, U87MG and 
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HEK cells where HA-PKM2 was overexpressed. The results suggested that formation of 
multi-nucleus by exogenous PKM2 overexpression is a common phenomenon in 
mammalian cells.  
It was reported that Cdc14A overexpression in U-2-OS human osteosarcoma cells 
induces formation of multi-nucleus due to interfering centrosome separation (Mailand, 
Lukas et al. 2002). To identify genes that are subject to PKM2 regulation, we carried out 
expression analyses. PKM2 was expressed in SW480 cells. The RNA profile was 
examined via Affimetrix human 2.0 microarray. The array analyses revealed that Cdc14A 
mRNA level was increased to 4 folds in SW480 cell upon expressing PKM2, which 
indicated a possible transcriptional regulation of Cdc14A by PKM2 in SW480 cells. 
Thus, we hypothesized that PKM2 regulates Cdc14A expression in SW480 cells and 
consequently induce the formation of multiple nuclei. To test this hypothesis, the 
expression level of Cdc14A was examined in SW480 cells with epitoptic PKM2 
expression. The Cdc14A expression level was increased more than 4 folds (Fig 2A). 
Meanwhile, mRNA level of Cdc14A was also examined via RT-PCR. The RT-PCR 
primers were designed according to Cdc14A pre-mRNA sequence as extended from exon 
11 to exons 13-14 interrupted by intron 13-14. It was clear that 3.2 folds increase in 
Cdc14A mRNA in SW480 cells in which PKM2 was overexpressed (Fig 3B). To verify 
whether PKM2 overexpression induces multiple nuclei, SW480 cells overexpressing 
PKM2 were stained with the Lamin B1 antibody. It was clear that PKM2 overexpression 
induced multiple nuclei in SW480 cells (Fig2 B). 
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4.3.2 Nuclear PKM2 Regulates the Expression of Cdc14A 
PKM2 is an enzyme acting in the glycolysis. The protein is highly expressed and 
mainly localizes in the cytosol to catalyze ATP production. To investigate whether the 
regulatory function of PKM2 in controlling Cdc14A expression was by cytoplasmic 
PKM2 or a nuclear protein, we constructed a mutant PKM2 with addition of nuclear 
localization signals (NLS) at C- and N- terminal ends. Western blot results showed that 
over 95% NLS-PKM2 localized in the nucleus. The analyses function of NLS-PKM2 in 
regulating Cdc14A expression was examined in SW480 cells. Western blot analyses 
showed that Cdc14A levels were increased when NLS-PKM2 was expressed in SW480 
cells (Fig3A). Immunofluorescence stainging results showed that NLS-PKM2 induced 
formation of mutli-nucleus in SW480 cells 
 
4.3.3 PKM2 and p68 RNA Helicase Co-regulate Cdc14A Protein Expression 
Our previous study showed that PKM2 interacts with p68 RNA helicase both in the 
cytosol and nucleus. p68 RNA helicase is a transcription co-activator (Warner, 
Bhattacherjee et al. 2004; Bates, Nicol et al. 2005). We questioned whether p68 RNA 
helicase also plays a role in regulating Cdc14A expression. To this end, p68 RNA 
helicase was overexpressed in SW480 cells and the Cdc14A expression levels was 
examined by immnoblot using a commercially avaible Cdc14A antibody. The results 
showed that Cdc14A expression level was up-regulated upon the overexpression of p68 
RNA helicase (Fig2A). RT-PCR analyses showed that Cdc14A mRNA was upregulated 
2.3 folds when p68 RNA helicase was expressed in SW480 cells. Meanwhile, the mRNA 
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level increased 3.8 folds when exogenous NLS-PKM2 was overexpressed in SW480 
cells. Cdc14A mRNA level was also upregulated to 2.5 folds when HA-PKM2 was 
overexpressed (Fig3B).   
It is believed that the transcription regulation of p68 RNA heliase does not depend 
on its ATPase activity (Yang, Lin et al. 2007). To investigate whether the function of p68 
RNA helicase in regulating Cdc14A transcription is dependent on its ATPase activity, a 
p68 mutant (RGLD), which lacks of ATPase activity, was overexpressed in SW480 cells. 
Western-blot analyses showed that the p68 mutant and wild type have very similar effect 
in regulating Cdc14A expression (Fig4a). The result indicated that the function of p68 
RNA helicase in regulating Cdc14A most likely was ATPase independent.  
In our previous study, we showed that PKM2 and p68 RNA helicase interact with 
each other. However, we speculated that the regulatory function of p68 RNA helicase and 
PKM2 in Cdc14A are inter-related. To test this conjecture, p68 was knocked down via 
the RNAi and PKM2 was expressed in p68 knockdown cells. As controls, wild-type p68 
and the Y593F mutant were also expressed in the p68 knockdown cells. It was clear that 
the function of PKM2 in regulating Cdc14A expression was abolished if p68 RNA 
helicase was knocked down (Fig4b). To further verify that p68 RNA helicase was 
required for regulating Cdc14A by nuclear PKM2, NLS-PKM2 was introduced in p68 
knocked down cells. Consistently, Cdc14A expression level was not affected by the 
overexpression of cytosolic and nuclear PKM2 (Fig4c). On the other hand, the 
requiremtn of PKM2 for p68 RNA helicase in regulating Cdc14A expression was tested. 
PKM2 was knocked down by RNAi in SW480 cells and wild type p68 RNA helicase 
were introduced into the p68 knocked down cells. The experiments showed that the 
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function of p68 RNA helicase in regulating Cdc14A transcription was almost abolished 
(Fig4d). Taken together, our results showed that the p68 and nuclear PKM2 co-regulate 
Cdc14A transcription.   
 
4.3.4 PKM2 and p68 RNA Helicase Bind to Cdc14A Promoter Region 
PKM2 and p68 RNA helicase co-regulated the transcription of Cdc14A gene. It is 
reported that p68 RNA helicase is a gene transcriptional co-activator (Bates, Nicol et al. 
2005). In our previous report, nuclear PKM2 associated with the promoter region of 
MEK gene to regulate its transcription. To investigate transcriptional role of PKM2 in 
cancer cells, the ChIP-on-chip experiments were carried out to examine the interaction of 
PKM2 with promoter. The ChIP-on-chip data showed that PKM2 was associated with the 
Cdc14A promoter. ChIP-on-chip analyses using antibody against p68 also showed that 
p68 RNA helicase associated with the same promoter region of Cdc14A promoter. The 
Chip-on-Chip analyses suggested a possibility that nuclear PKM2 and p68 RNA helicase 
bind to the same promoter region of Cdc14A gene to regulate its transcription. To 
confirm the Chip-on-chip analyses, chromatin immunoprecipitation experiment was 
carried out. Primers were designed according to Chip-on-chip analyses. Chip analyses 
showed that p68 RNA helicase and nuclear PKM2 indeed interacted with Cdc14A 
promoter at the same region (Fig5).  
 
4.3.5 Cdc14A Mediates the Effect of PKM2 in Induction of Formation of 
Multinuclei  
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To further investigate whether Cdc14A is the target mediating the effects of PKM2 
in induction of multinucleus, PKM2 was knocked down in SW480 cells using 
SMARTpool RNAi and the expression level of Cdc14A was then examined. The 
expression of Cdc14A in both protein and mRNA levels were decreased around 3 folds 
when PKM2 was knocked down (Fig 6 c, d). Immunostaining experiments were carried 
out to examine the multinuclei in PKM2 knocked down cells. The cell numbers with 
multi-nuclei was decreased 2 folds when PKM2 was knocked down in SW480 cells (Fig 
6E). 
 
4.3.6 PKM2 Overexpression Induces formation of Multi-nucleus Only in Less 
Aggressive Cancer Cells 
The effects of PKM2 on induction the formation of multi-nuclei were different 
from cell line to cell line. We suspected the expression of Cdc14A in different cancer cell 
line were different. Thus, Cdc14A expression level in 13 cancer cell lines were examined 
including LN686, M4C1, SW480, SW620, WM115, WM266, H146, H460, T98G, 
U87MG, HeLa and HEK cells. Expression of Cdc14A in T98G, U87MG, SW480, HEK 
cells was clearly evident. The expression of Cdc14A in other cell lines, such as SW620, 
HeLa, WM115 and WM266 could not be detected (Fig 7). To examine whether 
expression of PKM2 induces formation of multi-nucleus in these cell lines, the cells 
expression of PKM2 were stained with antibody against γ-tubulin 48 hours after PKM2 
overexpression. The formation of multi-nucleus was not observed with WM115, 
WM266, HeLa and SW620 cells (data not shown). The formation of multi-nuclei clearly 
correlated with Cdc14A expression in testing cancer cells. Furthermore, expression of 
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Cdc14A was examined in SW620 cells where the epitogic PKM2 was expressed. 
Western blot analyses showed that Cdc14A expression level was not increased, even 
when PKM2 reintroduced in SW620 cells. Consequently, immunofluorescence staining 
did not show the formation of multi-nucleus in SW620 cells in which epitomic PKM2 or 
p68 RNA helicase were expressed (Fig7C right panel). All these data indicated that 
PKM2 regulated Cdc14A expression results in formation of multi-nucleus.  
 
4.4 Discussion 
The glycolysis is an important metabolic pathway which provides energy as well as 
phosphor intermediates for macromolecules synthesis in cancer cells. Many glycolytic 
enzymes have cellular functions other than glycolysis. Oxidative stress induces 
cytoplasmic Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) nuclear 
translocation. Nuclear GAPDH induces ATG12 expression lead to resist to caspase-
independent cell death (Colell, Ricci et al. 2007). Studies from ours and other 
demonstrated that, PKM2, translocate to the nucleus of cancer cells. PKM2 translocate 
into the nucleus under the stimulation of Interleukin-3 in BB13 cells and nuclear PKM2 
promotes Ba/F3 cells proliferation (Hoshino, Hirst et al. 2007) . Contrary, Stetak et al 
reported that nuclear PKM2 may induce apoptosis in Cos-7 cells by a caspase 
independent pathway (Stetak, Veress et al. 2007). In our study, nuclear PKM2 regulates 
Cdc14A expression to induce the formation of multi-nuclei in less proliferation cancer 
cells. The different functions of nuclear PKM2 may be due to the difference of cell types.  
Cdc14A was identified as a downstream target of PKM2 for multi-nuclei cells. The 
localization of PKM2 in the nucleus may inhibit the action of PKM2 in induction of 
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centrosome separation. The centrosome is the microtubule organization center, which 
regulates the formation of bipolar spindle during mitosis (Khmelinskii and Scheibel 
2008). Abnormal regulation of the centrosome separation may lead to aneuoploidy. 
Centrosomes duplicate in S phase and the number is tightly controlled in normal 
mammalian cells. Recently, studies showed that Cdc14B knockdown induces the 
amplification of centrosomes (Wu, Cho et al. 2008). Meanwhile, centrosome separation 
is critical for cells to maintain chromosome numbers. One possibility is the 
overexpression of Cdc14A may deregulate the dephsophorylation of Cdh1, which cause 
the malfunction of APC complex resulting in aneuploidy in the tumor cells.  
The background level of multi-nucleus cells for SW480 is around 5±2%. As shown 
in Fig7A, The multi-nucleus caused by Cdc14A overexpression was not completely 
abolished by Cdc14A knocked down. This is probably due to incomplete knocked down. 
Alternatively, additional mechanism contributes to the formation of multinucleus cells. In 
this study, 11 cell lines were screened for the expression of Cdc14A. The expression 
levels of Cdc14A vary in different cell lines. However, there is a clear correlation 
between the expression levels of Cdc14A with the formation of multinuclei in less 
proliferation cancer cell lines. The multinuclei cells may undergo apoptosis. This 
indicated the distinct functions of nuclear PKM2 in different cancer cells. That is, in 
more proliferating cancer cells, expression of PKM2 in the nucleus promotes cell 
proliferation via regulating MEK5 gene transcription (Gao et al, Oncogene, revised, 
2009). In less proliferating cancer cells, expression of PKM2 in the nucleus may lead to 
cell apoptosis by regulating Cdc14A gene transcription to form multinuclei.      
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4.5 Materials and Methods 
4.5.1 Plasmids Construction, Reagents and Antibodies 
cDNA of PKM2 and PKM1 were purchased from OriGene Technologies. The 
cDNA of PKM2 was cloned into bacteria expression vector pET30a and mammalian 
expression vectors pHM6, PC3.1 et al. The primers and empty pET30a vector were 
digested with EcoR1 and Not1 two enzymes. The digestion products were purified with 
mini kit from QIAGENE and ligated with ligase enzyme. The HA-tagged full length of 
p68 (wild p68, Y593F, Y595F, and LGLD) expression plasmids were constructed in 
pHM6 vectors as indicated in the previous papers from our laboratory. Mutations in 
pHM6 vector were obtained via multisites mutation method (QuikChange® Multi Site-
Directed Mutagenesis Kit, Stratagene). Cdc14A, γ-tubulin, Lamin A/C, GAPDH and β-
actin antibodies were purchased from Abcam and Cellsignal. 
 
4.5.2 Cell culture, Transient Transfection Assays 
SW480, SW620, T98G, HeLa, U87MG, H146, H460 Cell lines were purchased 
from ATCC and cultured by following the vendor’s instructions. Cells were transiently 
transfected using Fugene-HD reagent (Roche) according to the manufacture’s instruction. 
Briefly, 2ug of the plasmid was combined with 5ul of the HD reagent in 100ul of 
optimum medium, the mixture was added to the wells after 20 minutes incubation. For 
fluroscent immunostainning experiments, cells were seeded into chambers 24 hours 
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before transfection. For IP or western-blot experiments, cells were harversted 48 hours 
after transfection. 
 
4.5.3 Relative Real Time PCR (RT-PCR) 
Total RNA was extracted from cells under appropriate treatments using RNeasy kit 
by following the manufacturer’s instruction (Qiagen). Reverse transcription process was 
performed with ImProm-II reverse transcription system (Promega). RT-PCRs were 
performed with 1 µg of cDNA and Fast SYBR green master mix (Applied biosystems). 
RT-PCR process was performed in Applied Biosystems Real-Time PCR 7500. Standard 
RT-PCR primer set was purchased from RealTimePrimers.com. RT-PCR primers was 
designed as 5’-CCTAGATGATATGTCTATTGGTGG-3’  
5’-TGAACTTAATCTGAAAGGCTGG-3’ 
 
4.5.4 Chromatin Immunoprecipitation 
Chromatin immunoprecipitation method was performed as we describe before 
(Yang et al, Cell, 2006). Generally, for one T-150 flask of SW620 cells, cells was fixed 
with 1% formaldehyde solution by incubating 10min in 37°C and stopped with 125mM 
glycine. The fixed cells were washed with cold PBS supplemented with protease 
inhibitors three times and lysated in 1ml SDS lysis buffer (Imgenex) with protease 
inhibitors. The cell lysate was sonicated on ice 2 min and centrifuged at 15,000 rpm to 
pellet insoluble material. The shearing performance was examined with 1% TAE agarose 
gel. The supernatant was aliquot and pre-cleared with 100ul salmon sperm DNA/protein 
G agarose by incubating for 2 hours. The antibody was added to the clear supernatant and 
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rotated at 4°C overnight. 100 ul of salmon sperm DNA/protein G agarose was added to 
each tube and rotated for 2 hours. The immuno-complex was eluted with elution buffer 
(Imgenex) after extensive washing 8 times. The cross-link was reversed by adding 4ul of 
5M NaCl and incubating at 65°C overnight. The released DNA was purified using the 
phenol chloroform extraction method. Regular PCR was performed in Mastercycle® 
Gradient PCR machine (Eppendorf) and the result was analyzed with 2% agarose.  
 
4.5.5 RNA Interference 
The duplex RNA oligonucleotides of SMARTpool for PKM2 and Cdc14A were 
purchased from Dharmocon. The RNA interference method was performed as described 
below. Briefly, cells were grown to 30-50% confluence and transfected with siRNA (150 
pmole) using lipo2000 transfection agent. 24 hours later, mutants were transfected using 
FuGene HD following the manufacturer’s instrument. For transient expression of WT 
p68 or mutants in p68 knockdown cells, the cells were harvested with an additional 48 
hours after knockdown. 
 
4.5.6 Subcellular Extracts Preparation, Co-immunoprecipitation and Western blot 
Whole cell lysate, nuclear extract, cytoplasm were made fresh. Briefly, for whole 
cell lysate, cells with appropriate treatments were harvested and lysated in RIPA buffer 
supplemented with complete proteases inhibitors. Co-IP experiments were performed in 
RIPA buffer supplemented with complete proteases inhibitors as well as phosphatase 
inhibitors (1mMSoV, 5mMNaF). Whole cell lysate or subcellular extracts were diluted 
with RIPA buffer and incubated with appropriate primary antibody overnight at 4. The 
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next day, 30ul of protein G agarose bead slurry was added into reaction tube and was 
rotated for 2h at 4°C. The immuno-complexs were harvested with centrifuging at 800 
rpm for 10min. The immuno-complex samples were washed with 600 µl of NETS buffer 
(150 mM NaCl, 50 mM tris-HCl [pH 7.5], 5 mM EDTA, 0.05% NP-40) five times and 
were denatured with SDS-PAGE loading buffer by incubating at 95°C for 8 mins. The 
immuno-complexes were separated in SDS-PAGE and transferred to nitrocellular 
membranes. Appropriate primary antibodys were incubated with the membranes 
overnight at 4°C. After washing with TBST buffer three times, secondary antibody was 
incubated with the membranes for additional 2 hours at room temperature. The blotting 
signals were detected with SuperSignal West Dura Extended Duration Substrate (Pierce).  
 
4.5.7 Immunostaining and Multinucleated Cells Analysis 
SW480, SW620, T98G, HeLa cells were seeded in 6 cell plates to 30% density. 24 
hours later cells were fixed with cold methanol for 15 min at -20°C. The cells were 
washed with PBS 3 times and peameablized with 1%Trixon-X for 20 min. The cells were 
blocked with 2.5% BSA (in PBS) for 30min at room temperature. The cells were 
incubated with γ-tubulin or HA-flurescent primary antibody with appropriate dilutions 
overnight at room tempature. The next day, the cells were washed with PBS three times 
and secondary Goat anti-Rabbit antibody was incubated with cells for additional two 
hours. For multinucleated cell analysis, DAPI (1mg/ml) was applied to stain transfected 
cells and examined with Confocal microscope. 150 cells were counted from each slide to 
analyze the percentage of multinucleated cells. 
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Fig 4.1 HA-PKM2 Expression Induces the Formation of Multinuclei in SW480 Cells  
(A) Fluroscent immunostaining of exogenous expressed PKM2 using the antibody 
PabHA in SW480. The green signal represents staining of exogenous PKM2 in the cells 
(a). (b) is the overlay of HA antibody staining and DAPI staining. The blue signal 
represents DAPI staining of DNA. (B) shows the percentage of the number of multinuclei 
cells in the whole populations of expressing HA-PKM2. (a) is the population of two 
nuclei in the whole populations of expressing HA-PKM2. (b) is the percentage of triple 
nuclei population in the whole populations expressing HA-PKM2. (c) is the percentage 
of single nucleus population in the whole population expressing HA-PKM2. Error bars in 
(B) are standard deviations of three measurements  
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Figure 4.2 Cdc14A Expression is Up-regulated by PKM2 and p68 RNA Helicase 
(A) Cellular levels of Cdc14A in SW480 cells 48 hours after transfection of the cells with 
plasmids vectors that carry PKM2 cDNA expression vector (HAPK), p68 RNA helicase 
(WTp68), Y593F mutant of p68 RNA helicase (593F) or empty vector (Vec) were 
analyzed by immunoblot with anti-Cdc14A (IB: Cdc14A). The exogenously expressed 
HA-PKM2 or p68 was examined by immunoblot using anti-HA antibody. Immunoblot of 
β-actin (IB:β-actin) were loading control. (B) is the centrosome staining in multi nuclei 
cell induced by PKM2 overexpression. (a) The red signal represents staining of γ-tubulin. 
(b) The blue signal represents DAPI staining of DNA. (c) The green signal represents 
staining of exogenous expression of PKM2 in in the cells. (d) is the overlay of HA 
antibody, γ-tubulin and DAPI staining.  
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Figure 4.3 Nuclear PKM2 Regulates Cdc14A Expression  
(A) Cellular levels of Cdc14A in SW480 cells 48 hours after transfection of the cells with 
plasmids vectors that carry PKM2 cDNA expression vector (HAPK), p68 RNA helicase 
(WTp68), nuclear localization signal mutant of PKM2 (NLS-PK) or empty vector (Vec) 
were analyzed by immunoblot of anti-Cdc14A (IB:Cdc14A) in whole cell lysate. The 
exogenously expressed HA-PKM2, p68 was examined by immunoblot using anti-HA. 
immunoblot of β-actin (IB:β-actin) is loading control. (B) RT-PCR experiment was 
applied to examine Cdc14A mRNA expression level. The RT-PCR primers were 
designed according to Cdc14A pre-mRNA sequence as extend from exon 11 to exon 13-
14 interrupted with intron 13-14. Error bars are standard deviations of three 
measurements. (C) Immunostaining of exogenous nuclear PKM2 induced multinuclei in 
SW480. The red signal represents staining of Lamin B1 (a). The blue signal represents 
DAPI staining of DNA (b). The green signal represents staining of HA. (d) is the overlay 
of HA antibody and DAPI staining.  
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Figure 4.4 Cdc14A Expression is Co-regulated by PKM2 and p68 RNA Helicase.  
(A) The regulatory function of p68 for Cdc14A transcription was helicase activity 
independent. Cellular levels of Cdc14A and exogenously expressed p68 RNA helicase 
(WTp68), Y593F mutant of p68 RNA helicase (593F) , RNA helicase inactive mutant of 
p68 RNA helicase (RGLD) or empty vector (Vec) in SW480 were analyzed by 
immunoblot using antibodies against Cdc14A (IB:Cdc14A) and HA (IB:HA). (B) p68 
was required for the regulatory function of PKM2 to Cdc14A transcription. Endogenous 
p68 was knocked down with RNAi (sip68). Exogenous PKM2, wild type or mutant p68 
was expressed in p68 knocked down cells. (C) p68 was required for the regulatory 
function of nuclear PKM2. p68 in the cells was knocked down with RNAi (sip68). Wild 
type or mutant PKM2 was exogenously expressed in p68 knocked down cells. (D) PKM2 
was required for the regulatory function of p68. PKM2 was knocked down with RNAi 
(siPK). Wild type or mutant p68 was exogenously expressed in PKM2 knocked down 
cells. In (A), (B), (C) and (D) Immunoblot of β-actin (IB:β-actin) is a loading control. 
The exogenously expressed PKM2 or p68 (wild type or mutants) was examined by 
immunoblot using anti-HA antibody. 
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Fig 4.5 PKM2 Interacts to Cdc14A Gene Promoter  
ChIP analyses of Cdc14A promoter using PKM2antibody in SW480 cells (αPKM2). 
ChIP analyses using rabbit IgG (IgG) was a negative control. Inputs were PCR products 
from DNA extracts without ChIP. (a) ChIP-using PCR primer pair targeting to promoter 
reion Cdc14A gene. Chip-1 primers: Forward 5’-GAAGGAGGATCCGGAGCAG-3’  
Reverse 5’-CCTGGGAAACGCAGACCAG-3’ (b) ChIP-using anthour PCR 
primer targeting to promoter region of Cdc14A gene. Chip-2 primers: Forward 5’-
TCGGGTTCCCCTCGGAATG-3’ Reverse 5’-AAGCGAGATACGCACGGGG-3’ (c) 
ChIP− using PCR primer pair targeting a down stream region of exon 1 of Cdc14A gene 
is a negative control. (d) ChIP targeting GAPDH using antibody against PKM2 was 
another negative control 
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Fig4.6 Cdc14A Transcription is Regulated by PKM2 Expression  
(A) & (C) Expressions of Cdc14A (IB: Cdc14AMEK5) in SW480 were analyzed by 
immunobloting whole cell lysate (WCL) prepared from the cells in which PKM2 was 
knocked down by RNAi (PKM2, IB: PKM2). Expression of HA-PKM2 in SW480 was 
examined by immunobloting whole cell lysate with anti-HA (IB: HA). The blot of β-
actin (IB:β-actin) are the loading controls. (B) & (D) were RT-PCR results 
corresponding to (A), (C). (E) shows the percentage of the number of multinuclei cells in 
the whole populations of PKM2 knocked down cells. (a) is the population of two nuclei 
in the whole populations of PKM2 knocked down cells. (b) is the percentage of triple 
nuclei population in the whole populations PKM2 knocked down cells. (c) is the 
percentage of single nucleus population in the whole population PKM2 knocked down 
cells. Error bars in (E) are standard deviations of three measurements 
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Fig 4.7 Cdc14A Expression in Cancer Cell Lines  
Expressions of Cdc14A in SW620/SW480, LN686/M4C1, and H146/H460 were 
analyzed by immunobloting whole cell lysate (WCL) with anti-Cdc14A. The blot of β-
actin (IB: β- actin) are the loading controls. 
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CHAPTER 5 CONCLUSIONS AND DISCUSSIONS 
 
5.1 Conclusions 
The Warburg effect has been known for decades. The detailed mechanism of the 
Warburg effect is still not known. It has been shown that metabolic adjustment benefits 
cancer cells in many aspects. For example, the change provides phosphor intermediates 
for macromolecule synthesis as well as help cancer cells to avoid apoptosis. In this study, 
we discovered that there were more nuclear PKM2 in metastatic cancer cells than the non-
metastatic cancer cells. The nuclear PKM2 levels were correlated with cancer cell 
proliferation rates. PKM2 regulated MEK5 gene transcription to promote cell proliferation. 
Nuclear PKM2 phosphorylated Stat3 at Y705 site using PEP as a phosphoryl group donor 
to regulate MEK5 gene transcription. Our study also showed that double phosphorylated 
p68 RNA helicase at Y593/595 residues interacted with PKM2 at its FBP binding site. 
Under the stimulation of growth factors, p68 interacted with PKM2 to promote its protein 
kinase activity. The transcription regulatory function of nuclear PKM2 was also defined 
in regulating Cdc14A gene transcription resulting in a multi-nucleus phenomenon in less 
aggressive cancer cells. These results provided part explanations for Warburg effect.     
 
5.2 Nuclear PKM2 Interacts with Tyrosine-phosphorylated p68 RNA Helicase 
p68 RNA helicase is a multifunctional protein dominantly localized in the nucleus, 
and plays a crucial role in RNA biogenesis as well as tumorigenesis. The 
phosphorylations of p68 RNA helicase have diverse functions (Huang and Liu 2002; Liu 
2002). In 2007, Yang et al reported that p68 RNA helicase is double phosphorylated at 
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Y593 and Y595 residues in some cancer cells, such T98G and HeLa cells (Yang, Lin et 
al. 2007). The double phosphorylated p68 RNA helicase facilitates cancer cells in 
resistance of TRAIL induced-apoptosis. To further examine p68’s physiological 
functions in cancer cells, it was important to uncover proteins that interacted with 
phosphorylated p68 RNA helicase in the nucleus. PKM2 was found to interact with p-
Y593/595 peptides. However, this method did not detect other associated proteins with 
low enrichment to tyrosine-phosphorylated peptides due to the limitation of its 
sensitivity, or the weak interactions with phoshprylated p68. Meanwhile, whether nuclear 
PKM2 has functions in regulating RNA biogenesis with p68 RNA helicase remains 
elusive.     
 
5.3 Tyrosine-phosphorylated p68 Peptides Change the Quaternary Structure of 
PKM2  
In 2008, Cantley’s group reported that PKM2 binds to tyrosine phosphorylated 
peptides in tumor cells. The binding of phosphorylated peptides to PKM2 releases 
fructose-1,6-bisphosphate (FBP), the allosteric activator of PKM2. Binding to the 
phopshorylatd peptides also inhibits its pyruvate kinase activity (Christofk, Vander 
Heiden et al. 2008; Christofk, Vander Heiden et al. 2008). The inhibitory effect of 
tyrosine phosphopeptides on PKM2 also exists in living cells. However, the interaction 
example of a tyrosine phospho protein with PKM2 is not yet revealed. In our study, we 
found a tyrosine phospho peptides, p-Y593/595, derived from p68 RNA helicase, 
interacted with PKM2 at FBP binding site. Our experiments further demonstrate the 
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interaction of the phosphor-p68 with PKM2. The pyruvate kinase activity of PKM2 was 
decreased when interacting with p68 RNA helicase.  
During tumorigenesis, PKM2 is converted to dimeric form in tumor cells. The 
dimeric form has a low affinity to PEP. The low affinity to PEP slows down the 
glycolysis so that more phosphorylated intermediates from glycose are used to synthesize 
nucleic acids and amino acids for cell proliferation. One interesting question is how to 
convert the tetrameric PKM2 to a dimer in living cells. It is conceivable to think that the 
binding of tyrosine phosphopeptides to PKM2 changes its quaternary structure from a 
tetramer to a dimer so that the glycolytic activity of PKM2 is decreased and FBP is 
released. In our study, the binding of p-Y593/595 to PKM2 changed its quaternary 
structure from tetrameric to dimeric. The pyruvate kinase activity of PKM2 is decreased 
to certain level to benefit cancer cells for macromolecule synthesis. On the other hand, 
the dimeric PKM2 was shuttled into the nucleus by p68 RNA helicase to regulate gene 
transcription for promoting cell proliferation. Therefore, PKM2 plays a central role to 
modulate both cancer cell motabism and gene transcription.  
In addition, phosphorylation can occur at Serine, Threonine as well as Tyrosine 
residues. What are the functions of Serine and Theronine phosphorylated proteins 
binding to PKM2? Do they have the similar functions as Tyrosine phosphorylated 
proteins binding to PKM2 to affect cell proliferation as well as the glycolysis process? It 
will be very interesting to find out the physiological roles of these phosphorylated 
proteins to PKM2. 
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5.4 Nuclear PKM2 Regulates MEK5 Gene Transcription to Promote Cell 
Proliferation  
To analyze the function of nuclear PKM2, we screened the nuclear PKM2 levels in 
five pairs of cancer cell lines. The levels of nuclear PKM2 correlated with the 
proliferation status of cancer cells. According to these studies, we hypothesized that 
nuclear PKM2 may function in gene transcription in cancer cells to promote cell 
proliferation. Both expression array and Chip-on-chip suggested that PKM2 plays a role 
in MEK5 gene transcription. Our results showed that regulation of MEK5 gene 
transcription mediated the role of PKM2 in promoting cell proliferation. Our results also 
indicated that MEK5 was highly expressed in more metastatic cancer cells than in less 
aggressive cancer cells from the same tissues, such as lung, melanoma and colorectal 
cancer cells. According to our expression array analysis, there were also many other 
genes related to cell proliferation, such as ribosomes proteins and cyclin D1. Further 
studies will be carried out with these genes. 
Interestingly, PKM2 is not the only metabolism enzyme acting in gene 
tranascription in the nucleus. It was reported that some other glycolytic proteins played 
roles in the regulation of gene transcription in the nucleus, such as GAPDH. GAPDH 
interacts with the Oct-1 transcriptional factor in the nucleus as a co-activator to regulate 
H2B gene transcription (Zheng 2003). Nuclear GAPDH binds to DNA as well as RNA to 
play multiple roles in many other cellular processes, such as nuclear tRNA transport, 
DNA replication and repair (Sirover, 2005). It was also reported that GAPDH induces 
ATG12 expression to resist the caspase-independent cell death process {Colell, 2007 
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#6009}. Another example is Lactate dehydrogenase (LDH), which catalyzes the pyruvate 
to lactate conversion, was also discovered as a DNA-helix-destabilizing protein, which 
plays roles in gene transcription in the nucleus. LDH-A and LDH-B are transcriptional 
co-activators with functions in cell-cylce regulation. Hexokinase 2 induces 
transcriptional repression in the nucleus of yeast {Rodriguez, 2001 #6013}. An isoform 
of Enolase 1 represses the transcriptional activity of the c-Myc gene in HeLa cells 
[Ghosh et al., 1999]. In addition, some other glycolytic proteins, such as 
phosphoglycerate kinase and aldolase, are also detected in the nucleus {Ronai, 1993 
#6010}. It is very interesting to investigate whether nuclear PKM2 also regulates other 
gene transcriptions to perform diverse biological functions, such as nuclear tRNA 
transport, DNA processing and apoptosis. 
 
5.5 Nuclear PKM2 Phosphorylates Stat3 in the Nucleus to Regulate its 
Transcriptional Activity 
PKM2 does not have a clearly defined DNA binding motif. Thus, an open question 
is how PKM2 is able to function in gene transcription. We hypothesized that nuclear 
PKM2 acts as a co-activator to regulate gene transcription and PKM2 may target other 
transcription factors. It was reported that Stat3 regulateed MEK5 transcription (Song, Jin 
et al. 2004). It was also shown that Stat3 was a tyrosine phosphopeptides binding 
proteins. Thus, we questioned whether Stat3 interacted with PKM2 in the nucleus. Our 
experiments indeed showed the interaction between nuclear PKM2 and Stat3. In this 
study, the transcription activity of the downstream target of Stat3 is MEK5. MEK5 is the 
major effector in the control of cell proliferation regulated by nuclear PKM2. The 
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transcriptional activity of other downstream targets of Stat3, such as Cyclin D1, remains 
to be elusive. Whether nuclear PKM2 interacts with other transcriptional related-factors 
to play a role in regulating gene transcription is not yet known. Further study needs to be 
carried out in this direction.  
 
5.6 Overexpression PKM2 Forms Multinucleus in Less aggressive Cancer Cells  
The overexpression of PKM2 in less aggressive cancer cells, such as T98G, 
SW480 cells, induces formation of multinucleus cells. The molecular mechanism that 
leads to the formation of multinuclear cells is not clear. Gene array analysis demonstrated 
that PKM2 control Cdc14A expression. The regulation function of PKM2 in regulating 
Cdc14A expression depends on the expression of p68 RNA helicase, which provided 
another example of the function of p68 RNA helicase as a co-activator. In addition, p68 
RNA helicase activity was not related to its gene regulation function. One possible 
mechanism for formation multinucleus phenomenon induced by PKM2 overexpression is 
the overexpression of Cdc14A dephosphorylated Cdh1, which activated the APC 
complex to exit mitosis, resulting in aneuploidy, an abnormal number of chromosomes, 
in tumor cells. The aberrant mitosis may result in apoptosis in these cancer cells after a 
certain number of generations. Under these circumstances, overexpression of PKM2 may 
not promote cell proliferation, which explains well why PKM2 does not promote cell 
proliferation in less aggressive cancer cells. On the other hand, aneuploidization is found 
in many cancer cells. After more than a hundred years, it is still debatable whether 
aneuploidy, is a cause of cancer (von Hansemann, D. (1890) Boveri, T. (1914)). It was 
also reported that Cdc14A upregulation induced aberrant, premature centrosome 
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splitting. The centrosome is the microtubule organization center, which plays pivotal 
roles in regulating the formation of bipolar spindles during mitosis. The pre-mature 
splitting of centrosomes in the S phase may cause formation of multinucleus in these 
cancer cells.  
 
5.7 Dimeric PKM2 Phosphorylates Stat3 Using PEP as Phosphoryl Group Donor 
Both nuclear and cytoplasmic PKM2 exist in different quaternary structures in 
many cancer cell lines, such as SW480 and SW620 cells. Nuclear PKM2 does not form a 
tetramic structure like the cytosolic version. Whether nuclear PKM2 forms a dimer or 
exists as a monomer is not yet determined. We observed that nuclear PKM2 purified 
from SW620 cells migrated at 120KD position in a native gel. However, it is not known 
whether nuclear PKM2 has a post-translational modification that lead to the change in 
mobility in PAGE. Recently, it was reported that PKM2 was sumoylated and the 
sumoylation promotes nuclear localization (Spoden, Morandell et al. 2009). It will be 
interesting to test whether the band shift is due to PKM2 sumoylation or possibly other 
modifications. 
Tetrameric forms of PKM2 have a higher affinity to PEP, which is regulated by 
FBP binding. Our results showed that nuclear PKM2 phosphorylated Stat3 uses PEP as a 
phosphoryl group donor. The phosphorylation of Stat3 by PKM2 was also observed with 
PKM2 purified from cytosolic extract. However, the cytosolic PKM2 exhibited much 
week activity in phosphorylating Stat3 compared to that of nuclear PKM2. This is most 
likely due to cytosolic PKM2 exists mostly as a tetramer. Another possibility is that the 
tetrameric PKM2 can not bind to Stat3 because the binding sites for Stat3 are buried 
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according to structural analysis of PKM2. The binding site for Stat3 on PKM2 is located 
an ADP binding cleft, which is located between the two dimers. In the glycolysis process, 
ADP is small enough to access to the site. Stat3 is a large molecule, around 80 KDa. 
Thus, the access to the binding site is blocked.  
 
5.8 Arginine 399 Changes the Quaternary Structure of PKM2 
Arginine 399 is crucial for maintaining the tetrameric structure of PKM2 by 
forming charge-charge interaction with Glutamic Acid 418, Aspartic Acid 357, Glutamic 
Acid 396. To test the conjecture, a mutant was made to eliminate the interactions. Studies 
showed that this mutant interfered with the interaction between the two dimers of PKM2 
both in vivo and in vitro. Interestingly, an NES signal was detected in the PKM2 
sequence using the peptide graft technique. The NES signal is also expressed in the 
interface between the two dimers. The mutant in this region destroyed the formation of 
tetrameric PKM2. This NES mutant also diminishes the FBP binding site of PKM2. 
Interestingly, the recombinant R399E mutant protein was shown to phosphorylate Stat3 
proteins in vitro. This result also confirmed that R399E mutant may share a similar 
function with nuclear PKM2 to phosphorylate Stat3.  
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CHAPTER 6 MATERIAL AND METHODS 
6.1 Nucleic Acids Related Techniques 
6.1.1 Mini Preparation for DNA 
DNA Spin Mini Kit (Qiagen) was applied to isolate DNA plasmids from bacteria. 
Single colony was picked using a sterile inoculation loop from agar plates and 
resuspended in 1 ml LB culture medium containing appropriate antibiotics (50 ng/ml 
Kanamycin or Ampicillin). The bacteria were incubated at 37°C on a rotary shaker with 
220 rpm overnight. The next day, the bacteria medium was transferred into an Eppendoft 
tube and centrifuged at 13,000 rpm for 2 min. Then, the bacteria pellet was completely 
resuspended in 250 ul resuspension buffer. 250 ul of lysate buffer, P2, containing RNase 
was added into the tube. The tube was gently inverted back and forth 5-6 times to 
completely lysate the bacteria. Then, 350ul of neutralization buffer, N3, was added into 
the tube and inverted gently 5-6 times to completely neutralize the lysate. The lysate 
solution was then transferred into a spin column and centrifuged at 13,200 rpm for 1 min 
to allow DNA to be captured to the membrane. Then, the membrane was washed with 
500 ul of buffer PB by centrifuging at 13,000 rpm for 1 min to remove trace nuclease 
activity. Next, the membrane was washed with 0.75 ml of PE buffer to purify DNA by 
centrifuging at 13,000 rpm for 1 min. With additional 1 min centrifuging at 13,000 rpm, 
the membrane was dried. 20~30 ul ddH2O or TE buffer was loaded to the membrane to 
elute DNA from the membrane by centrifuging at 13,000 rpm for 1 min. The eluted DNA 
was confirmed by either gel electrophoresis or DNA sequencing.   
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6.1.2 Midi Preparation for DNA 
Bacteria containing DNA plasmid were cultured in 1 ml LB medium supplemented 
with appropriate antibiotics (50 ng/ml Kanamycin or Ampicillin). Then, the bacteria 
culture was transferred into 150 ml warm LB medium and cultured overnight to amplify 
plasmid DNA. The next day, the culture was centrifuged at 6,000 rpm for 10 min to get 
cell pellet. The bacteria pellet was resuspended in 3 ml of resuspension buffer and lysated 
with 3 ml of lysate buffer. The lysate was neutralized with the adding of 3 ml of 
neutralization buffer. Then, the solution was centrifuged at 15,000 for 20 min and the 
supernatant was carefully collected into a 50 ml conical tube. 10ml of DNA purification 
resin provide with the kit was added to the tube and mixed gently with the supernatant 
containing DNA plasmids. The mixture was loaded to a midi preparation column and 
applied to vacuum equipment to remove supernatant. The resin beads with DNA plasmids 
were washed with washing buffer twice (10 ml each time). After the washing buffer 
completely passed through the column, the vacuum was applied to the column for 
additional 1 min to dry the resin. The leftover of washing buffer was removed by 
centrifuging at 10,000 rpm for 1 min. During this time, 2 ml of ddH2O or TE buffer was 
heat to 70°C in a heat blocker. 300 ul of warmed ddH2O was added into the column and 
incubated for 2 min. Then, DNA plasmid was eluted from the column by centrifuging at 
13,200 rpm for 1 min. The DNA plasmid was purified with Phenol/Chloroform/Ethanol 
method and the concentration was measured with spectrometry at OD260nm.  
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6.1.3 Agarose Gel Electrophoresis and Gel Extraction of DNA  
DNA plasmids or DNA fragments could be visualized by using a double stranded 
DNA binding dye, Ethidium Bromide, under a UV transilluminator. 1 % agarose gel was 
prepared by adding 1 g of agarose beads into 100 ml TAE buffer. The solution was heated 
with microwave to completely liquefy agarose beads. The solution was quickly cooled 
down to 50-60 °C with a water bath for 1 min. 6 ul of Ethidium Bromide was added into 
100 ml warmed agarose solution and the solution was poured into a gel casting apparatus. 
Well inserts was set up in the gel casting apparatus to make suitable wells. 10 ul of DNA 
ladder was loaded into one well to refer to molecular weight of DNA fragments. The gel 
was run at constant voltage of 120 V until the blue dye reached to the middle of agarose 
gel.  
 
6.1.4 Quantification of DNA and RNA 
Nucleic acids concentration was measured using a spectrophotometer (UV-1700 
Spectrophotometer, Shimadzu Co.) at OD260 nm. The absorbance obtained at OD260 nm 
was applied to this formula: DNA concentration (ug/ml) = (OD260nm) X (dilution 
factor) X (50 ug DNA/ml) / (1 OD260nm unit). The purity of DNA was measured by the 
ratio of the absorbance of OD260nm /OD280nm. The purify was acceptable when the 
ratio was between 1.8 and 2.0. 
 
 
 
6.1.5 Polymerase Chain Reaction (PCR) Method 
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PCR method was applied to amplify a target sequence from plasmid DNA or 
mutate specific nucleic acids of a plasmid vector. Generally, 0.5 ug of template DNA was 
mixed with 1 mM dNTP, 0.5 ug forward and reverse primers, and 2 unit of pfu 
polymerase in 1X reaction buffer. The reaction mixture was denatured at 95 °C for 2 min 
and then was followed by 25-35 cycles: 95 °C denaturation for 30 seconds, 57-62 °C 
annealing for 45 seconds, 72 °C elongation for 45 seconds. An additional elongation step 
at 72 °C for 10 min was performed to stabilize the double strands. The PCR product 
might be visualized by agarose gel electrophoresis.  
 
6.1.6 Restriction Enzyme Digestion and Plasmids Construction. 
To exogenous introduce proteins into mammalian cells or express recombinant 
proteins in bacteria, cDNA of target genes must be constructed into expression vectors. 
Restriction enzyme digestion was applied to generate the specific restriction enzyme 
digestion sites. DNA sequence maps of these vectors were available from companies. 
According to the detailed description of these restriction enzyme sites, two suitable 
restriction enzymes would be chosen to digest PCR products or targeting cDNA 
sequences. To apply the restriction enzymes correctly, cDNA or PCR products sequence 
must be scanned by computer with the sequences of restriction enzymes to avoid mis-
targeting. All restriction enzymes have optimum conditions for their activities. To 
perform two restriction enzymes digestion simultaneously (double digestion), two 
enzymes must have compatible reaction conditions. Otherwise, the restriction digestions 
should be carried out one by one. In general, for 1ug DNA or 30ul PCR product, 1ul 
enzyme (20 unit) was used. ddH2O was added to the tube to make the final digestive 
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system to 30 ul or 50 ul. The mixture was incubated at a temperature ranging from 30 °C 
to 37 °C for 1 to 2 hours. Agaorse gel electrophoresis was performed to separate the 
digested vectors.  
T4 ligase was applied to ligase the digested DNA into the vector. T4 ligase can join 
the 3’-OH of one nucleic acid and the 5’ phosphate of the other nucleic acid. The ratio of 
insert DNA to vector was critical to make the ligation successful. An optimum ratio of 
insert DNA to plasmid vector was around 3:1. The ligation process was performed in 1x 
ligation buffer with 2 ul of T4 ligase. The mixture was incubated at 4 °C overnight. The 
next day, the ligation product was transformed into competent bacteria.   
 
6.1.7 Site-directed Mutation Method  
Site-directed mutation was carried out using QuikChange II XL site-directed 
mutagenesis kit (Stratagene). The primers were designed using an on-line program--The 
QuikChange®Primer Design Program. 0.5 ug of primers was applied to PCR system. 2 ul 
of Dpn1 enzyme (20 unit) was added to the reaction system to digest unmutated plasmid 
vectors. The reaction was performed at 37°C for 2 hours. After purification, the mutated 
plasmid vectors were transformed into XL1-Blue competent cells. The transformed XL1-
Blue cells were cultured in agar plates containing appropriate antibiotics overnight. The 
next day, 6-12 colonies were picked to be cultured in 1 ml LB medium overnight. The 
following day, mini-prep was performed to isolate plasmid DNA from XL-1 Blue cells 
and the mutated DNA sequences were confirmed with DNA sequencing technique at the 
core facility of Georgia State University. 
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6.1.8 DNA Sequencing 
DNA sequencing experiment was performed to examine a DNA sequence from a 
mutation or ligation experiment. The sequencing primer was designed according to 
plasmid vector maps, which was 50-100 nucleic acids upstream of the target sequence. 
The sequencing primer was diluted in 20 uM. The plasmid vector was diluted to 0.1-0.2 
ug/ul. Some sequencing primers were provided by the core facility of Georgia State 
University, such as T7, S4 primers.  
 
6.1.9 Ethanol Purification of DNA 
Ethanol purification was performed to remove any salt or protein contaminations in 
DNA samples. Firstly, 1/10 volume of 3 M sodium acetate was added to DNA sample 
and mixed thoroughly. 2 volumes of 100% ethanol was added into the mixture and placed 
in -20°C for 30 min. the mixture was centrifuged at full speed for 10 min at room 
temperature to pellet DNA. The DNA pellet was washed with cold 70% ethanol twice 
and centrifuged at 4°C. DNA pellet was dried by air at room temperature until the pellet 
becomes transparent. Then, the pellet was dissolved in ddH2O and the concentration was 
measured with a spectrophotometer at OD260nm. 
 
6.1.10 RNA Extraction 
Total RNA was isolated from mammalian cells by using RNeasy Plus Kit 
(Qiagen). Mammalian cells were cultured in a 6-well plate and washed with cold PBS 
twice. Then, 350 ul of RLT buffer supplemented with 3ul of 2-Mercaptoethanol was 
added to each well. The attached cells were lifted from the culture plate with a cell lifter 
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and loaded onto a QiaShredder column (Qiagen) to be homogenized. The loaded column 
was centrifuged at full speed for 2 min in a microcentrifuge machine. The eluted samples 
were loaded onto a gDNA eliminator spin column to remove genomic DNA. After 
centrifuging at 13,200 rpm for 2 min, the eluted solution was mixed thoroughly with one 
equivalent volume of 70 % ethanol. The mixture was loaded onto an RNeasy spin column 
and centrifuge at full speed for 1 min. Then, the column was washed with 700 ul of RW1 
buffer once and RPE buffer twice. The column was centrifuged for one more minute to 
dry the membrane. Finally, RNA was eluted with 30 ul of RNase-free H2O twice. The 
elution was combined together and RNA concentration was measured with a 
spectrophotometer at OD260 nm. RNA samples were stored at -80°C for a couple 
months. 
 
6.1.11 Reverse Transcription PCR 
Reverse transcription was performed to generate cDNA from mRNA. 1 ug of total 
RNA extract was mixed with 1 ul of oligo dt15 to a final volume of 5 ul with adding of 
RNase-free H2O. The mixture was incubated at 25 °C for 5 min and followed by 
incubating at 70 °C for 5 min. Then, the mixture was incubated on ice for 5 min. To each 
reaction, 1 ul of reverse transcriptase, 1 ul of RNase inhibitor, 4 ul of MgCl2 (25 mM) 
and 4 ul 5X reaction buffer were mixed thoroughly. The reaction was incubated at 25 °C 
for 5 min, 45 °C for 1 hour and 70 °C for 15 min. The final products were stored at -80 
°C. 
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6.1.12 Relative Real Time PCR  
Total RNA was extracted from cells using a RNeasy kit. Reverse transcription 
process was performed with ImProm-II reverse transcription system (Promega). RT-PCR 
process was performed in Applied Biosystems Fast Real-Time PCR 7500. RT-PCRs were 
performed with 1 µg of cDNA and 25 ul of Fast SYBR green master mix (Applied 
biosystems). The solutions were mixed in a 0.5 ml PCR tube and loaded to a RT-PCR 
plate. The plate was tightly sealed with a piece of adhesive film. The plate was 
centrifuged at 1,000 rpm for 2 min at room temperature and loaded onto real-time PCR 
machine. The amplification process was carried out by the following the cycles: 95 °C 
for 15 seconds, 95 °C for 3 seconds and 60 °C for 30 seconds. The amplification was 
analyzed with the Applied Biosystems SDS v1.4 program. After the cycles, a dissociation 
curve was generated by increasing the temperature to 95 °C for 30 min. Standard RT-
PCR primer set was purchased from RealTimePrimers.com.  
 
6.1.13 Chromatin Immunoprecipitation  
Mammalian cells were cultured in normal medium to 70% confluence. Then, cells 
was fixed with 1% formaldehyde solution by incubating 10 min at 37 °C and the reaction 
was stopped with the adding of 125 mM glycine. The fixed cells were washed with cold 
1X PBS three times supplemented with protease inhibitors and lysated in 1 ml SDS lysis 
buffer (Imgenex). The cell lysate was sonicated on ice for 2 min and centrifuged at 
15,000 rpm to pellet insoluble material. The success of shearing was examined with 
agarose gel. The supernatant was aliquoted and pre-cleared with 100 ul salmon sperm 
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DNA/protein G agarose by incubating for 2 hours. The primary antibody (10~20 ul) was 
added to the supernatant and incubated at 4 °C overnight. The next day, 100 ul of salmon 
sperm DNA/protein G agarose was added to each tube and incubated for 2 hours. The 
immuno-complex was eluted with 200 ul elution buffer. The cross-link was reversed with 
4 ul of 5 M NaCl incubating at 65° overnight. The released DNA was purified using the 
phenol chloroform extraction method. Regular PCR was performed in Mastercycle® 
Gradient PCR machine (Eppendorf) and the result was analyzed on a 2% agarose gel.  
 
6.1.14 ChIP-on-chip 
For ChIP-on-chip analysis, GeneChip human promoter 1.0R array was applied in 
this research. The immuno-complex from Chromatin Immunoprecipitation was cleaned 
up with phenol chloroform extract method. The immunoprecipitated DNA targets were 
amplified with PCR method with random primers. The amplified DNA targets were 
fragmented using cDNA fragmentation buffer (GeneChip WT Double-stranded DNA 
terminal labeling kit). The fragmented DNA was labeled with DNA labeling reagent 
(GeneChip WT Double-stranded DNA terminal labeling kit) and examined with gel-shift 
analysis. The labeled target was hybridized with arrays in hybridization oven 
(Hybridization Oven 640 Affymetrix) at 60 rpm for 16 hours. The arrays were then 
scanned with Affymetrix GeneChip 3000 scanner. The ChIP-on-chip data was analyzed 
with affymetrix Tiling Analysis software 1.1 and Integrated Genome Browser. All 
parameters were set up as described in the tiling analysis software tutorial from 
Affymetrix website. 
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6.1.15 Microarray analysis 
GeneChip® Human Genome U133 Plus 2.0 Array was performed in this research. 
Total RNA from cells expressing HA-tagged PKM2 or control was extracted with 
RNeasy kit by following the manufacturer’s instruction (Qiagen). The total RNA 
concentration was determined by spectrometer reading at OD 280 nm. 10ug of total RNA 
of each sample was used for synthesizing the (−) strand cDNA with ImProm-II reverse 
transcription system (Promega). Synthesized cDNA were purified with the phenol-
chloroform extraction method. In vitro transcription reaction was performed by using the 
GeneChip® IVT Labeling Kit (Affymetrix). The labeled cRNA was fragmented in 
fragmentation buffer (Affymetrix) and hybridized to GeneChip® Human Genome U133 
Plus 2.0 Array. The arrays were scanned with Affymetrix GeneChip 3000 scanner. The 
data were analyzed by Affymetrix GeneChip Operating Software (GCOS) Version 1.0.  
 
6.1.16 Electrophoretic Mobility Shift Assay.  
Stat3 consensus binding probe 5’-GATCCTTCTGGGAATTCCTAGATC-3’ was 
purchased from Santa Cruz. The DNA probes were labeled with γ-32P using T4 
polynucleotide kinase. Nuclear protein extracts (10 ug each) were incubated with the 32P 
labeled Stat3 consensus-binding probe for 20 minutes at room temperature in binding 
buffer (5 % glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM 
Tris-HCl, 0.05 mg/ml poly(dI-dC)). For supershift analyses, the nuclear extracts were 
preincubated with Stat3 monoclonal antibody (invitrogen) for 1hour at room temperate 
before loading. The protein-DNA complexes were separated in 4 % native 
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polyacrylamide gel (acrylamide: polyacrylamide 60:1). The 4 % native polyacrylamide 
gel was pre-run at 200 V for 45 min in 0.5X TBE buffer at 4 °C. Protein-DNA complexes 
were loading in wells with loading buffer and run at 200 V until the blue dye migrated to 
¾ length of the gel. The gel was transferred to Whatman paper. The gel was covered with 
Saran Wrap and dried at 80 °C in vacuum dryer for 2hours. The gel was placed in 
phosphoimagine plate in 4 °C overnight. The gel plate was read in Storm 840 
phosphoimager, Amersham Biosciences and analyzed with ImageQuant TL.  
 
6.2 Bacterial Techniques  
6.2.1 Bacterial Culture and Storage  
The E. coli strains, such as JM109, XL1-blue, BL-21 were used for plasmid DNA 
amplification or recombinant protein expression. E. coli stains were inoculated in 
autoclaved Luria Broth (LB) medium prepared in 1 % bacto-tryptone w/v, 0.5 % bacto-
yeast-extract w/v and 1 % NaCl w/v. 50μg/ml of Ampicillin or Kanamycin was added 
into warmed LB medium (50~60 ºC) for antibiotic resistant strains selection. The bacteria 
were cultured in shakers or incubators in 37 ºC. Agar plates were prepared in LB medium 
with the addition of 1.5% Agar prior to autoclaving. For long term storage of transformed 
bacteria, the transformed strains were mixed with sterile 30 % glycerol w/v and preserved 
at -80 ºC. 
 
6.2.2 Transformation  
For large scale plasmid DNA preparation, transformation was carried out in JM109 
E.coli strain. JM109 competent cells were thawed on ice and 100ul of JM109 was 
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aliquoted into a test tube. 1~5 μg of plasmid DNA was added into the tube and incubated 
with JM109 competent cells for 30min on ice. Heat shock was performed to the mixture 
at 42 ºC for 90 seconds. The mixture was chilled on ice for additional 2 min and 200 ul of 
warmed LB were added into the tube. Then, the tube was incubated at 37 ºC in a shaker 
with 220 rmp for 1 hour. The transformed bacteria were spread onto agar plates 
containing appropriate antibiotics and incubated at 37 ºC overnight. The next day, 
colonies were picked with sterile plastic sticks from the agar plates and dipped into 
antibiotics containing LB medium for large scale amplification.  
 
6.3 Protein Techniques 
6.3.1 Recombinant PKM2 Protein Expression and Purification 
Human PKM2 cDNA was constructed into pET30a bacteria expression vector. BL-
21 expression host was transformed with PKM2-pET30a vector and cultured in LB 
medium containing 50 ng/ml Kanamycin. BL-21 was cultured in 50 ml LB and the next 
day was transferred into 1L warmed LB medium shaking at 220 rmp at 37 °C until 
OD600nm reached between 0.4 and 0.6. Isopropyl-β-D-thiogalactoside (IPTG) was 
added to LB medium to a final concentration at 1mM to induce recombinant protein 
expression. 4 hours later, bacteria were collected with centrifuging at 6,000 rpm at 4 °C 
for 10 min. Bacteria pellet was washed with cold PBS twice and lysated in lysis buffer 
containing 1mg/ml lysozome. The bateria lysate was sonicated for 1 min on ice and 
centrifuged at 17,000 rpm for 20 min. The expression of recombinant PKM2 was 
detected with SDS-PAGE gel. Most recombinant PKM2 protein was expressed in 
inclusion bodies. The pellets were washed with washing buffer (0.5M Urea and 50mM 
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phoshorylate buffer pH7.4) twice and lysated in a denature buffer (8 M Urea and 50 mM 
phosphorylate buffer, pH7.4). The inclusion body was lysated at RT for 1 hour and 
centrifuge at 16,000 rpm for 30 min. The supernatant was collected and diluted dropwise 
with 50 mM phosphorylated buffer till 0.5 M Urea. Recombinant PKM2 protein was 
purified with HiTrap column using Akta purifier 100 FPLC system. Recombinant PKM2 
protein was gradient eluted with 0.5 M imidazole. The eluted protein was collected and 
dialysis in buffer (50 mM Tris, pH 7.5, 0.1 M KCl, and 20% glycerol). 25mM DTT was 
added into the buffer and dialysis into the refolding buffer (50 mM Tris, pH 8.0, 0.1 M 
KCl, 20% glycerol, 0.1 M EDTA, 1 mM DTT) 
 
6.3.2 Gel Filtration  
Size filtration chromatograph was applied to separate tetrameric and dimeric PKM2 
from the subcellular extracts. The separation process was performed in Superdex 200 
10/300GL column with Akta purifier 100 FPLC system. Superdex 200 10/300GL column 
can separate proteins molecular weight range from 10KD~600KD. Blue dextran, 2,000 
KD, was applied to measure void volume (Vo) of the column. 100 ul of blue dextran was 
loaded into the column with concentration at 1 mg/ml. The column was calibrated with 
molecular weight standards, such as Aprotinin  6.5 KD, Ribonuclease A 13.7 KD, 
Carbonic Anhydrase 29 KD, Ovalbumin 44 KD, Conalbumin 75 KD, Ferritin 440 KD, 
Thyroglobulin 669 KD. These standards were dissolved in the same buffer as subcellular 
extracts or recombinant proteins with salt concentration higher than 0.15M. The protein 
standards concentration was 3 mg/ml or 4 mg/ml. UV280nm protein detector was applied 
to monitor the chromatography. The flow rate was 0.4 ml/min. The standard curve was 
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calculated by following the manufacture’s instruction. 100 ul cytosolic or nuclear extract 
(500 ug) was loaded into Superdex 200 10/300GL column and eluted with elution buffer 
(50 mM sodium phosphate buffer pH7.2, 0.15 M NaCl). The elution fraction was 
collected in 300 ul aliquots. The molecular weight of each aliquot was calculated based 
on the calibration curve made from standard proteins. 30 ul of each aliquot was analyzed 
with 10 % SDS/PAGE gel followed by western blot procedure.  
 
6.3.3 Protein Quantification 
Protein concentration was determined with BioRad Protein Assay. The standard 
curve was generated with a serial of diluted Bovine Serum Albumin (BSA) at the range 
of 2.0-10.0 ug/ul. The standard curve was generated according to the absorption values of 
BSA using Microsoft Excel. 1-2 ul of sample solution was diluted in 800 ul ddH2O 
mixed with 200 ul BioRad dye solution. The optical density was examined with a 
spectrophotometer at a wavelength of 595 nm. The protein concentration was calculated 
according to the absorption values. 
 
6.3.4 Sodium Dodecyl Sulfate Polyacryalmide Gel Electrophoresis (SDS-PAGE)  
SDS-PAGE gel was applied to separate protein complexes according to their 
electrophoretic mobilities. The electrophoresis apparatus was assembled according to the 
manufacturer’s instructions. Separating gel was prepared by following the recipes. The 
solution was mixed in a 100 ml glass beaker and poured between the glass plates. 500 ul 
isopropanol was poured on top of separating gel to remove air bubbles. Roughly, it took 
45 min for separating gel to be polymerized. After the separating gel was polymerized, 
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isopropanol was poured off and the top of the separating gel was rinsed with ddH2O 
gently. The leftover of ddH2O was removed by a small piece of filter paper. Then, 4 % 
stacking gel was prepared and poured on top of the separating gel. A comb was inserted 
into the stacking gel to generate wells. The prepared SDS-PAGE gels were overlaid with 
1X SDS-PAGE running buffer at 4 °C for a couple days. Protein samples were mixed 
with 5X loading buffer and boiled at 95 °C for 8 min. Protein samples were loaded into 
the wells with fine tips. The unused adjacent wells were loaded with 1X sample buffer. 
SDS-PAGE running buffer was added into both the inner chamber and the outer 
chamber. Run the gel at 60 V until the dye had reached the front of separating gel and 
then switch to 120 V until the blue dye running out of the gel.  
Separating gel buffer  
375 mM Tris-HCl; pH 8.8  
0.1% SDS  
4% Stacking gel buffer 
125 mM Tris-HCl; pH 6.8  
0.1% SDS   
SDS-PAGE running buffer 
25 mM Tris; pH 8.3  
250 mM Glycine  
0.1% SDS  
pH = 8.3  
5X protein gel sample loading buffer 
50 mM Tris-HCl; pH 6.8  
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2% SDS  
10% Glycerol  
1% β-Mercaptoethanol  
0.02 % Bromophenol Blue  
12.5 mM EDTA  
 
6.3.5 Coomassie Blue Staining 
Proteins on SDS-PAGE gel can be detected with Coomassie blue stain. The gel was 
washed with ddH2O for 2 min. Then, gel was stained with Coomassie blue solution for 30 
min. The gel was destained with destaining buffer to remove extra coomssive blue dyes.  
Coomssive blue solution 
0.1 % Coomassive Brilliant Blue 
20% Methanol  
10% Acetic Acid 
Destain buffer 
40%Methanol 
10% Acetic Acid 
 
6.3.6 GelCode Staining   
Small amount of proteins on SDS-PAGE Gels can be detected with GelCode 
staining (Pierce). The gel was washed with ddH2O twice (5 min/each) at room 
temperature. GelCode staining buffer without dilution was added into the staining tray 
that would just cover the gel. The gel was stained for 2 hours at room temperature and 
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destained with ddH2O for 2 hours. The protein bands were visualized with a UV 
transilluminator with CCD camera. 
 
6.3.7 Native Gel Preparation 
Native gel was prepared and run by following the method of SDS-PAGE in the 
absence of SDS. 
 
6.3.8 Protein In-gel Digestion 
Protein complexes were separated in SDS-PAGE gel or native gel. The presences of 
interested protein bands were stained with Coomassie blue, SYPRO Rube dye, or 
GelCode. The protein bands were carefully cut from the gel using a scalpel. The gel piece 
were placed in a siliconized Eppendorf tube and destained with 200 ul of destaining 
solution twice. The destaining process might be incubated in 37 ºC. The gel piece was 
dried using a Speed Vac for 30 min. 20 ul (0.4ug of Trypsin) of Trypsin solution and 50 
ul of the Trypsin reaction buffer were added into the tube and incubated with the gel 
piece at 37 ºC overnight. The next day, the liquid was removed from the tube and 
transferred into a new tube. 50 ul of peptide extraction solution was added to the gel 
piece and incubated at 37 ºC for 30 min. The peptide extraction solution was removed 
from the tube and combined with the liquid recovered from the previous step. Then, the 
sample was ready for MALDI-MS analysis.   
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6.3.9 Protein Identification by Peptide Mass Fingerprinting  
The proteins complexes were separated in SDS-PAGE and digested with Trypsin. 
The sample solution was concentrated with a Speed Vac to less than 10 ul. Then, the 
sample was desalted with ZipTip (uC18) tips. 1.5 ul of neat formic acid was added into 
the sample and mixed thoroughly. 8.5 ul of 0.1 % TFA was added into the tube and 
mixed with the sample. The tip was wet with wetting solution (50 % ACN) twice and 
equilibrated with 0.1 % TFA several times. The sample solution was aspirated and 
dispensed with the tip 5 times. The bound sample was washed with 0.1 % TFA 10 times. 
The sample was eluted from the ZipTip with 50 % ACN/0.1 % formic acid and spotted 
directly onto a wax-coated MALDI-TOF plate. The matching of the experimental peptide 
mass with database was examined with Peptident proteomic tools in ExPASy Molecular 
Biology Server (http://www.expasy.ch/). The MALDI-TOF/TOF database was from 
NCBInr. 
 
6.3.10 Antibody Generation and Purification 
Rabbits were immunized with KLH-conjugated peptides or recombinant proteins to 
generate antibodies. KLH-conjugated peptides were synthesized in Global Peptide 
Services Com.  Recombinant proteins were expressed in BL-21 and purified with 
HiTrap columns in FPLC systems. For each rabbit, 5 ml pre-immune blood was 
harvested from the auricular artery for test controls. The blood was allowed to clot at 
room temperature and the serum was collected by centrifuging at 3,000 rpm for 15 min at 
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4°C. 0.1 % NaN3 was added to the serum and the serum was stored at -80 °C. Antigens 
(peptides or recombinant proteins) were emulsified by mixing with an equal volume of 
complete Freund’s adjuvant. The emulsified antigen was injected into three subcutaneous 
dorsal sites in each rabbit. 0.2 mg of peptides or 0.5 mg of proteins was used per 
immunization. Two weeks later, 0.2 mg peptides or 0.5 mg of proteins were emulsified 
with incomplete Freund’s adjuvant and injected into three subcutaneous dorsal sites of 
the same rabbits. Four weeks later, 20 ml of production blood was bled from the rabbits. 
The serum was collected by centrifuging at 3,000 rpm for 15 min at 4 °C and stored at -
80 °C. Seven weeks later, 0.2 mg peptides was mixed with equal volume of incomplete 
Freund’s adjuvant and injected into rabbits. Eight weeks later, the second bleeding was 
carried out and 20 ml blood was harvested from the auricular artery. Nine weeks later, 
the rabbits were immunized with 0.2 mg peptides mixed with equal volume of incomplete 
Freund’s adjuvant. Ten weeks later, 50 ml production was bled.  
 
6.3.11 Kinase Assay 
SW620 cells were cultured in Leibovitz's L-15 Medium in flasks. SW620 cells were 
seeded to 70% confluence in T150 flasks and infected with 200 ul adenoviruses lysate 
(1X1013 pfu/ml) packed with PKM2 cDNA per flask. The infected cells were harvested 
after 3 days and the nuclear extract were prepared. 100 ul of anti-HA antibody was 
incubated with the nuclear extract from SW620 cells in NETs buffer supplemented with 
protease inhibitors overnight. The next day 200 ul of agarose G beads were added and 
incubated for 2 hours. The immunoprecipated complex was harvested with centrifuging 
500 rpm at 4 ºC for 5 min. The beads were washed with NETs buffer 4 times and high 
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salt solution (20mM Tris.HCl, 1M NaCl, pH7.5) for two times. Then the beads were 
washed with kinase buffer twice. The kinase assay was performed in kinase solution 
(100mM Tris.HCl, 100mM MgCl2, 2mM DTT, and 50 KCl). The recombinant protein 
Stat3 was incubated with purified HA-PKM2 in agarose beads at 4 ºC for 1hours. The 
reaction was stopped by adding 5XSDS-PAGE loading buffer and heating at 95 ºC for 8 
min. The phosphorylation level of recombinant Stat3 was analyzed with phosphor-Tyr-
705-Stat3 antibody.   
 
6.4 Mammalian Cell Techniques  
6.4.1 Mammalian Cell Culture and Storage  
LN686, M4C1, SW480, SW620, WM115, WM266, T98G, U87MG, H146 and 
H460 cell lines were purchased from ATCC and cultured by following the vendor’s 
instructions. To freeze cells, cells were cultured to 60-70 % confluence in a T75 flask and 
trypsinized. Cell numbers were measured using hemocytometer. Cell pellets were 
harvested with centrifuging at 1,000 rpm for 10 min. Then, cells were resuspended in 
freezing medium (10% v/v DMSO, 10% FBS, 80%culture medium) and aliquoted into 
freezing vials (5 x 106 cells/vial). The vials were stored in a freezing container at -80°C 
overnight. The next day, freezing vials were transferred to a liquid nitrogen reservoir for 
longer storage.  
 
6.4.2 Transient Transfection Method 
Mammalian cells applied in this project were transiently transfected with Fugene-
HD reagent (Roche) by following the manufacture’s instruction. Mammalian cells were 
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cultured in normal medium in 6-well plates. The next day, cell density would reach 70-
90% confluence depending on cell types. The plasmids DNA-Fugene-HD mixture was 
prepared in polystyrene transfection tubes. For each well, 2 ug of plasmid DNA was 
added into 100 ul Opti-MEM medium and mixed thoroughly. Then, 5 ul of Fugen-HD 
reagent was added into the tube and mixed with plasmid DNA thoroughly. The 
transfection complex would be formed in 20 min at room temperature. The plates were 
washed with fresh normal medium twice and fed back with 1ml normal medium. Then, 
the transfection complex was added to each well dropwise. The transfected cells were 
cultured in an incubator with/without 5 % CO2 at 37 °C for 48-72 hours before harvested.  
For immuno-stain experiments, cells were cultured in chambers 24 hours after 
transfection. Fluorescent microscope was applied to examine the fluorescent tagged 
protein 48 hours after transfection.  
 
6.4.3 RNA Interference 
RNA interference technique was applied to knock down endogenous protein 
expressions. Cells were seeded to 30-50 % confluence in 6-well plate in normal medium 
one day before knockdown experiment performance. The next day, 2 ml Opti-MEM 
medium was used to wash each well to remove FBS. siRNA duplex for PKM2, p68, 
MEK5 or Stat3 were purchased from Dharmacon RNA Technologies. RNA duplex was 
dissolved in DEPC-treated H2O to 40 pmol/ul. 200 pmol siRNA duplex was diluted in 
250 ul Opti-MEM medium. 5 ul of transfection reagent, lipofectamine RNAiMAX 
(invitrogen), was diluted into 250 ul Opti-MEM medium. The two solutions were 
combined together and incubated for 30 min at room temperature. 0.75 ml of Opti-MEM 
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medium was added into each well. Then, the mixture was added into each well dropwise. 
Fresh medium might be added into each well next day. For re-expression wild type or 
mutant proteins in knockdown cells, 24 hours later, knockdown cells were transfected 
using FuGene HD by following the manufacturer’s instruction. 48 hours later, cells were 
lifted by cell lifter and harvested by centrifuging at 1,000 rpm for 10 min at 4 °C.  
 
6.4.4 Growth Factor Treatment of Cells  
For growth factors stimulation, mammalian cells were starved for 6-12 hours with 
Opti-MEM medium prior to treatment. Growth factors dissolved in either DMSO or 
ddH2O were diluted in Opti-MEM medium. The starved cells were cultured in Opti-
MEM medium containing growth factor for a given amount of time. DMSO or ddH2O 
was used as a control. The cells were harvested once the treatment was done and stored at 
-80 °C immediately.   
 
6.4.5 Whole Cell Lysate Preparation 
Mammalian cells were washed with cold 1X PBS twice and collected by 
centrifuging at 1,000 rpm for 10 min at 4ºC. Whole cell lysate was prepared with cold 1X 
RIPA buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 0.25 % deoxycholic acid, 1 % NP-
40 and 1 mM EDTA) supplemented with Protease Inhibitors Cocktail (PIC) (Sigma) and 
phosphatase inhibitors cocktail (Pierce). In general, 1X106 cells were resuspended in 1 ml 
cold RIPA buffer and incubated for 1 hour on a rotary plate at 4 ºC. Then, cells were 
centrifuged at 13,200 rpm for 10min at 4°C to get cell debris pellet. The supernatant was 
removed carefully and stored at -80 ºC for later applications.  
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6.4.6 Nuclear Extract and Cytoplasmic Extract Preparation 
Nuclear extract and cytosolic proteins were made with a nuclear extraction kit from 
Active Motif. Mammalian cells were washed with cold 1X PBS twice supplemented with 
PIC to completely remove culture medium. The attached cells were harvested gently with 
a cell lifter. The suspension cells were harvested with centrifuging at 1,500 rpm for 10 
min at 4 ºC. In general, 1X106 cells were resuspended in 1 ml of 1X hydrophobic buffer 
supplemented with PIC and incubated on ice for 15 min. Then, 50ul of detergent was 
added into tube and the tube was vortexed at maximum speed for 30 seconds. The 
supernatant was collected and stored at -80 ºC up to 2 months. The pellet, which was the 
nucleus, was washed with cold 1XPBS twice to avoid cytoplasmic protein contamination. 
Then, the nuclear pellet was resuspended in AM1 lysis buffer containing PIC and 1 mM 
DTT and incubated at 4 ºC for 1hour. Next, the tube was centrifuged at 13,200 rpm for 10 
min at 4 ºC. The supernatant was collected and stored at -80ºC for further applications.  
 
6.4.7 Suspension Growth of HeLa S3 Cell 
HeLa S3 cells were firstly cultured in MEM medium supplemented with 10 % FBS 
on 2-3 plates. Medium was changed every 2 days until cell density reached 95 % 
confluent. Then, cells were trypsinized and spinned down in a 15 ml conical tube. Cells 
were resuspended in fresh medium and cell density was approximately 4X105 /ml. Cells 
were transferred into a small spinner flask using 10 ml peptides from side arms. The 
volume was around 100 ml in small spinner flask. The top lid and side arms was sealed 
with parafilm tightly. The next day, cell density was carefully measured and cells were 
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spinned down in 50 ml tubes. Then, cells were resuspended in fresh medium in a large 
spinner flask to reach a density of 4X105 /ml. Cells were fed every day with flash 
medium and cell density was maintained to 4~5x105 /ml. Finally, cells were cultured in a 
one liter spinner flask and cell density might reach 6~7x105 /ml. Cells were collected 
with centrifuging at 1,500 rpm for 10 min and were ready for later use.      
 
6.4.8 Large Scale Nuclear Extract Preparation 
To prepare large scale of nuclear extract for proteomic applications, we applied this 
method to extract nuclear proteins from mammalian cells. Suspension cells were 
harvested in 800 ml glass bottles spinning at 1,500 rpm for 10 min at 4°C. Cell pellets 
were transferred in cold 1xPBS to 50 ml Falcon tubes. The tubes were spinned at 3,000 
rpm for 5 min at 4 °C and the packed cell volume was noticed. The cell pellets were 
resuspended in 5 times the packed cell volume of buffer A and quickly centrifuged at 
3,000 rpm for 5 min at 4°C. A small sample was taken for microscope slide. The cell 
pellets were resuspended in 2 times the packed cell volume of buffer A and allowed to 
swell in buffer A for 10 min on ice. Then, the cells were homogenized in a large 40 ml 
glass Dounce homogeniser with a B type pestle for 20 up and down strokes. The cell 
lysate was examined under microscope. Additional strokes might be taken until cell lysis 
was greater than 90%. The swollen nuclei were about the same size as unlysed cells. The 
solution was transferred into a plastic tube and centrifuged at 4,000 rpm for 15 min at 
4°C. The supernatant, the cytoplasmic fraction, was removed and the volume was 
estimated. 0.11 volumes of buffer B was added to the supernatant and transferred to a 
plastic tube. The mixture was centrifuged at 3,400 rpm for 1 hour at 4°C. The supernatant 
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was dialyzed with the nuclear fraction later. The pellet volume was carefully estimated 
and ½ volume of buffer C (low salt) was added to the nuclear fraction. The mixture was 
then transferred to a small cold baked glass beaker at 4°C. ½ volume of buffer D was 
added to the beaker dropwise. Stirring was continued for 30 min. The mixture was 
transferred to plastic tubes and centrifuged at 8,000 rpm for 30 min at 4°C. The 
supernatant was collected and dialyzed in buffer E. The supernatant was distributed in 
eppendorf tubes and spinned for 20 min at 4°C. The supernatant was collected and stored 
at -80°C. 
 
Buffer A (hypotonic) 
10mM Tris pH7.9 
1.5mM MgCl2 
10mM KCl 
0.5mM DTT 
0.2 mM PMSF 
Buffer B 
0.3 M Tris pH7.9 
1.4M KCl 
30mM MgCl2 
0.5mM DTT 
Buffer C (low salt) 
20mM Tris pH7.9 
25% Glycerol 
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1.5mM MgCl2 
20mM KCl 
0.2mM PMSF 
0.5Mm DTT 
Buffer D (high salt) 
20mM Tris pH7.9 
25% Glycerol 
1.5mM MgCl2 
1.2M KCl 
0.2mM PMSF 
0.5Mm DTT 
Buffer E 
20Mm Tris Ph7.9 
20% Glycerol 
0.1M KCl 
0.2mM EDTA 
0.5mM DTT 
 
6.4.9 Immunoprecipitation (IP) and Co-immunoprecipitation (Co-IP) 
IP and Co-IP experiments were performed in 1X RIPA buffer supplemented with 
1X PIC and phosphatase inhibitors (1mM SoV, 5mM NaF). 500ug of whole cell lysate or 
subcellular extract were incubated with appropriate primary antibody in 1X RIPA buffer 
overnight at 4°C. The next day, 50ul protein G agarose bead slurry was added into the 
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reaction tube and incubated on a rotating platform for 2 hours at 4 °C. The beads were 
washed with 600 µl 1XRIPA or NETS buffer (150 mM NaCl, 50 mM Tris-HCl [pH 7.5], 
5 mM EDTA, 0.05 % NP-40) five times. The tubes were centrifuged at 1,000 rpm for 5 
min at 4 °C. The immuno-complex samples were denatured with equal volume of 
2XSDS-PAGE loading buffer by incubating at 95 °C for 8 min. The immuno-complexes 
were separated in SDS-polyacrylamide gel electrophoresis (PAGE) and the presence of 
interested protein bands were detected with western blot technique. 
 
6.4.10 Western Blot  
Certain amount of recombinant proteins, whole cell lysate, subcellular lysate or 
immuno-complex was mixed with 5X SDS-PAGE loading buffer and denatured by 
incubating at 95 ºC for 8 min. Proteins complex were separated in 8~10% SDS-PAGE 
and transferred to nitrocellular membranes. Nitrocellular membranes, sponges and filter 
papers were firstly soaked in transfer buffer (Tris-HCl, pH8.3, Glycine and 40 % 
methanol) for 10 min. The transfer sandwich was assembled by following the 
manufacturer’s instructions. The transferring was carried out at 100 mA for 1hour. After 
transferring, the transfer sandwich was disassembled and the nitrocellular membranes 
was stained with Pancrea S dye for 10 seconds and destained with ddH2O for 1 min to 
remove extra dye. The protein bands would be visualized on the membranes. The 
membranes were washed with TBST for 10 min to remove Panceau S dye completely. 
The membranes were incubated with primary antibody with suitable dilutions in 2%BSA-
TBST buffer at 4 °C for 2 hours to overnight. The next day, the membranes were washed 
with TBST buffer three times totally for 15~20 min. Then, membranes were incubated 
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with the secondary antibody (1:2,000 dilutions in TBST buffer) for 2 hours at room 
temperature. The membranes were incubated with SuperSignal West Dura Extended 
Duration Substrate (Pierce) for 2 min and the blotting signals were detected with a CCD 
camera. 
 
6.4.11 Cell Proliferation Assay 
Cell proliferation rate was measured with BrdU cell proliferation assay by following 
the manufacture’s instructions (Calbiochem). Briefly, cells were seeded into a 96 well 
culture plate (1X104 cells/well). The next day, cells were transfected with adenovirus 
containing expression plasmid vectors. Two days later, BrdU was diluted in a working 
solution with fresh culture medium. 20 ul of working solution was added into each well 
and incubated with cells in a cell culture incubator. 24 hours later, culture medium was 
removed and cells were fixed with 50ul Fixative/Denaturing solution. Then, 20 ul of anti-
BrdU antibody was added into each well and incubated with cells for 1 hour at room 
temperature. After extensive washing with washing buffer, secondary antibody 
conjugated with HRP was added into wells and incubated with cells for 30 min at room 
temperature. The plates were flooded with ddH2O and incubated with substrate solution 
for 15 min. 50ul of stop solution was added into each well and absorbance was measured 
using a spectrophotometric plate reader (Wallac 1420 multilabel counter) at wavelengths 
of 450-540nm.   
 
6.4.12 Recombinant Adenovirus Generation and Infection in Mammalian Cells 
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PKM2 cDNA was purchased from OriGene Technologies. Recombinant 
adenoviruses expressing PKM2 was constructed according to the method reported by Dr. 
Tong-Chuan He (Luo J et al, Nature protocols, 2007, 2(5), 1236-1247). Briefly, PKM2 
cDNA was cloned into a shuttle vector pAdEasy-1 with EcoRI and NotI restriction 
endonuclease sites. The resultant plasmid was digested with Pme1 and transformed into 
competent AdEasier cells containing the adenoviral backbone plasmid pAdEasy-1 by 
electroporation method (BJ5183-AD-1, Stratagene). Recombinants were selected for 
kanamycin resistance and further confirmed by restriction endonuclease analyses. The 
confirmed plasmid with PKM2 cDNA was digested with PacI restriction endonuclease 
and transformed into HEK-293 cells expressing adenovirus E1 (Stratagene). The 
production of recombinant adenoviruses in HEK-293 cells was examined with GFP 
expression under fluorescent microscope. The amplified virus was released from HEK-
293 cells by four freeze-thaw-vortex cycles. Cell debris was removed by centrifugation at 
500 rpm at 4 °C for 15min. The recombinant adenoviruses were amplified three rounds in 
HEK-293 cells to get higher titers. Titers were measured with GFP expression in HEK-
293 cells with a series of 10 folds dilutions of virus lysate. The titer in the initial lysate 
was around 1.43X109 pfu/ml. After three rounds of amplification the titer reached 
1.09X1013 pfu/ml. All viral lysates was stored in -80 °C for further appluications. To 
infect cells, cells were seeded in 48-well plates to 70~80 % confluence one day before 
infection. 50ul of viral lysate (1.09X1013 pfu/ml) was added to each well of a 48-well 
plate and incubated with cells for 3-5 hours. For 24-well and 6-well plates, the scales 
were increased according to the plate sizes. Fresh medium was changed 3~5 hours later. 
The expression of HA-PKM2 was examined by Western blot 48 hours later.  
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6.4.13 Metabolism Measurement 
Pyruvate, lactate, and glucose assay kits are purchased from BioVision. Mammalian 
cells overexpressing HA-PKM2 or control vectors were lysated in corresponding assay 
buffers. The cell lysate were centrifuged at 13,000 rpm to precipitate insoluble material. 
10 ul of the clear extracts was applied for assay test. The standard curves were generated 
using probes supplied with the kits. Pyruvate, lactate, and glucose amounts were 
measured by following the manufacture’s instruction. 
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6.5 Materials 
Table 2 Antibody List 
 
Name Antigen Source Company 
8E4 β-catenin Mouse  Upstate 
12CA5 HA Mouse Roche 
124H6 Stat3 Mouse Cell sigaling  
27E8 His Mouse  Cell signaling 
β-actin Actin Rabbit Cell Signaling 
γ-tubulin γ-tubulin Rabbit Abcam 
Anti-HA conjugated with 
fluorescent dye 
HA Mouse Roche 
Anti-HA poly HA Rabbit Georgia State 
University, 
Animal center 
facility 
Beta-catenin poly Beta-catenin Rabbit  Cell Signaling  
Biotin-labeled antibody for IHC  Rabbit KPL 
CRM1 CRM1 Rabbit Abcam 
D2E12 Jak2 Rabbit Cell signaling  
D3A7 p-Tyr-Stat3 
(Tyr705) 
Rabbit Cell signaling  
DCS-291 Cdc14A Mouse Abcam 
Eg5 Eg5 Rabbit Abcam 
Fibrillarin Fibrillarin Rabbit Abcam 
GAPDH GAPDH Mouse Cell signaling 
Histone 2A Histone Mouse Cell Signaling 
KPNA2 KPNA2 Rabbit Abcam 
Lamin A/C Lamin A/C Rabbbit Cell Signaling 
Lamin B1 Lamin B1 Rabbit Abcam 
MAP2K5 antibody, clone 1B4, MAP2K5 Mouse Abnova 
MAP2K5(pSer311/Thr315)  MAP2K5 Rabbit AnaSpec 
NTF97/importin β NTF97 Mouse Abcam 
P68 P68 RNA helicase 
C-terminal 
Rabbit Georgia State 
University, 
Animal center 
facility 
P68-rgg P68 RNA helicase Mouse Auburn University 
Hybridoma 
Facility 
Phosphor S10 Hstone H3 Mouse Abcam 
PKM2 PKM2 specific 
sequences  
Rabbit Georgia State 
University, 
Animal center 
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facility 
PY20 Phosphor-Tyrosine Mouse Abcam 
p-Tyr-100 Phosphor-Tyrosine Mouse Cell signaling 
RNA polymerase II RNA polymerase II Mouse Abcam 
Tyr1007/1008 p-Jak2 Rabbit Cell signaling  
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Table 3 Primers List 
Construction Primers  Vector 
His-PKM2 5’-GGGGAATTCTCGAAGCCCCATAGTGAAGC-3’ 
5’-GGGGCGGCCGCCGGCACAGGAACAACACGC-3’  
pET30a 
HA-PKM2 5’-GGGGAATTCCTCGAAGCCCCATAGTGAAGC-3’ 
5’-GGGGCGGCCGCTTCGGCACAGGAACAACACGC-
3’ 
pHM6 
NLS-PKM2 5’-
GGGGAATTCCCCTAAGAAGAAGCGCAAGGTGTCG
AAGCCCCATAGTGAAGC-3’ 
5’-
GGGGCGGCCGCTTCACCTTGCGCTTCTTCTTAGGC
GGCACAGGAACAACACGC-3’  
pHM6 
eGFP-PKM2 5’-GGGGATATCAATCGAAGCCCCATAGTGAAGC-3’ 
5’-
GGGGCGGCCGCTTACGGCACAGGAACAACACGC-
3’  
pcDNA3
. 
 
GST-PKM2 5’-GGGGGATCCTCGAAGCCCCATAGTGAAGC-3’ 
5’-GGGGAATTCGCTTACGGCACAGGAACAA-3’    
pGEX2
T 
K433E-PKM2  pHM6 
R399E-PKM2 5'-
CAATTATTTGAGGAACTCGAGCGCCTGGCGCCCAT
TACC-3' 
5'-
GGTAATGGGCGCCAGGCGCTCGAGTTCCTCAAAT
AATTG-3' 
pHM6 
NLS-PKM2 5'-CATAATCGTCCTCACCGAGTCTGGCAGGTCTGC-
3' 
5'-
GCAGACCTGCCAGACTCGGTGAGGACGATTATG-3' 
pHM6 
PKM2- C-
terminal 
deletion mutant 
5’-GGGGAATTCCATGTCGAAGCCCCATAGTGA-3’   
5’-
GGGGCGGCCGCTTTCAGCTGGTAATGGGCGCCAG-
3’        
pHM6 
L398A of 
PKM2 
 
5’-GCAGCTGAGGAAGCCCGCCGCCTGGC-3’ 
5’-GCCAGGCGGCGGGCTTCCTCAGCTGC-3’ 
pHM6 
L401A of 
PKM2 
 
5’-GAAGCCCGCCGCGCGGCGCCCATTAC-3’ 
5’-GTAATGGGCGCCGCGCGGCGGGCTTC-3’ 
pHM6 
P403A of 
PKM2 
 
5'-GCCGCGCGGCGGCCATTACCAGCG-3' 
5'-CGCTGGTAATGGCCGCCGCGCGGC-3' 
pHM6 
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I404A of 
PKM2 
5'-CGCGCGGCGGCCGCTACCAGCGACCC-3' 
5'-GGGTCGCTGGTAGCGGCCGCCGCGCG-3' 
pHM6 
K270M of 
PKM2 
5’-
AAGAACATCAAGATTATCAGCATGATCGAGAATC
ATGAGGGGGTTC-3' 
5'-
GAACCCCCTCATGATTCTCGATCATGCTGATAATC
TTGATGTTCTT-3' 
pHM6 
pET30a
+ 
1-432 
truncating 
mutant of 
PKM2 
5’-GGGGAATTCCTCGAAGCCCCATAGTGAAGC-3’    
5’-
GGGGCGGCCGCTAGGTGAGGACGATTATGGCCC-
3’   
pHM6 
1-515 
truncating 
mutant of 
PKM2  
5’-GGGGAATTCCTCGAAGCCCCATAGTGAAGC-3’  
5’-GGGGCGGCCGCTATCCGGTCAGCACAATGACC-
3’ 
pHM6 
1-269 
truncating 
mutant of 
PKM2  
5’-GGGGAATTCCTCGAAGCCCCATAGTGAAGC-3’  
5’-
GGGGCGGCCGCTAGCTGATAATCTTGATGTTCTTT
C-3’   
pHM6 
270-432 
truncating 
mutant of 
PKM2  
5’-GGGGAATTCCAAAATCGAGAATCATGAGGGG-
3’  5’- 
GGGGCGGCCGCTAGGTGAGGACGATTATGGCCC-
3’ 
pHM6 
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Table 4 Mammalian Cell Lines  
Name Company Origin Culture medium 
SW480 ATCC Human colorectal 
adenocarcinoma 
cells 
Leibovitz L-15 + 10 
% FBS 
SW620 ATCC Human colorectal 
adenocarcinoma 
cells derived from 
metastatic site: 
lymph node 
Leibovitz L-15 
Medium + 10% FBS
WM115 ATCC Human skin 
melanoma cells 
MEM + 10 % FBS 
WM266 ATCC Human skin 
metastatic 
melanoma cells 
MEM + 10 % FBS 
H460 ATCC Human primary 
lung 
DMEM + 10 % FBS
H146 ATCC Human metastatic 
lung 
DMEM + 10 % FBS
T98G ATCC Human brain 
glioblastoma cells  
MEM + 10 % 
FBS+1mM pyruvate 
kinase+1mM non-
essential amino acid 
U-87 MG ATCC Human brain 
astrocytoma cells  
MEM +10 %  
FBS+1mM pyruvate 
kinase+1mM non-
essential amino acid 
HeLa S3 ATCC Human cervix 
adenocarcinoma 
cells 
F12K/DMEM + 10 
% FBS 
HEK293 ATCC Human kidney 
epithelial cells 
immortalized by 
adenovirus 5 DNA  
DMEM+ 10 %FBS 
HEL 299 ATCC Human lung normal 
fibroblast cells  
MEM + 10 % FBS 
NIH/3T3 ATCC Mouse embryo 
fibroblast cells  
DMEM + 10 % FBS
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Table 5 Chemicals 
Name of chemical Company 
α-Cyano-4-hydroxycinnamic acid Agilent Tech, Santa Clara 
[γ-32P] ATP PerkinElmer, Waltham 
2-Mercaptoethanol Sigma Aldrich, St. Louis 
Acetic acid VWR International, West Chester 
Acetone VWR International, West Chester 
Acrylamide/bisacrylamide solutions Fisher BioReagent, Fairlawn 
Agar Sigma-Aldrich, Saint Louis 
Agarose MP Biomedicals, Aurora 
Ammonium persulfate Sigma-Aldrich, Saint Louis 
Anhydrous acetonitrille Applied Biosystems, Foster City 
Bacto Yeast Extract BD Bioscience, Spark 
Bacto Tryptone BD Bioscience, Spark 
Bovine serum albumin Promega, Madison 
Bromophenol Blue EMD Biosciences, San Diego 
Coomassie blue Sigma-Aldrich, Saint Louis 
Deep purple total protein stain Amersham Biosciences, Piscataway 
Dithiothreitol Shelton Scientific, Shelton 
Ethanol AAPER Alcohol & Chemical, Shelbyville 
Ethidium bromide Sigma-Aldrich, Saint Louis 
Ethylenedinitro-tetraacetic acid (EDTA) Sigma-Aldrich, Saint Louis 
Fetal calf serum  HyClone, Logan 
Formaldehyde Calbiochem, San Diego 
Formic acid EMD Biosciences, San Diego 
FuGENE 6 Transfection Reagent Roche Applied Science, Indianapolis 
GelCode Blue Stain Reagent Pierce, Rochford 
Glycine MP Biomedicals, Aurora 
HiTrap affinity columns Amersham Biosciences, Piscataway 
Hydrochloric acid VWR International, West Chester 
Imidazole Sigma-Aldrich, Saint Louis 
Isopropyl-ß-D-thiogalactopyranosid Sigma-Aldrich, Saint Louis 
Isopropanol VWR International, West Chester 
Kanamycin solution Teknova, Hollister 
Lipofectamine 2000 Invitrogen, Carlsbad 
Lipofectamin RNAiMAX Invitrogen, Carlsbad 
Lysozyme Sigma-Aldrich, Saint Louis 
Magnesium Chloride Fisher Biotech, Fairlawn 
Methanol VWR International, West Chester 
Molecular weight marker (DNA) MBI Fermentas, Hanover 
Molecular weight marker (protein) MBI Fermentas, Hanover 
N- (2-hydroxyethyl) piperazine-N`-(2- Sigma-Aldrich, Saint Louis 
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ethanesulfonic acid) (HEPES) 
Nickel-nitrilotriacetic acid (Ni-NTA) agarose Qiagen, Hilden 
Ni-TED™ Silica Active Motif, Carlsbad 
N, N, N’, N’-Tetramethylethylenediamine Promega, Madison 
Nonidet P40 Roche Applied Science, Indianapolis 
Normal goat serum (10%) KPL, Gaithersburg 
Phenol/Chloroform  Promega, Madison 
Phenylmethylsulfonyl fluride Fluka, Switzerland 
Phosphatase inhibitor cocktail Sigma-Aldrich, Saint Louis 
Poly-L-lysine solution Sigma-Aldrich, Saint Louis 
Ponceau S Sigma-Aldrich, Saint Louis 
Protease inhibitor cocktail tablets Roche, Germany 
Protein G agarose Upstate, Charlottesville 
Protein G sepharose 4 fast flow Amersham Biosciences, Piscataway 
Sephadex G-25 Amersham Biosciences, Piscataway 
Superdex 200 HR 10/30 Amersham Biosciences, Piscataway 
Sodium acetate Promega, Madison 
Sodium azide Fluka, Switzerland 
Sodium bicarbonate Sigma-Aldrich, Saint Louis 
Sodium chloride Fisher BioReagent, Fairlawn 
Sodium dodecyl sulfate Fisher BioReagent, Fairlawn 
Sodium fluoride Fluka, Switzerland 
Sodium hydroxide Fisher BioReagent, Fairlawn 
Sodium orthovanadate EMD Biosciences, San Diego 
Sodium pyruvate Cellgro, Herndon 
Triton X-100 Sigma-Aldrich, Saint Louis 
Trypan Blue Sigma-Aldrich, Saint Louis 
Trypsin proteomics grade Sigma-Aldrich, Saint Louis 
Tween-20 Sigma-Aldrich, Saint Louis 
Urea Fisher Biotech, Fairlawn 
X-tremeGene siRNA Transfection Reagent Roche, Germany 
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Table 6 Experimental Kits  
 
Name Company 
AminoLink Plus Immobilization Kit Pierce, Rockford 
BrdU cell proliferation assay Calbiochem, 
ChIP-IT kit Active Motif, Carlsbad 
DAB reagent set KPL, Gaithersburg 
EZ-link NHS-PEO solid phase 
biotinylation kit 
Pierce, Rochford 
Glucose Assay Kit BioVision, Mountain View 
Improm-II Reverse Transcription System Promega, Madison 
Lactate Assary Kit BioVision, Mountain View 
MinElute PCR Purification Kit Qiagen, Valencia 
Nuclear Extract Kit Active Motif, Carlsbad 
ProteoSliver Plu Sliver Stain Kit Sigma-Aldrich, Saint Louis 
Pyruvate Assay Kit BioVision, Mountain View 
RNeasy Plus Kit Qiagen, Valencia 
Qiaprep Spin Mini-Prep  Qiagen, Valencia 
Qiaquick Gel Extraction Kit Qiagen, Valencia 
QuickChange II XL site-directed 
Mutagenesis Kit 
Stratagene, La Jolla 
Quick-ChIP Imgenex, San Diego 
Trypsin Profile IGD kit for in-gel digests Sigma-Aldrich, Saint Louis 
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CHAPTER 7: APPENDIX 
7.1 Detection of Associated Nuclear Proteins to Phosphorylated p68 RNA Helicase 
7.1.1 Abstract 
P68 RNA helicase, a member of DEAD box family, is involved in pre-mRNA 
splicing progress as well as many other important biogenesis processes. P68 RNA 
helicase is phosphorylated at its tyrosine residues, which plays crucial roles in cancer 
developments. Here we applied MALDI-TOF method to detect its phosphorylation sites 
from HeLa cells. We also performed proteomic methods to examine the associated 
nuclear proteins to p68 RNA helicase, which may be important for further study about 
p68 biological functions in the nucleus.  
 
7.1.2 Introduction 
P68 is a member of the DEAD (Aspartic acid–Glutamic acid–Alanine–Aspartic 
acid) box family proteins. DEAD box proteins have been shown to be involved in a wide 
range of biological processes, such as pre-mRNA splicing, ribosome biogenesis and 
translation (Liu 2002; Kahlina, Goren et al. 2004) . Protein phosphorylation is one of the 
major post-translational modifications playing important roles in signal transduction 
pathways. P68 RNA helicase is phosphorylated at its tyrosine residues in cancer cells 
(Yang, Lin et al. 2005). Phosphorylation at Y593 tyrosine residue is required for colon 
cancer cells proliferation and epithelial to mesenchymal transition (EMT) stimulated by 
PDGF (Yang, Lin et al. 2007). Phosphorylation at Y593 residue of p68 promotes β-
catenin translocate into the nucleus in colon cancer cells (Yang, Lin et al. 2006). To 
  240
further illustrate the physiological functions of phosphorylated p68 in cancer cells, we 
examined the nuclear associated proteins to phosphorylated p68 with proteomic methods.  
 
7.1.3 Methods 
7.1.3.1 Co-Immunoprecipitation and Peptide Pulldown 
IP and Co-IP experiments were performed in NETS buffer (150 mM NaCl, 50 mM 
tris-HCl[pH 7.5], 5 mM EDTA, 0.05% NP-40). SDS was added to a final concentration 
of 1%. 30 ul of p68 mono-antibody was incubated with 500 ug of nuclear extract in 1 ml 
NETS buffer for 3 hr at 4 °C. 100 ul of protein G agarose bead slurry was added into the 
tube and incubated for 2 h. The beads were recovered by centrifuging at 1000 rpm for 10 
min and washed with 600 µl of NETS five times. The proteins complexes were separated 
in SDS-PAGE gel. For peptide pulldown experiment, 500 ug of nuclear extract was pre-
cleared with 50 ul of naked beads by incubating for 30 minutes at 4 °C. After 
centrifuging, 100 ul of beads conjugated with phosphorylated or non-phosphorylated 
peptides were incubated with the supernatant at 4 °C overnight. The tube was centrifuged 
at 1,000 rpm for 10 min at 4 °C. The precipitated mixture was washed with 600 µl of 
NETS five times and with 1% SDS twice.  
 
7.1.3.2 Two-Dimensional SDS-PAGE Analysis 
Protein samples were washed with 1 ml ddH2O twice. The protein samples were 
then solubilized in re-hydration buffer (7 M Urea, 2 M thiourea, 2% CHAPS, 0.8% 
ampholyte, 0.02% bromophenol blue, and 65 mM DTT). A dry strip was removed from -
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20 °C and was equilibrated in equilibration buffer [0.38 M Tris-base, pH 8.8, 6 M urea, 
2% (w/v) SDS and 20% (v/v) glycerol] at room temparature for 15 min. The samples 
were loaded into the rehydration tray. A paper wick was palaced at both ends of the 
focusing try channel covered with 30 ul ddH2O. The tray was set into IEF cell and run 
the following program: 250V for 20 min, 8000 V for 2.5 h and 8000 v for 20,000 Volt-
Hours. The next day, IPG strip was taken out from IEF cell and set in a clean tray with 
gel side up. 3.5 ml Equilibration buffer was added into IEF cell and incubated with the 
strip for 10 min. The IPG strip was dipped in 1X SDS-PAGE gel running buffer. Then, 
the strip was laid onto the top of the prepared SDS gel and sealed with 1% agarose in gel 
box. The gel box was filled with 1X running buffer (25 mM Tris, 190 mM glycine and 
0.1% SDS) and run at 60 volt for 20 min, then the volt was changed to 100 volt. After 
electrophoresis, the gel was wash with ddH2O for 5 min. The gel was stained with Deep 
Purple fluorescent dye or silver stain (Amersham Biosciences) according to the 
manufactures instructions. 
 
7.1.3.3 Protein Identification by Peptide Mass Fingerprinting  
The proteins complexes were separated in 10% SDS-PAGE or 2-D gel. The 
targeting proteins spots were picked up with Ettan spot picker. The samples were 
digested with trypsin. After ZipTip purification, the digested peptide solution was eluted 
from ZipTip with 50% ACN/0.1% formic acid and spotted directly onto a wax-coated 
MALDI target plates. Nano LC MALDI TOF/TOF MS analysis was performed in 
Applied Biosystems 4700 proteomics analyzer. The matching of the experimental 
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sequences with tryptic peptide masses from database was performed with Peptident 
proteomic tools in ExPASy Molecular Biology Server (http://www.expasy.ch/). The 
MALDI-TOF/TOF database was from NCBInr.  
 
7.1.4 Results and Discussions 
 
7.1.4.1 Identification of Phosphorylated Residues of p68 RNA Helicase with 
MALDI-TOF 
Matrix-assisted laser desorption/ionization (MALDI)-time of flight (TOF) MS is a 
well established tool for peptide or protein identification. The addition of a phosphate 
monoanion to a hydroxyl group of tyrosine results in mass increases of the proteins or 
peptides by 79.966 Da in monoisotopic mass. It is possible to estimate the number of 
phosphates on a protein by comparing the mass shift between the modified and original 
peptides. The strength of peptide signals in MALDI-TOF is important for detecting the 
mass shift. In most cases, the protein staining method in SDS-PAGE gel may affect the 
enrichment of peptide signals. To this purpose, we applied two protein staining methods 
to detect p68 peptides digested by trypsin. The results showed that GelCode staining was 
more sensitive for MALDI-TOF signal enrichment of the digested peptides than 
Coomassive blue staining (Fig 7.1). Therefore, we applied Gelcode staining method in 
the following experiments to detect the phosphorylated residues of p68. P68 RNA 
helicase was immunoprecipated from the nuclear extract of HeLa cells. The presence of 
p68 in the immunoprecipitated complex was confirmed by western-blot. P68 RNA 
helicase was in-gel digested with trypsin and the presence of peptides was detected with 
MALDI-TOF. Our results showed that the detected peptide signals were recovered 
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around 70% by comparing with control (matrix only). The recovered peptides, including 
1336.6 D, 1348.6 D, 1389.6 D, 1574.7 D, 2131.9 D, 2361.4 D, matched with theoretical 
peptide masses (Fig 7.2). All the peptides above 1000 D were detected in MALDI-TOF 
except one peptide, whose molecular weight was 5967.4D. Our result showed a peak 
around 5571.8 D in the peptide complex. Whether this peak was due to the hydrolysis 
effect or some other modifications was not known. The peptide, 2396.4 D, was found 
163.4 D shift from 2133.04 D peptides whose compose was FVINYDYPNSSEDYIHR 
including three tyrosine sites (Fig 7.2). According the prediction from Netphos 2.0, Y418 
and Y425 sites had the high potential possibilities of phosphorylation. The shifted peak 
may be the two phosphorylatd sites from Y418 and Y425. These phosphorylation sites 
needs to be further confirmed with other biological methods, such as mutagenesis. 
 
7.1.4.2 Detection of p68 Associated Nuclear Proteins Using 2-D Gel 
 
P68 RNA helicase plays crucial roles in many biological process. To elucidate its 
other functions in the nuclear, it is important to examine the associated proteins. To this 
end,  Co-IP experiment was performed to precipitate these associated proteins with p68 
antibody. Three antibodies generated from the C-terminal sequence and one from N-
terminal sequence of p68 were applied to immunoprecipitate p68-associated proteins. 
The precipitated protein complexes were separated in 2-D gel. The results showed that 
some associated proteins specially precipated by the C-terminal antibody, which 
indicated these proteins may be only associated with the C-terminal phosphorylated p68 
RNA helicase (Fig 7.2). Some spots were picked up and will be identified with MALDI-
TOF/TOF peptide fingerprinting method.  
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7.1.4.3 Analysis of Nuclear Associated Proteins to Phosphorylated p68 using 
Peptide-protein Interaction Screening Method 
To specificly identify phosphorylated p68 RNA helicase associated proteins, we 
synthesized two peptides according to its C-terminal sequences. One had double 
phosphorylation sites at tyrosine residues, Y593 and Y595. The other was non-
phosphorylated peptide with the same amino acid sequence. The synthesized peptides 
were coupled to agarose beads. The associated proteins were pull down with agarose 
beads conjugated with peptides. 2-D gel was performed to separate the protein 
complexes. The results showed that three proteins spots specificly presented in the 
complex precipitated with phosphorylated peptides, not with non-phosphorylated 
peptides. Nine proteins spots specially presented in the protein complex pulled down 
with non-phosphorylated peptides. These targeting proteins will be identified by MALDI-
TOF/TOF (Fig 7.3). 
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Fig 7.1.1 P68 Post-translation Modifications Analysis with MALDI-TOF.  
(A) shows digested peptides of p68 by trypsin via GelCode staining. (B) shows digested 
peptides from p68 by trypsin via Coomassive blue staining.  
 
  248
 
     
 
 
A   
 
 
 
   
 
      B 
  249
 
Fig 7.1.2 2-D Gel Analyses of p68-associated Nuclear Proteins Immunoprecipitated with 
p68 Antibodies  
(A). 2-D gel analysis of p68 associated nuclear proteins immunoprecipitated by p68 
antibody generated from the recombinant protein derived from C-terminal sequence of 
p68. (B). 2-D gel analysis of p68 associated nuclear proteins immunoprecipitated by p68 
antibody generated from the recombinant protein derived from N-terminal sequence of 
p68. In (A) and (B), both gels were stained with silver staining.  
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Fig 7.1.3 2-D Gel Analysis of p68-associated Nuclear Proteins Pulled Down with 
Phophorylated Peptides Derived from p68  
(A). 2-D gel analysis of p68 associated nuclear proteins pulled down using non-
phosphorylated peptides derived from C-terminal sequence of p68. The cycled spots 
showed the specific associated protein to non-phosphorylated peptides (B). 2-D gel 
analysis of p68 associated nuclear proteins pulled down by phosphorylated peptide 
derived from N-terminal sequence of p68. The cycled spots showed the specific 
associated protein to phosphorylated peptides. In (A) and (B), both gels were stained with 
silver staining. 
 
 
